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The clinical effectiveness and cost-effectiveness of
point-of-care tests (CoaguChek system, INRatio2 PT/INR
monitor and ProTime Microcoagulation system) for the
self-monitoring of the coagulation status of people
receiving long-term vitamin K antagonist therapy,
compared with standard UK practice: systematic review
and economic evaluation
Pawana Sharma,1* Graham Scotland,1,2 Moira Cruickshank,1
Emma Tassie,2 Cynthia Fraser,1 Chris Burton,3 Bernard Croal,4
Craig R Ramsay1 and Miriam Brazzelli1
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2Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
3Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK
4Department of Clinical Biochemistry, University of Aberdeen, Aberdeen, UK
*Corresponding author p.sharma@abdn.ac.uk
Background: Self-monitoring (self-testing and self-management) could be a valid option for oral
anticoagulation therapy monitoring in the NHS, but current evidence on its clinical effectiveness or
cost-effectiveness is limited.
Objectives: We investigated the clinical effectiveness and cost-effectiveness of point-of-care
coagulometers for the self-monitoring of coagulation status in people receiving long-term vitamin K
antagonist therapy, compared with standard clinic monitoring.
Data sources: We searched major electronic databases (e.g. MEDLINE, MEDLINE In Process & Other
Non-Indexed Citations, EMBASE, Bioscience Information Service, Science Citation Index and Cochrane
Central Register of Controlled Trials) from 2007 to May 2013. Reports published before 2007 were
identified from the existing Cochrane review (major databases searched from inception to 2007).
The economic model parameters were derived from the clinical effectiveness review, other relevant
reviews, routine sources of cost data and clinical experts’ advice.
Review methods: We assessed randomised controlled trials (RCTs) evaluating self-monitoring in people
with atrial fibrillation or heart valve disease requiring long-term anticoagulation therapy. CoaguChek® XS
and S models (Roche Diagnostics, Basel, Switzerland), INRatio2® PT/INR monitor (Alere Inc., San Diego, CA
USA), and ProTime Microcoagulation system® (International Technidyne Corporation, Nexus Dx, Edison,
NJ, USA) coagulometers were compared with standard monitoring. Where possible, we combined data
from included trials using standard inverse variance methods. Risk of bias assessment was performed using
the Cochrane risk of bias tool. A de novo economic model was developed to assess the cost-effectiveness
over a 10-year period.
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Results: We identified 26 RCTs (published in 45 papers) with a total of 8763 participants. CoaguChek was
used in 85% of the trials. Primary analyses were based on data from 21 out of 26 trials. Only four trials
were at low risk of bias. Major clinical events: self-monitoring was significantly better than standard
monitoring in preventing thromboembolic events [relative risk (RR) 0.58, 95% confidence interval (CI)
0.40 to 0.84; p= 0.004]. In people with artificial heart valves (AHVs), self-monitoring almost halved the
risk of thromboembolic events (RR 0.56, 95% CI 0.38 to 0.82; p= 0.003) and all-cause mortality (RR 0.54,
95% CI 0.32 to 0.92; p= 0.02). There was greater reduction in thromboembolic events and all-cause
mortality through self-management but not through self-testing. Intermediate outcomes: self-testing,
but not self-management, showed a modest but significantly higher percentage of time in therapeutic
range, compared with standard care (weighted mean difference 4.44, 95% CI 1.71 to 7.18; p= 0.02).
Patient-reported outcomes: improvements in patients’ quality of life related to self-monitoring were
observed in six out of nine trials. High preference rates were reported for self-monitoring (77% to
98% in four trials). Net health and social care costs over 10 years were £7295 (self-monitoring with
INRatio2); £7324 (standard care monitoring); £7333 (self-monitoring with CoaguChek XS) and
£8609 (self-monitoring with ProTime). The estimated quality-adjusted life-year (QALY) gain associated
with self-monitoring was 0.03. Self-monitoring with INRatio2 or CoaguChek XS was found to have ≈ 80%
chance of being cost-effective, compared with standard monitoring at a willingness-to-pay threshold of
£20,000 per QALY gained.
Conclusions: Compared with standard monitoring, self-monitoring appears to be safe and effective,
especially for people with AHVs. Self-monitoring, and in particular self-management, of anticoagulation
status appeared cost-effective when pooled estimates of clinical effectiveness were applied. However,
if self-monitoring does not result in significant reductions in thromboembolic events, it is unlikely
to be cost-effective, based on a comparison of annual monitoring costs alone. Trials investigating the
longer-term outcomes of self-management are needed, as well as direct comparisons of the various
point-of-care coagulometers.
Study registration: This study is registered as PROSPERO CRD42013004944.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
People with clinical conditions such as atrial fibrillation (irregular heart rhythm) or heart valve disease arerequired to take lifelong blood-thinning drugs (warfarin or other vitamin K antagonists) known as oral
anticoagulation therapy (OAT) to avoid the risks of blood clot (thromboembolism). Over- or underdosing of
warfarin can result in serious side effects including bleeding or thromboembolic complications; therefore,
treatment with warfarin requires frequent and regular monitoring. Self-monitoring, which is the use
of a personal testing machine at home (i.e. point-of-care devices) to test the blood coagulation status
(self-testing), or to test the coagulation status and manage the dose at the same time (self-management),
is an option for warfarin monitoring. The use of point-of-care tests for self-monitoring may allow regular
monitoring to prevent serious adverse events. This appraisal assessed the effects (clinical and economical)
of self-monitoring using CoaguChek® S and XS, INRatio2® and ProTime® point-of-care devices, compared
with standard clinic monitoring in people receiving long-term OAT. We found 26 trials (reported in
45 papers) in which 8763 patients receiving OAT were randomly assigned to self-monitoring or standard
monitoring. Thromboembolic events were reduced in all patients performing self-monitoring. In people
with artificial heart valves, self-monitoring almost halved the risk of thromboembolic events and all-cause
mortality. There was greater reduction in thromboembolic events and all-cause mortality through
self-management but not through self-testing. Self-monitoring with INRatio or CoaguChek XS was
found to have ≈ 80% chance of being cost-effective, compared with standard monitoring.
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Scientific summary
Background
There are increasing numbers of people with atrial fibrillation, heart valve disease or other cardiac
conditions who are at high risk of thrombosis, requiring long-term oral anticoagulation therapy (OAT).
It is estimated that 1.4% of the population in the UK requires treatment with OAT. The goal of OAT,
generally with warfarin (a type of vitamin K antagonist), is to establish a balance between bleeding and
clotting. Underanticoagulation increases the risk of thromboembolism, while overanticoagulation increases
the risk of haemorrhage; hence treatment with warfarin requires frequent monitoring. The blood
coaguability of people taking warfarin is monitored by the use of the international normalised ratio (INR),
which is a standardised unit for measuring the time it takes for blood to clot. As standard practice,
warfarin monitoring is managed by health-care professionals in anticoagulant clinics based in hospitals
using laboratory testing or managed in primary care (with or without the use of laboratory services).
Another option for warfarin monitoring is the use of a personal testing machine at home (known as a
point-of-care test) which allows people to perform self-testing (when people perform the test themselves
and the results of the test are managed by health-care professionals) or self-management (when people
perform the test and alter the dose of anticoagulation therapy themselves according to a personalised
protocol). Self-testing and self-management are together referred to as self-monitoring. Self-monitoring is
considered as one of the options for warfarin monitoring in the NHS, but there is limited evidence on its
clinical effectiveness compared with other ways of delivering services.
Objectives
This assessment investigates the clinical effectiveness and cost-effectiveness of point-of-care coagulometers
for the self-monitoring of coagulation status in people receiving long-term vitamin K antagonist therapy.
CoaguChek® system (both the S and the XS models) (Roche Diagnostics, Basel, Switzerland), INRatio2®
PT/INR monitor (Alere Inc., San Diego CA, USA) and ProTime Microcoagulation system® (International
Technidyne Corporation, Nexus Dx, Edison, NJ, USA) coagulometers are being considered in this
assessment as an alternative to standard UK anticoagulation therapy services.
Methods
Clinical effectiveness
Comprehensive electronic searches were undertaken to identify relevant reports of published studies up
to May 2013. We searched major electronic databases (e.g. MEDLINE, MEDLINE In Process & Other
Non-Indexed Citations, EMBASE, Bioscience Information Service, Science Citation Index and Cochrane
Central Register of Controlled Trials) from 2007 to May 2013. Reports published before 2007 were
identified from the existing Cochrane review (major databases searched from inception to 2007). Evidence
was considered from randomised controlled trials (RCTs) evaluating the point-of-care tests under
consideration for the self-monitoring of anticoagulation therapy. The population were those with atrial
fibrillation or heart valve disease for whom long-term vitamin K antagonist therapy was intended. Self-INR
monitoring supervised by primary or secondary care using CoaguChek system (both the S and the XS
models), INRatio2 PT/INR monitor or ProTime Microcoagulation system was considered in this assessment.
The comparator considered was standard clinical practice, which consisted of INR monitoring managed by
health-care professionals in primary care, in secondary care or in a ‘shared provision’ setting.
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Data on clinical outcomes, intermediate outcomes and patient-reported outcomes were extracted from the
included studies. Dichotomous and continuous data (when possible) were meta-analysed as pooled
summary effect sizes using standard inverse variance methods. Apart from the prespecified subgroup
analysis according to the type of anticoagulation therapy management (self-testing and self-management),
post-hoc subgroup analyses according to the type of the target clinical condition (i.e. atrial fibrillation,
heart valve disease and mixed clinical indication) and according to the type of service provision for
anticoagulation management (i.e. primary care, secondary care and shared provision) were performed.
A post-hoc sensitivity analysis by excluding the studies conducted in the UK was performed. Risk of bias
assessment for all included RCTs was performed using the Cochrane Risk of Bias tool.
Cost-effectiveness
A review of existing economic evaluations identified 12 studies of potential relevance to the scope of this
assessment. These studies demonstrated mixed results with respect to the cost-effectiveness of self-testing
or self-management strategies versus standard primary or secondary care monitoring. Only two studies
were directly relevant to the NHS setting, and none addressed all of the comparisons set out in the scope
for this assessment.
A de novo economic model was developed in TreeAge Pro (TreeAge Software 2013, Inc Williamstown,
MA, USA) to assess the cost-effectiveness of INR self-monitoring (self-testing and self-management) versus
standard primary or secondary care clinic monitoring. The alternative point-of-care devices considered for
self-monitoring were CoaguChek XS system, INRatio2 PT/INR monitor and ProTime Microcoagulation system.
The model simulated the occurrence of thromboembolic and bleeding events over a 10-year period for a
cohort of people on long-term vitamin K antagonist therapy. Indications for vitamin K antagonist therapy
included atrial fibrillation and artificial heart valves (AHVs). Baseline risks of events for people with the
different underlying conditions (under standard monitoring) were derived from a focused review of existing
literature, and the relative effects of self-testing and self-management on these events were derived from
the meta-analysis of existing RCTs. Other parameters including cost and utility inputs were derived
from focused literature searches, previous economic models and routine data sources.
Results
Clinical effectiveness
In total, 26 RCTs (published in 45 papers) were included in the clinical effectiveness review with mean
sample size of 337 participants (range 16–2922 participants). Primary analyses were based on data from
21 out of the 26 included trials relevant to the comparisons and outcomes of interest. The majority of trials
(85%) investigated the use of the CoaguChek system including model ‘XS’ (n= 414 in four trials), model
‘S’/CoaguChek (n= 3910 in 17 trials) and CoaguChek Plus (n= 1155 in one trial) for the self-monitoring of
anticoagulation therapy. Two trials utilised both CoaguChek and INRatio together (n= 222), while another
two trials utilised ProTime (n= 3062). No trials that exclusively assessed the clinical effectiveness of INRatio
were identified.
Only four trials were judged at low risk of bias. Three of these trials used either the CoaguChek model ‘S’
or the model ‘XS’ for INR measurement, while the other trial used CoaguChek XS to measure INR
in children.
Major clinical events
The results of this assessment indicate that self-monitoring (self-testing or self-management) of
anticoagulation therapy leads to significantly fewer thromboembolic events [relative risk (RR) 0.58,
95% confidence interval (CI) 0.40 to 0.84; p= 0.004], compared with standard primary care or
anticoagulation control in specialised clinics. Self-monitoring (self-testing and self-management) did not
demonstrate a significant reduction in the number of major and minor bleeding events compared with
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standard care (RR 0.95, 95% CI 0.74 to1.21; p= 0.66). In people with AHVs, self-monitoring almost
halved the risk of thromboembolic events (RR 0.56, 95% CI 0.38 to 0.82; p= 0.003) and all-cause
mortality (RR 0.54, 95% CI 0.32 to 0.92; p= 0.02). There was greater reduction in thromboembolic events
and all-cause mortality through self-management but not through self-testing. Fewer thromboembolic
events were observed among people who self-monitored their therapy, compared with those who were
managed by their general practitioner or physicians but not compared with those managed in specialised
anticoagulation clinics. The subgroup analysis was not, however, statistically significant.
Intermediate outcomes
While no significant differences were found between self-management and standard care for time in
therapeutic range (TTR) [weighted mean difference (WMD) 0.47, 95% CI –1.40 to 2.34; p= 0.62],
self-testing showed a modest but significantly higher percentage of TTR than standard care (WMD 4.44,
95% CI 1.71 to 7.18; p= 0.02). None of the UK-based trials showed significant difference between
self-monitoring and standard care for major complications, deaths or anticoagulation control.
Patient-reported outcomes
Improvements in quality of life in the self-monitoring group were observed in six of the nine trials that
reported quality-of-life outcomes. Two UK-based trials reporting quality-of-life data did not show
significant difference between self-monitoring and standard care. Four trials that assessed the patient’s
acceptability for point-of-care devices reported high rates of preference for both self-testing and
self-management (77% to 98%).
Cost-effectiveness
Self-monitoring (50% self-testing, 50% self-management) was found to increase the INR monitoring
costs, compared with standard primary/secondary care monitoring. The incremental monitoring costs
(incorporating training costs and annuitised device cost) associated with self-monitoring over the 10-year
period were £639, £675, and £1923 with INRatio2, CoaguChek XS and ProTime Microcoagulation System,
respectively. However, applying the pooled RRs of adverse events to people completing training and
continuing with self-monitoring, it was estimated that the cumulative incidence of thromboembolic events
at 10 years would be 2.4% lower than with standard monitoring. This, in turn, resulted in quality-of-life
gains and future cost-savings associated with acute and long-term care. Thus, the difference in total health
and social care costs was less pronounced after 10 years: £7295 (self-monitoring with INRatio2); £7324
(standard primary/secondary care monitoring); £7333 (self-monitoring with CoaguChek XS); and £8609
(self-monitoring with ProTime).
The estimated quality-adjusted life-year (QALY) gain associated with self-monitoring at 10 years was 0.03.
Assuming that the benefits of self-monitoring were applied equally to all point-of-care devices,
self-monitoring with INRatio2 dominated standard monitoring under the base-case assumptions. The
incremental cost-effectiveness ratio for CoaguChek XS and ProTime versus standard monitoring was £319
and £47,604 per QALY gained, respectively. Within the base-case analysis, self-testing alone was not
found to be cost-effective (due to its higher cost and small non-significant effect on thromboembolic
events), while self-management was found to be less costly and more clinically effective than
standard monitoring.
Deterministic sensitivity analysis indicated that the cost-effectiveness results were most sensitive to the
estimated effects of self-monitoring on thromboembolic events. Applying RRs obtained from UK trials only,
self-monitoring was not found to be cost-effective at the testing frequency observed in these clinical trials.
Self-monitoring with INRatio2 and CoaguChek XS was found to be slightly less costly than standard
secondary care monitoring when there was no increase in testing frequency (with no difference in effects
assumed), but this finding was sensitive to several other costing assumptions. Applying the base-case
assumptions, self-monitoring with CoaguChek XS or INRatio2 had ≈ 80% chance of being cost-effective at
a threshold ratio of £20,000 per QALY gained.
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Discussion
The included trials varied considerably in terms of clinical indications for anticoagulation therapy, type of
control care, reporting structure for the time and/or values in therapeutic range, type and structure of the
preintervention training and education programme, length of follow-up and methodological study quality.
While the meta-analysis results demonstrated low statistical heterogeneity, there remains uncertainty
around the fact that clinical heterogeneity could have over- or underestimated the effects. Only limited
data were available for people with atrial fibrillation and, consequently, no reliable conclusions could be
drawn in relation to this patient population. The majority of trials investigated the use of the CoaguChek
system for the self-monitoring of anticoagulation therapy and it proved unfeasible to conduct reliable
comparisons according to the type of point-of-care device. While the CoaguChek device has the most
robust evidence, ProTime and, particularly INRatio, do not.
Generalisability of the findings
All included trials enrolled highly selected samples of people requiring anticoagulation therapy, and so it
was uncertain whether or not there was strong external validity (i.e. applicability of the study results
to the entire population of eligible participants). There remains some uncertainty on the applicability of
the pooled results to the UK population. In our view, the greatest uncertainty relates to the applicability
of the standard care comparators in the trials and not to the participants in the trial.
Conclusions
Based on available evidence, our findings suggest that self-monitoring using point-of-care devices by
people at home, compared with standard care, is safe and clinically effective for anticoagulation control,
especially for people with AHVs. Self-monitoring, and in particular self-management, of anticoagulation
status appeared cost-effective when pooled estimates of clinical effectiveness were applied. However, if
self-monitoring does not result in significant reductions in thromboembolic events, it is unlikely to be
cost-effective from the NHS and personal social services perspective, based on a comparison of annual
monitoring costs alone.
The base-case cost-effectiveness results are most applicable to self-monitoring strategies using
CoaguChek XS. The majority of clinical effectiveness evidence related to a previous version
of CoaguChek (CoaguChek S), to which the current version (CoaguChek XS) has been shown to
have very similar or slightly superior performance in terms of accuracy and precision.
Implications for research
Trials investigating the longer-term outcomes of self-management versus usual care are needed. Future
trials should include direct comparisons of the various point-of-care coagulometers. The technology
related to point-of-care testing devices is constantly changing and future research needs to target larger
cohorts of people with different clinical indications requiring long-term anticoagulation therapy who
may benefit from the use of these new generations of devices.
Study registration
This study is registered as PROSPERO CRD42013004944.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background and definition of the
decision problem(s)
Conditions and aetiologies
Brief statement describing the health problem
People with certain clinical conditions such as atrial fibrillation or heart valve disease are at high risk of
thrombosis (blood clot). Untreated, these may lead to thromboembolism affecting the brain (causing a
stroke), the lungs (pulmonary embolism) or other parts of the body. Many people with these conditions are
required to take lifelong blood-thinning drugs (called vitamin K antagonists) to avoid the risks associated
with thrombosis. Treatment using blood-thinning drugs is termed anticoagulant therapy and it is estimated
that 1.4% of the population in the UK require anticoagulant therapy.1
Warfarin is the most common vitamin K antagonist drug given to prevent clot formation and stroke.
However, serious side effects including bleeding or stroke can result from people being on the wrong dose
of warfarin (over- or underdosing). Therefore, it is necessary to ensure that people taking warfarin have
ongoing monitoring of their blood coaguability.
Epidemiology and prevalence
There are increasing numbers of people with atrial fibrillation, heart valve replacement or other clinical
conditions requiring long-term oral anticoagulation therapy (OAT).2 As up to 60% of people with atrial
fibrillation might be undiagnosed, screening programs have the potential to increase diagnoses and
associated use of OAT.3 The prevalence of atrial fibrillation has recently been described as ‘approaching
epidemic proportions’4 and it has been predicted that, by 2050, more than 5.6 million adults in the USA
will be diagnosed with atrial fibrillation, compared with 2.3 million in 2001.5 Increased use of OAT has
intensified pressure upon resources, with some haematology services becoming unable to cope.6
Atrial fibrillation
In the USA, prevalence of atrial fibrillation has been reported as 0.1% in adults< 55 years of age and
9% in those ≥ 80 years old.5 Over 6 million people in Europe have atrial fibrillation7 and a recent Swedish
study reported prevalence of 2.9% in adults > 20 years.8 Atrial fibrillation is the most common heart
arrhythmia and affects around 800,000 people in the UK, or 1.3% of the population.9 Prevalence increases
with age, being 0.5% among people aged 50–59 years and approximately 5% to 8% among people aged
> 65 years.10,11 Atrial fibrillation is more likely to affect men than women and is more common in people
with other conditions, for example high blood pressure, atherosclerosis, or other heart conditions such
as heart valve problems. For people with atrial fibrillation, there is a five times higher risk of stroke
and a three times higher risk of congestive heart failure.12 One-fifth of all strokes are a result
of atrial fibrillation.7 An average proportion of 47% of people with atrial fibrillation currently receive
anticoagulation therapy, such as warfarin.1
Heart valve disease
Aortic stenosis is the most common type of heart valve disease. It affects 1 in 20 adults over the age
of 65 years.13,14 Data from the UK Heart Valve Registry indicate that approximately 0.2% of the UK
population has prosthetic heart valves.15 Around 6500 adult heart valve replacements (using mechanical or
biological valves) are carried out each year, of which around 5000 are aortic valve replacements.15,16
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Impact of health problem: significance for the NHS and burden of disease
The blood coaguability of people taking warfarin is monitored by the use of the international normalised
ratio (INR), which is a standardised unit for measuring the time it takes for blood to clot. INR monitoring
can be delivered using various options in the NHS. The options include INR monitoring managed by
health-care professionals in anticoagulant clinics based in hospitals using laboratory testing or managed in
primary care (with or without the use of laboratory services). The use of a personal INR testing machine
at home (known as a point-of-care test) allows people to perform self-testing (when people perform the
test themselves and the results of the test are managed by health-care professionals) or self-management
(when people perform the test and alter the dose of anticoagulation therapy themselves according
to a personalised protocol). Self-testing and self-management are together referred to as self-monitoring.
Self-monitoring is considered as one of the options for INR monitoring in the NHS, but there is limited
evidence on the clinical effectiveness compared with other ways of delivering services.
The use of point-of-care coagulometers for self-monitoring may avoid unnecessary visits to hospitals
while allowing regular INR monitoring and timely adjustment of warfarin dosing to avoid adverse events.
For people requiring monitoring of their coagulation status, this may result in better quality of life.17
Measurement of disease
The goal of anticoagulant therapy is to establish a balance between bleeding and clotting18 and it is
desirable for people on warfarin to remain within a narrow INR therapeutic range, generally between
2.0 and 3.0.19,20 If the dose of anticoagulation therapy is too low (underanticoagulation), the risk of
thromboembolism increases, while if it is too high (overanticoagulation), the risk of haemorrhage increases.
Individuals’ reactions to warfarin vary according to modifiable (e.g. diet) and non-modifiable factors
(e.g. age, concomitant diseases). Adequate control of INR is necessary to avoid serious complications such
as stroke. Therefore, repeated and regular measurements of INR are required to allow adjustments to
size and/or frequency of dosage.21
Description of technologies under assessment
Summary of point-of-care tests
Point-of-care devices for measuring coagulation status in people receiving long-term vitamin K antagonist
therapy allow both self-testing and self-management, defined as follows:
l Self-testing: point-of-care test carried out by the patient with test results managed by their health-care
provider [e.g. general practitioner (GP), nurse, specialised clinic].
l Self-management: point-of-care test carried out by trained patient, followed by interpretation of test
result and adjustment of dosage of anticoagulant according to a predefined protocol.
Self-testing and self-management are together referred to as self-monitoring for the purposes of this report.
The purpose of this assessment was to appraise the current evidence for the clinical effectiveness and
cost-effectiveness of self-monitoring (self-testing and self-management) using either the CoaguChek®
system (Roche Diagnostics, Basel, Switzerland), the INRatio2® PT/INR monitor, (Alere Inc., San Diego, CA,
USA) or the ProTime Microcoagulation system® (International Technidyne Corporation, Nexus Dx, Edison,
NJ, USA), compared with standard clinical monitoring in people with atrial fibrillation or heart valve disease
for whom long-term vitamin K antagonist therapy is indicated.
All of these point-of-care devices, which are currently available for use in the NHS, are CE marked and
Food and Drug Administration (FDA) approved. Point-of-care instruments work basically in the same way:
a drop of capillary whole blood is obtained by a finger puncture device, applied to a test strip and inserted
into a coagulometer. However, they differ in terms of methods of clot detection and general
operational functions.
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Summary of CoaguChek system
The CoaguChek system is a point-of-care testing device developed by Roche Diagnostics and measures
prothrombin time and INR (the globally recommended unit for measuring thromboplastin time) in people on
oral anticoagulation (vitamin K antagonist) therapy. A low INR indicates an increased risk of blood clots, while
a high INR indicates an increased risk of bleeding events. CoaguChek S and CoaguChek XS devices are
intended for patient self-monitoring. The CoaguChek XS model comprises a meter and specifically designed
test strips for blood sample analysis (fresh capillary or untreated whole venous blood). The CoaguChek XS
system purports to have the following advantages over the CoaguChek S: (1) the thromboplastin used in the
prothrombin time test strips is a human recombinant thromboplastin, which is more sensitive and has a lower
International Sensitivity Index (ISI) of 1.0 compared with 1.6; (2) test strips have onboard quality control that is
automatically run with every test, rather than having to perform external quality control; (3) test strips do not
have to be refrigerated; (4) a smaller blood sample can be used; and (5) the meter is smaller and lighter. The
CoaguChek XS Plus model is aimed primarily at health-care professionals and possesses additional features to
the XS system, including increased storage and connectivity for data management.
Summary of INRatio2 PT/INR monitor
The INRatio2 PT/INR monitor performs a modified version of the one-stage prothrombin time test using a
recombinant human thromboplastin reagent. The clot formed in the reaction is detected by the change in
the electrical impedance of the sample during the coagulation process. The system consists of a monitor
and disposable test strips and the results for prothrombin time and INR are reported.
Summary of ProTime Microcoagulation system
The ProTime Microcoagulation system is designed for measuring prothrombin time and INR. The test is
performed in a cuvette which contains the reagents. Two different cuvettes are available depending on
the amount of blood that needs to be collected and tested: the standard ProTime cuvette and the
ProTime3 cuvette.
Identification of important subgroups
There are a number of clinical conditions which require long-term vitamin K antagonist therapy to reduce
the risk of thrombosis. These conditions include atrial fibrillation and heart valve disease.
Atrial fibrillation
Atrial fibrillation results in unorganised atrial electrical activity associated with mechanically ineffective
fibrillation, that contraction which can lead to blood stagnating in parts of the atria and as a result forming
a clot. This clot may then move from the heart, causing thromboembolism, most commonly in the brain
where it causes stroke. People with atrial fibrillation are at a five to six times greater risk of stroke, with
12,500 strokes directly attributable to atrial fibrillation every year in the UK. Treatment with warfarin
reduces the risk by 50–70%.1,22,23
Artificial heart valves
Valve disease can affect blood flow through the heart in two ways: valve stenosis, where the valve does
not open fully, and valve regurgitation (or incompetence), where the valve does not close properly,
allowing blood to leak backwards. The most effective treatment for many forms of valve disease is heart
valve replacement. Replacement heart valves are either artificial (mechanical), or from humans or animals
(tissue). The human valve could be from the same patient (autograft) when the native pulmonary valve
is used in the aortic position (part of the Ross procedure); or from another patient (heterograft). People
with mechanical heart valves generally require long-term anticoagulant treatment to prevent clotting
related to the valve.
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Current usage in the NHS
The National Institute for Health and Care Excellence (NICE) clinical guideline on atrial fibrillation24
recommends that self-monitoring of INR should be considered for people with atrial fibrillation receiving
long-term anticoagulation, if they prefer this form of testing and if the following criteria are met:
l the patient (or a designated carer) is both physically and cognitively able to perform the
self-monitoring test
l an adequate supportive educational programme is in place to train participants and/or carers
l the patient’s ability to self-manage is regularly reviewed
l the equipment for self-monitoring is regularly checked via a quality control programme.
Comparators
In UK clinical practice, INR monitoring is currently managed by a range of health-care professionals,
including nurses, pharmacists and GPs. INR monitoring can be carried out in primary care and secondary
care. Primary care anticoagulant clinics use point-of-care tests or laboratory analysers. In the latter, blood
samples are sent to a central laboratory based at a hospital (‘shared provision’). In the case of secondary
care, INR monitoring can be carried out in hospital-based anticoagulant clinics using point-of-care tests or
laboratory analysers.
Care pathways
The clinical population considered for the purpose of this assessment includes people with atrial fibrillation
or heart valve disease for whom long-term vitamin K antagonist therapy is intended. According to the
NICE clinical guideline on atrial fibrillation and the Scottish Intercollegiate Guidelines Network clinical
guideline on antithrombotics,24,25 the most effective treatment considered for the treatment of atrial
fibrillation is dose-adjusted warfarin, the most common vitamin K antagonist drug. Lifelong anticoagulation
therapy with warfarin is also recommended in all people after artificial valve replacement.26 Warfarin,
especially if taken incorrectly, can cause severe bleeding (haemorrhages). Therefore, it is necessary to
ensure that people taking warfarin have ongoing monitoring of their blood coaguability.
The routine monitoring of blood coagulation can take several configurations. The NICE anticoagulation
commissioning guide1 states that UK anticoagulation therapy services can be delivered in a number of
different ways, and that mixed models of provision may be required across a local health economy. This
could include full service provision in primary or secondary care, shared provision, domiciliary provision or
self-management.
This assessment focuses on the role of point-of-care tests (for the self-monitoring of INR by people at
home) as an alternative to standard UK anticoagulation care.
Outcomes
Outcomes of interest for this review were as follows.
Clinical outcomes
l Frequency of bleeds or blood clots.
l Morbidity (e.g. thromboembolic and cerebrovascular events) and mortality from INR testing and
vitamin K antagonist therapy.
l Adverse events from INR testing, false test results, vitamin K antagonist therapy and sequelae.
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Patient-reported outcomes
l People‘s anxiety associated with waiting time for results and not knowing their current coagulation
status and risk.
l Acceptability of the tests.
l Health-related quality of life.
Intermediate outcomes
l Time and values in therapeutic range.
l INR values.
l Test failure rate.
l Time to receive test result.
l Patient compliance with testing and treatment.
l Frequency of testing.
l Frequency of visits to primary or secondary care clinics.
Overall aim and objectives of this assessment
The aim of this assessment was to appraise the current evidence for the clinical effectiveness and
cost-effectiveness of self-monitoring (self-testing and self-management) using CoaguChek, INRatio2 PT/INR
monitor and ProTime Microcoagulation system point-of-care devices, compared with standard monitoring,
in people with atrial fibrillation or heart valve disease receiving long-term vitamin K antagonist therapy.
The specific objectives of this assessment were to:
1. systematically review evidence on the clinical-effectiveness of self-monitoring (self-testing and
self-management) using CoaguChek, INRatio2 PT/INR monitor and ProTime Microcoagulation system
point-of-care devices, compared with standard monitoring practice, in people receiving long-term
vitamin K antagonist therapy
2. systematically review existing economic evaluations on self-monitoring technologies for people receiving
long-term vitamin K antagonist therapy
3. develop a de novo economic model to assess the cost-effectiveness of both self-testing and
self-management (using CoaguChek XS system, INRatio2 PT/INR monitor and ProTime Microcoagulation
system as self-monitoring technologies) versus standard monitoring practice in people receiving
long-term vitamin K antagonist therapy.
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Chapter 2 Assessment of clinical effectiveness
Methods for standard systematic review of
clinical effectiveness
An objective synthesis of the evidence for the clinical effectiveness of self-monitoring in people receiving
long-term vitamin K antagonist therapy using either CoaguChek system, INRatio2 PT/INR monitor or ProTime
Microcoagulation system compared with current standard monitoring practice has been conducted. The
evidence synthesis has been carried out according to the general principles of the Centre for Reviews and
Dissemination guidance for conducting reviews in health care,27 the recommendations of the Cochrane
Handbook for Systematic Reviews of Interventions28 and the indications of the NICE Diagnostics Assessment
Programme Manual.29 Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations
were followed for reporting.30
Identification of studies
Comprehensive electronic searches were undertaken to identify relevant reports of published studies.
Highly sensitive search strategies were designed using both appropriate subject headings and relevant
text word terms, to retrieve randomised controlled trials (RCTs) evaluating the point-of-care tests under
consideration for the self-monitoring of anticoagulation therapy. A 2007 systematic review with similar
objectives to those of the current assessment was identified in The Cochrane Library.31 As extensive literature
searches had already been undertaken for the preparation of this systematic review, the literature searches
for the current assessment were run in May 2013 for the period ‘2007 to date’ to identify newly published
reports. All RCTs included in the Cochrane review were obtained and included for full-text assessment.
Searches were restricted to publications in English. MEDLINE, MEDLINE In Process & Other Non-Indexed
Citations, EMBASE, Bioscience Information Service, Science Citation Index and Cochrane Central Register of
Controlled Trials (CENTRAL) were searched for primary studies, while the Cochrane Database of Systematic
Reviews, the Database of Abstracts of Reviews of Effects and the Health Technology Assessment (HTA)
database were searched for reports of evidence syntheses.
Reference lists of all included studies were perused in order to identify additional potentially relevant
reports. The expert panel provided details of any additional potentially relevant reports.
Searches for recent conference abstracts (2011–13) were also undertaken and included the annual
conferences of the American Society of Haematology, the European Haematology Association and the
International Society on Thrombosis and Haemostasis, as well as the proceedings of the 12th National
Conference on Anticoagulant Therapy. Ongoing studies were identified through searching Current
Controlled Trials, Clinical Trials, World Health Organization, International Clinical Trials Registry and
NationaI Institutes of Health Reporter. Websites of professional organisations and health technology agencies
were checked to identify additional reports. Full details of the search strategies used are presented in
Appendix 1.
Inclusion and exclusion criteria
The initial scoping searches performed for this assessment identified a Cochrane review31 and a few
technology assessment reports21,32,33 assessing different models of managing OAT. These publications
focused on several RCTs, which reported relevant clinical outcomes. In particular, the Cochrane review
included both the CoaguChek S and the CoaguChek XS devices. The CoaguChek XS system is
the upgraded version of CoaguChek S and uses the same technology as its precursor. Details of the
performance of the two CoaguChek models compared with standard INR monitoring are provided below
(see Performance of point-of-care devices).
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The studies fulfilling the following criteria were included in this assessment.
Population
People with atrial fibrillation or heart valve disease for whom long-term vitamin K antagonist therapy
was required.
Setting
Self-INR monitoring supervised by primary or secondary care.
Interventions
The point-of-care devices considered in this assessment were:
l CoaguChek system
l INRatio2 PT/INR monitor
l ProTime Microcoagulation system.
Comparators
The comparator considered in this assessment was standard practice, which consisted of INR monitoring
managed by health-care professionals. INR monitoring can be carried out in primary care, in secondary care
or in a ‘shared provision’ setting:
l Primary care: INR monitoring can be carried out in primary care anticoagulant clinics using
point-of-care tests or laboratory analysers. In the latter, blood samples are sent to a central laboratory
based at a hospital (shared provision).
l Secondary care: INR monitoring can be carried out in hospital-based anticoagulant clinics using
point-of-care tests or laboratory analysers.
Outcomes
The following outcomes were considered.
Clinical outcomes
l Frequency of bleeds or blood clots.
l Morbidity (e.g. thromboembolic and cerebrovascular events) and mortality from INR testing and
vitamin K antagonist therapy.
l Adverse events from INR testing, false test results, vitamin K antagonist therapy and sequelae.
Patient-reported outcomes
l People’s anxiety associated with waiting time for results and not knowing their current coagulation
status and risk.
l Acceptability of the tests.
l Health-related quality of life.
Intermediate outcomes
l Time and INR values in therapeutic range.
l Test failure rate.
l Time to receive test result.
l Patient compliance with testing and treatment.
l Frequency of testing.
l Frequency of visits to primary or secondary care clinics.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Study design
We identified relevant RCTs assessing the effectiveness of the CoaguChek system, the INRatio2 PT/INR
monitor and the ProTime Microcoagulation system. Therefore, non-randomised studies (including
observational studies) were not considered for this assessment. Systematic reviews were used as source
for identifying additional relevant studies.
Studies were excluded if they did not meet the prespecified inclusion criteria, and, in particular, the
following types of report were not deemed suitable for inclusion:
l biological studies
l reviews, editorials and opinions
l case reports
l non-English-language reports
l conference abstracts published before 2012.
Data extraction strategy
Two reviewers (PS and MB) independently screened the titles and abstracts of all citations identified by
the search strategies. Full-text copies of all studies deemed to be potentially relevant were obtained and
assessed independently by two reviewers for inclusion (PS and MC). Any disagreements were resolved
by discussion or arbitration by a third reviewer (MB).
A data extraction form was designed and piloted for the purpose of this assessment (see Appendix 2).
One reviewer (PS) extracted information on study design, characteristics of participants, settings,
characteristics of interventions and comparators, and relevant outcome measures. A second reviewer (MC)
cross-checked the details extracted by the first reviewer. There was no disagreement between reviewers.
Assessment of risk of bias in included studies
A single reviewer (PS) assessed the risk of bias of the included studies and findings were cross-checked by
a second reviewer (MC). There were a few disagreements which were resolved by consensus or arbitration
by a third reviewer (MB). The reviewers were not blinded to the names of studies’ investigators, institutions
and journals. Studies were not included or excluded purely on the basis of their methodological quality.
The risk of bias assessment for all included RCTs was performed using the Cochrane risk of bias tool
(see Appendix 3).28 Critical assessments were made separately for all main domains: selection bias
(‘random sequence generation’, ‘allocation concealment’), detection bias (‘blinding of outcome assessor’),
attrition bias (‘incomplete outcome data’) and reporting bias (‘selective reporting’). The ‘blinding of
participants and personnel’ was not considered relevant for this assessment due to the nature of
intervention being studied (i.e. patient performing the test themselves or under supervision of health-care
professionals). However, we collected information related to the blinding of outcome assessors, which was
considered relevant to the assessment of risk of bias.
We judged each included study as ‘low risk of bias’, ‘high risk of bias’ or as ‘unclear risk of bias’ according
to the criteria for making judgments about risk of bias described in the Cochrane Handbook for Systematic
Reviews of Interventions.28 Adequate sequence generation, allocation concealment and blinding of
outcome assessor were identified as key domains for the assessment of the risk of bias of the included trials.
Data analysis
For dichotomous data (e.g. bleeding events, thromboembolic events, mortality), relative risk (RR) was
calculated. For continuous data [e.g. time in therapeutic range (TTR)], weighted mean difference (WMD)
was calculated. Where standard deviations (SDs) were not given, we calculated them using test statistics
wherever possible. The RR and WMD effect sizes were meta-analysed as pooled summary effect sizes using
the Mantel–Haenszel (M–H) method and the inverse-variance (IV) method, respectively. We also calculated
95% confidence intervals (CIs). To estimate the summary effect sizes, both fixed-effect and random-effect
DOI: 10.3310/hta19480 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 48
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
models were used with RR and WMD. In the absence of clinical and/or statistical heterogeneity, the
fixed-effects model was selected as the model of choice, while the random-effects model was used to
cross-check the robustness of the fixed-effects model. However, in the presence of either clinical or
statistical heterogeneity, the random-effects model was chosen as the preferred method for pooling the
effect sizes, as in this latter situation, the fixed-effects method is not considered appropriate for combining
the results of included studies.28 Heterogeneity across studies was measured by means of the chi-squared
statistic and also by the I2 statistic, which describes the percentage of variability in study effects that
is explained by real heterogeneity rather than chance. It is worth noting that, for bleeding and
thromboembolic events, we used the total number of participants who were actually analysed as
denominator in the analyses. In contrast, for mortality, we used the total number of participants randomised
as denominator because participants could have died due to any causes after randomisation but before
entering the self-monitoring programme.
Apart from the prespecified subgroups analysis, according to the type of anticoagulation therapy
management (self-testing and self-management), we performed a post-hoc subgroup analysis according
to the type of the target clinical condition (i.e. atrial fibrillation, heart valve disease and mixed clinical
indication) and one according to the type of service provision for anticoagulation management (i.e. primary
care, secondary care and shared provision). Where trials had multiple arms contributing to different
subgroups, the control group was subdivided into two groups to avoid a unit of analysis error.
Sensitivity analyses were planned in relation to some of the study design characteristics. The
methodological quality (low/high risk of bias) and the different models of the CoaguChek system were
identified at protocol stage as relevant aspects to explore in sensitivity analyses. In addition to those
prespecified in the protocol, we performed a sensitivity analysis by excluding the studies conducted in
the UK.
Review Manager software (Review Manager 5.2, 2012, The Cochrane Collaboration, The Nordic Cochrane
Centre, Copenhagen, Denmark) was used for data management and all relevant statistical analyses for this
assessment. Where it proved unfeasible to perform a quantative synthesis of the results of the included
studies, outcomes were tabulated and described in a narrative way.
Results
Performance of point-of-care devices
A formal evaluation of the performance of the CoaguChek, INRatio and ProTime point-of-care systems
with regard to INR measurement was outside the scope of this assessment. An objective ‘true’ INR remains
to be defined and usually the calculation of INR measurement is based on different assumptions. INR
determined in the laboratory is regarded as the gold standard with which all other measurement methods
should be compared.34 Information on the precision and accuracy of these point-of-care devices was
gathered from the available literature. Normally, the precision or reproducibility of point-of-care devices is
expressed by means of the coefficient of variation (CV) of the variability, while the accuracy is the level of
agreement between the result of one measurement and the true value and is expressed as correlation
coefficient.35 Table 1 summarises the performance of the target point-of-care devices according to the FDA
self-test documentation and relevant published papers.
A systematic review published by Christensen and Larsen in 201235 assessed the precision and accuracy of
current available point-of-care coagulometers including CoaguChek XS, INRatio and ProTime/ProTime3.
The authors found that the precision of CoaguChek XS varied from a CV of 1.4% to one of 5.9% based
on data from 14 studies, while the precision of INRatio and ProTime varied from 5.4% to 8.4% based on
data from six studies. The coefficient of correlation for CoaguChek XS varied from 0.81 to 0.98, while that
for INRatio and ProTime varied from 0.73 to 0.95. They concluded that the precision and accuracy of
point-of-care coagulometers were generally acceptable, compared with conventional laboratory-based
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clinical testing. The same conclusions were drawn by the Canadian Agency for Drugs and Technologies in
Health report published in 2012 on point-of-care testing.41 Similarly, the international guidelines prepared
in 2005 by the International Self-Monitoring Association for oral Anticoagulation stated that ‘Point-of-care
instruments have been tested in a number of different clinical settings and their accuracy and precision are
considered to be more than adequate for the monitoring of OAT in both adults and children’ (p. 40).42
CoaguChek XS versus CoaguChek S
The CoaguChek S monitor was replaced in 2006 by the XS monitor, which offers a number of new
technical features such as the use of a recombinant human thromboplastin with a lower ISI and internal
quality control included on the test strip. The safety and reliability of CoaguChek S and CoaguChek XS
have been demonstrated in several studies in both adults and children.43–50 A number of studies have also
compared the performance of CoaguChek S with that of CoaguChek XS in relation to conventional INR
measurement. Even though a good agreement between the two CoaguChek models and conventional
laboratory-based results has been demonstrated, CoaguChek XS has shown more accurate and precise
results than its precursor in both adults and children, especially for higher INR values (> 3.5).34,36,51–54
Quantity of available evidence
A total of 658 records were retrieved for the assessment of the clinical effectiveness of the point-of-care
tests under investigation. After screening titles and abstracts, 563 were excluded and full-text reports of
120 potentially relevant articles were obtained for further assessment, including 25 full-text papers from
the 18 trials included in the Cochrane systematic review published by Garcia-Alamino and colleagues.31
In total, 26 RCTs (published in 45 papers) met the inclusion criteria and were included in the clinical
effectiveness section of this assessment. Three of the 26 included studies were randomised crossover
trials,32–34 while the remaining studies were parallel-group RCTs.
We based the primary analyses on data from 21 out of the 26 included studies relevant to the
comparisons and outcomes of interest (Table 2 provides further details).
Of these 21 trials which provided data for statistical analyses, 15 trials were the same as those included in
the Cochrane systematic review by Garcia-Alamino and colleagues31 and six were newly identified trials,
published in or after 2008.
Figure 1 shows a flow diagram of the study selection process. The list of 26 included RCTs (and other
linked reports) is given in Appendix 4.
TABLE 1 Summary of point-of-care devices performance data
Device
Precision Accuracy
Mean (SD) INR CV (%)
Correlation (r)Patient Professional Patient Professional
CoaguChek S36 2.42 (0.68) NR NR NR 0.95a
CoaguChek XS37 2.57 (0.13) 2.52 (0.13) 5.13 5.36 0.93
INRatio 238 2.70 (0.153) 2.93 (0.180) 5.68 6.16 0.93
ProTime 339 4.0 (0.19)b NR NR NR 0.95
NR, not reported.
a Medicines and Healthcare Products Agency, 2004.40
b ‘Within day’.
DOI: 10.3310/hta19480 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 48
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
TABLE 2 Studies considered relevant for this assessment but not included in the meta-analyses
Study ID Comparisons
Reason for exclusion from
meta-analyses
Reason for inclusion in
this assessment
Bauman
201055
Compares PSM with PST group
(PST was the usual care provided in
the study context)
Lack of data on SC group where
people received OAT are generally
managed by the primary or
secondary care
Only RCT that reported
acceptability outcomes on
the relevant subgroup of
interventions for children
Gardiner
200545
Compares PST with standard care The data collected by the
participants were not used for the
analysis. Instead, monthly data
collected by the health-care
professionals were used
Reports patient acceptability
of self-testing as secondary
outcome
Gardiner
200656
Compares PST with PSM and then
historically compares the included
subgroups with the standard care
they received for last 6 months
before their enrolment in the study
Lack of randomised data on SC
group where participants receiving
OAT are usually managed by the
primary or secondary care
Provide relevant data on
TTR on the subgroup of
interventions that were
of interest
Hemkens
200857
Compares PSM with standard
laboratory monitoring
Do not provide data on any relevant
clinical outcomes or intermediate
outcomes
Reports patient satisfaction
of self-management as
secondary outcome
Rasmussen
201258
Compares PSM with standard care Do not provide any relevant clinical
outcomes. Data provided for TTR
was in median (25th to 75th
percentile) which was not possible
to be converted into mean (SD)
Provide data on TTR
PSM, patient self-management; PST, patient self-testing; SC, standard care.
658 titles and abstracts identified from
primary searches 
563 excluded because irrelevant
95 papers selected for full-text screening
25 papers (18 RCTs)
from Cochrane review
120 papers selected for full-text screening
75 full-texts paper excluded:
• 25 not RCTs
• 8 not self-management
• 4 self-management dosage
   studies
• 3 not relevant test used
• 25 retained for background
   information
• 10 test accuracy
26 RCTs published in 45 papers were
included in the clinical effectiveness
review (data from 21 RCTs were
included in meta-analyses) 
FIGURE 1 Flow diagram outlining the selection process.
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Number and type of studies excluded
Appendix 5 lists the number of studies excluded after full-text assessment and the reasons for
their exclusion.
Quality of research available
Figure 2 illustrates a summary of the risk of bias assessment for all included studies. The majority of trials
were judged at ‘unclear’ or ‘high’ risk of bias. One trial was only reported in abstract and hence did not
allow for an adequate assessment of the risk of bias.59 Similarly, one trial was discontinued before the end
of the prespecified follow-up due to difficulties in the recruitment process.60 Overall, only four trials were
assessed to have adequate sequence generation, concealed allocation and blinded outcome assessment
and, therefore, were judged at low risk of bias.55,61–63 Three of these trials used either the CoaguChek
model ‘S’61,63 or the model ‘XS’62 for INR measurement, while the other trial used CoaguChek XS to
measure INR in children receiving anticoagulation therapy.55 Appendix 6 provides details of the risk of bias
assessment for each individual study. Main findings of the risk of bias assessment for all included studies
are described in detail below.
Selection bias
Of the 26 included trials, only seven trials reported adequate details on both generation of the
randomisation sequence generation and concealment of allocation.55,57,61–65 In 11 trials, the randomisation
process proved to be adequate but no information was provided on the way in which participants were
allocated to the study interventions.58,60,66–74 One trial75 reported adequate details about the generation of
the random sequence but failed to conceal the allocation of participants to study interventions. In contrast,
another trial76 reported adequate information on allocation concealment but failed to provide details on
the randomisation process. In six trials, both the randomisation process and the allocation concealment
were judged as ‘unclear’ due to the lack of adequate information.45,56,59,77–79
Attrition bias
Seventeen trials were judged to be at low risk of attrition bias. Six of them had limited missing data with
similar reasons for discontinuation across intervention groups.59,69,72,74,76,79 Seven trials relied on an
intention-to-treat approach and all dropouts were fully accounted for in the statistical analyses,55,61,63–65,71,75
while the other four reported no missing data.58,60,62,78 Eight of the 26 included trials were at high risk of
attrition bias, with more than 5% dropout rate and with missing data not appropriately tackled.45,56,57,66–68,73,77
In the Early Self-Controlled Anticoagulation Trial,70 the problem of incomplete outcome data was addressed
for the first 600 participants but not for all included participants.
0
Risk of bias (%)
20 40 60 80 100
Adequate sequence generation
Allocation concealment
Blinding of outcome assessment
Incomplete outcome data addressed
Free of selective reporting
Other sources of bias
Low risk of bias
Unclear risk of bias
High risk of bias
FIGURE 2 Summary of risk of bias of all included studies.
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Performance and detection bias
Owing to the nature of the interventions being studied (use of point-of-care devices), blinding of
participants or personnel was not feasible. Seven trials blinded the outcomes assessor (statistician or clinical
outcome assessor).55,58,61–63,72,77 In six trials, neither the participants nor the personnel involved in delivering
the interventions were blinded.60,65,66,71,74,75 One trial70 was described as ‘double blinded’ but no further
information was given. Another trial68 reported that one of the two standard care groups studied (the
untrained routine group) was blinded. In addition, this trial revealed that the nurses involved in transferring
data on dosing as well as the dosing physicians were blinded. The remaining of the included trials did not
provide information on blinding.
Reporting bias
With the exception of three trials,58,76,79 the outcomes reported in the trials were prespecified in the analysis
section and reporting bias was not obvious in the published papers.
Other sources of biases
No other sources of biases were obvious in the included trials.
Characteristics of the included studies
Table 3 summarises the main characteristics of the 26 included RCTs. The baseline characteristics of all
included trials are described below and tabulated in Appendix 7 (see Tables 31 and 32).
TABLE 3 Summary of the included RCTs
Study characteristics CoaguChek XS
CoaguChek S/
CoaguChek CoaguChek Plus CoaguChek+ INRatio ProTime
Total no. of studies 4 17 1 2 2
Self-monitoring
PSM 2 14 1 1 1
PST 2 2 0 1 1
PSM and PST 0 1 0 0 0
Standard care
AC clinic 4 9 0 2 1
GP/physician 0 4 1 0 1
AC clinic or
GP/physician
0 4 0 0 0
Country
UK 0 6 0 0 0
Non-UK 4 12 1 2 2
Clinical indication
AF only 0 2 0 0 0
AHV only 0 4 1 1 0
Mixed only
(AF+AHV+ others)
4 12 0 1 2
Total sample size 414 3910 1155 222 3062
AC, anticoagulant; AF, atrial fibrillation; AHV, artificial heart valve; PSM, patient self-management; PST, patient self-testing.
AC clinic-SC: in two trials, reporting CoaguChek XS55 and CoaguChek S56 PST within AC clinic was the usual care.
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Study details
The majority of included trials were conducted in Europe: six trials were conducted in Germany,57,59,60,70,72,78
six in the UK,45,56,64,67,69,73 three in Denmark,58,66,75 three in the Netherlands,68,76,79 one in Ireland,62 one
in Austria,63 one in France77 and one in Spain.61 Three trials were conducted in Canada55,65,74 and
one in the USA.71 Of the 26 included trials, seven were multicentred,60,63,64,67,68,71,72 while the remaining 19
were conducted in a single centre.
The length of follow-up ranged from 14 weeks57 to more than 4 years.63,71 Nine trials reported follow-ups
≥ 12 months.55,61,63,64,70,71,73,78,79 One trial, which was originally supposed to run for 2 years, was discontinued
prematurely due to the small number of recruited participants.60
Nine of the included trials were funded independently by professional organisations or national/
governmental agencies55,57–59,64–66,69,75 while 13 trials were fully or partly funded by industry. In the case of
the remaining four trials, the source of funding was not reported.70,76,78,79
Participants
Most of the included trials (15 out of 26) included participants with mixed indications of which atrial
fibrillation, artificial heart valves (AHVs) and venous thromboembolism were the most common clinical
indications,45,55–57,61–63,65,66,68,71,72,74–76 while six trials enrolled exclusively participants with AHVs59,70,73,77–79 and
two trials limited inclusion to participants with atrial fibrillation.60,69 Seven trials provided information on
risk factors, comorbidity, and/or previous bleeding and thromboembolic events but did not report
significant baseline differences between participants in self-monitoring and those in standard care
(see Appendix 7, Table 32).61,63,64,71,72,75,77
The mean sample size among the included trials was 337 participants (range 1639–292,271 participants).
Fifteen trials performed a power analysis and a sample size calculation,58,60–66,68,69,71,72,74–76 two trials, with
very small sample sizes, did not power their studies55,57 and the remaining trials did not provide information
on how the sample size was determined.45,56,59,67,70,73,77–79 The age of adult participants ranged from
16 to 91 years.62 The only trial which assessed children reported a median age of 10 years.55
Warfarin was the choice of vitamin K antagonist therapy in half of the included trials.45,55,56,58,62,64–67,69,71,73,74,78
In seven trials, participants were taking phenprocoumon and/or acenocoumarol and/or fluindione57,61,63,68,72,76,77
and, in one trial, participants received either warfarin or phenprocoumon.75 In the remaining four trials,
the type of vitamin K antagonist therapy was not reported.59,60,70,79 In nearly half of the included trials (12 out
of 26), participants had been on OAT for at least 3 months before randomisation.45,55,56,61,64,66–69,74–76
Three trials included vitamin K antagonist-naive participants for whom long-term OAT was recently indicated
but who had not been on anticoagulation therapy before.58,63,70 In the largest trial, The Home International
Normalised Ratio Study (THINRS),71 randomisation was stratified according to the duration of anticoagulation
but no significant differences were found between participants who had started anticoagulation therapy
within the previous 3 months and those who had received anticoagulation therapy for > 3 months. In the two
remaining trials, the included participants received OAT for< 3 months (1–2 months) before randomisation.62,65
Point-of-care tests used for international normalised ratio measurement
CoaguChek system for INR monitoring was used in 22 of the 26 included trials. Nine trials used the
S model,45,56,58,61,63,64,67,75,78 four used the XS model,55,62,66,74 one70 used the CoaguChek Plus model and
two trials used the first model of the CoaguChek series, which was simply referred to as ‘CoaguChek’.68,72
In six trials, it was unclear whether the CoaguChek device was the first model or its later versions.59,60,69,73,76,79
Either the INRatio or the CoaguChek S was used for INR measurement in two trials (but results were not
separated according to the type of the point-of-care device),57,77 and the ProTime system was used in other
two trials.65,71 In all six trials based in the UK, CoaguChek system (either CoaguChek or version S) was used
for the INR measurement.
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In 11 trials, in order to assure accuracy of the point-of-care devices being used, INR results measured
directly by participants were compared with those measured in a laboratory.45,55–58,64–67,69,77
Eight trials’ investigators who did not specify the model of the CoaguChek device (S or XS) used for INR
measurement were contacted for further details.60,68,69,72,73,76,77,79 Five of the them provided further
information on the model of the CoaguChek point-of-care device.58,68,72,77,79
Standard anticoagulant management
The type of standard care varied across trials. In 13 trials, INR was measured by professionals in
anticoagulant or hospital outpatient clinics,45,57,58,61,62,64,66,68,69,71,74,76,79 by a physician or a GP in a primary
care setting in six trials,59,60,65,67,70,78 and either by a physician/GP in a primary care setting or by
professionals in anticoagulant/outpatient hospital clinics in five trials.63,72,73,75,77 In two trials, comparing
self-testing with self-management,55,56 self-testing within anticoagulant clinics was considered as standard
care. In the majority of the included trials (17 out of 26), the anticoagulant clinic was led by a clinician
(general or specialist),58–61,63,65,66,68–73,75,77–79 by a nurse in five trials, (three conducted in the UK,45,48,64 one in
Canada55 and one in Germany57) and by a pharmacist in two trials, conducted in Canada74 and in Ireland.62
International normalised ratio measurement was carried out in a laboratory in all but two trials, where
CoaguChek S67 or another coagulometer75 was used instead.
Self-monitoring
The majority of the included trials (17 out of 26) compared self-management (participants performed the
test and adjusted the dose of anticoagulation therapy themselves) with standard care,57–61,63–65,67,70,72–76,78,79
six assessed self-testing (participants performed the test themselves with the results managed by
health-care professionals)45,62,66,69,71,77 and one evaluated both self-testing and self-management versus
either trained or untrained routine care (four arms).68 It is worth noting that for the subgroup meta-analysis
according to type of OAT management, this four-arm trial contributed to two studies: one on self-testing
and one on self-management. The two standard care groups (trained and untrained routine care) were
initially combined to produce an overall control group and subsequently subdivided into two groups for
the purpose of the subgroup analysis, which was undertaken to assess the effects of self-testing versus
self-management.
The remaining two trials compared self-testing with self-management (without standard care as a
comparator).55,56 One of these two trials enrolled exclusively a population of children55 while the other provided
a non-randomised comparison of participants in self-testing and self-management with those receiving
standard care for a period of 6 months before study enrolment.56 We deemed these two trials suitable for
inclusion as they provide relevant outcomes for participants in both self-testing and self-management.
In 19 out of 26 included trials, participants received training and education in order to perform self-testing and
self-management (see Appendix 7, Table 33).45,55,56,61,62,64–67,69,72–77,79–81 In most of these trials (11 out of 19), the
training was provided in group sessions which lasted for around 1–2 hours55,61,62,68,69,72,76,77,81 up to a maximum
of 3 hours.73,74 The training was usually administered by a single member of staff, either a nurse, a practitioner/
physician45,56,61,64,69 or a pharmacist.74 In a few trials, the training was provided by a team of professionals,
such as a specialist physician together with paramedical personnel,80 a research pharmacist coupled with an
haematologist62 or a physician assisted by a nurse.63,72 In five trials, the personnel responsible for delivering the
training was reported to be trained specifically on self-testing and self-management.56,61,63,64,72
Clinical effectiveness results
Overview
This section provides evidence from 26 included trials on the clinical effectiveness of self-monitoring using
CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system, compared with
standard practice (see Figures 3–14; Tables 4–6; Appendix 8). For clarity, the results are reported under the
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broad headings of ‘clinical outcomes’, ‘intermediate outcomes’ and ‘patient-reported outcomes’. The
summary effects of relevant clinical outcomes such as bleeding events, thromboembolic events and
mortality have been described separately within the ‘clinical outcomes’ section. Tables 4 and 5 show the
main findings of the five trials conducted in the UK and of the four trials using CoaguChek XS. The results
of the sensitivity analyses for each point-of-care test are displayed in Table 6.
Clinical outcomes
Bleeding
Twenty-one trials reported a total of 1472 major and minor bleeding events involving 8394 participants.59–79
Two trials reported that there were no bleeding events and hence did not contribute to the overall effect
size in the related meta-analysis.66,75 Twenty-one trials reported 476 major bleeding events in a total
of 8202 participants,59–65,67–74,77–79 while 13 trials reported 994 estimable minor bleeding events in a
total of 5425 participants.61,63,64,67,69,71–74,76,77 No statistically significant differences were observed between
self-monitoring participants (self-testing and self-management) and those in standard care for any bleeding
events (RR 0.95, 95% CI 0.74 to 1.21; p= 0.66) (Figure 3), major bleeding events (RR 1.02, 95% CI 0.86 to
1.22; p= 0.80) (Figure 4) and minor bleeding events (RR 0.94, 95% CI 0.65 to 1.34; p= 0.73) (Figure 5).
The results were not affected by the removal of the UK-based trials (see Appendix 8) or by the removal of
the trials assessing ProTime and/or INRatio (see Table 6 and Appendix 8). Similarly, sensitivity analyses
restricted to CoaguChek XS trials demonstrated no differences from the all-trials results (see Table 6 and
Appendix 8). A sensitivity analysis restricted to trials at low risk of bias slightly changed the estimate
of effect but did not significantly impact on the findings (RR 0.59, 95% CI 0.27 to 1.30; p= 0.19)
(see Appendix 8).
The subgroup analysis by type of anticoagulant management therapy did not show any difference between
self-management and standard care for any bleeding events (RR 0.94, 95% CI 0.68 to 1.30; p= 0.69) but
revealed a significant higher risk in self-testing participants than in those receiving standard care (RR 1.15,
95% CI 1.03 to 1.28; p= 0.02) (see Figure 3). When trials assessing ProTime and INRatio were removed
from the analysis, a non-significant trend was observed in favour of self-testing (0.58, 95% CI 0.22 to 1.47;
p= 0.25) (see Table 6 and Appendix 8). No significant differences in the risk of major bleeding were
observed between self-management (RR 1.09, 95% CI 0.81 to 1.46; p= 0.58) and self-testing (RR 0.99,
95% CI 0.80 to 1.23) versus standard care (see Figure 4). When only minor bleeding events were assessed
(see Figure 5), a significant increased risk was observed in self-testing participants (23%), compared with
those in standard care (RR 1.23, 95% CI 1.06 to 1.42; p= 0.005), but not in those who were self-managed
(RR 0.84, 95% CI 0.53 to 1.35; p= 0.47). Two trials enrolled participants with atrial fibrillation, six trials
enrolled participants with AHVs and 13 trials enrolled participants with mixed indication. No statistically
significant subgroup differences were found for bleeding events according to the type of clinical indication
(Figure 6). Similarly, for bleeding events, no significant differences were detected when trials were grouped
according to the type of control care (anticoagulant clinic care RR 0.84, 95% CI 0.50 to 1.42; p= 0.52;
GP/physician RR 1.09, 95% CI 0.79 to 1.50; p= 0.60; mixed care RR 0.94, 95% CI 0.79 to 1.13; p= 0.54)
(Figure 7).
Thromboembolic events
Twenty-one trials reported 351 major and minor thromboembolic events in a total of 8394 participants.59–79
Six of these trials did not contribute to the overall estimate of effect as they reported ‘zero’ events in both
groups.66–69,74,75 Self-monitoring (self-testing and self-management) showed a statistically significant
reduction in the risk of thromboembolic events by 42% (RR 0.58, 95% CI 0.40 to 0.84; p= 0.004),
compared with standard care (Figure 8). The risk reduction further increased to 48% when only major
thromboembolic events were considered (RR 0.52, 95% CI 0.34 to 0.80; p= 0.003) (Figure 9). The risk
of thromboembolic events significantly decreased when the analyses were restricted to non-UK trials
(RR 0.50, 95% CI 0.32 to 0.76; p= 0.001); to CoaguChek trials (RR 0.52, 95% CI 0.38 to 0.71; p< 0.0001);
and to trials at low risk of bias (RR 0.38, 95% CI 0.16 to 0.92; p= 0.03) (see Appendix 8).
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Self-management compared with standard care halved the risk of thromboembolic events (RR 0.51,
95% CI 0.37 to 0.69; p< 0.0001). In contrast, for self-testing participants59,62,71,77 no significant risk
reduction was observed compared with those in standard care (RR 0.99, 95% CI 0.75 to 1.31; p= 0.95)
(see Figure 8). The subgroup difference between self-management and self-testing was statistically
significant (p= 0.002). When trials assessing the ProTime system were removed from the analysis,
the risk reduction increased from 1% to 45% but the summary estimate of effect was not statistically
different from the all-trials summary estimate (RR 0.55, 95% CI 0.13 to 2.31; p= 0.41) (see Table 6 and
Appendix 8). Self-monitoring participants with AHVs showed a significant reduction in the number of
thromboembolic events, compared with those in standard care (RR 0.56, 95% CI 0.38 to 0.82; p= 0.003).
Among participants with mixed clinical indication (atrial fibrillation, AHVs or other conditions), the effect
was larger but not statistically significant than that observed in participants receiving standard care
(RR 0.57, 95% CI 0.30 to 1.09; p= 0.09) (Figure 10). The risk of thromboembolic events reduced in
self-monitoring participants by 55% when routine anticoagulation control was managed by a GP or
physician (RR 0.45, 95% CI 0.29 to 0.68; p= 0.0002). In contrast, even though fewer thromboembolic
events were observed in participants who self-monitored their therapy than in those managed in
specialised anticoagulation clinics (RR 0.65, 95% CI 0.30 to 1.42; p= 0.28) or those in mixed provision
managed by either a physician/GP or a specialist (RR 0.66, 95% CI 0.31 to 1.38; p= 0.27), no significant
subgroup differences were detected (Figure 11).
Mortality
Thirteen trials reported 422 deaths due to all-cause mortality in a total of 6537 participants.61,63,64,66,67,70–75,77,79
Two trials with zero fatal cases did not contribute to the overall estimate of effect.66,74 One trial of 1200
participants70 reported overall mortality data without separating the results for participants self-managed and
for those receiving standard care. We contacted the corresponding author of this trial for further information
but we did not receive any reply. Therefore, for mortality data, for this particular trial, we relied on the
estimates published in the previous meta-analysis by Garcia-Alamino and colleagues31 and in the HTA by
Connock and colleagues,21 which were based on individual patients’ data.
The risk reduction for all-cause mortality was not statistically significant different between self-monitoring
(self-testing and self-management) and standard care (RR 0.83, 95% CI 0.63 to 1.10; p= 0.20) (Figure 12).
The results were not affected by the removal of the UK-based trials or by the removal of trials at high or
unclear risk of bias. When the analysis was restricted to trials that used the CoaguChek system, the
summary estimate for self-monitoring was not different from the all-trials estimate (RR 0.68, 95% CI 0.46
to 1.01, p= 0.06) (see Table 6 and Appendix 8). Two trials reported six deaths out of a total of
932 participants, related to vitamin K antagonist therapy.61,63
Risk of death reduced by 32% through self-management (RR 0.68, 95% CI 0.46 to 1.01; p= 0.06) but
not through self-testing (RR 0.97, 95% CI 0.78 to 1.19; p= 0.74), even though the test for subgroup
differences was not statistically significant (p= 0.13) (see Figure 12). Self-monitoring halved the risk of
mortality in participants with AHVs (RR 0.54, 95% CI 0.32 to 0.92; p= 0.02) but not in those with
mixed clinical indication for AOT (RR 0.95, 95% CI 0.78 to 1.16; p= 0.61) (Figure 13). The subgroup
difference between participants with AHVs and those with mixed indication with regard to the number of
deaths was statistically significant (p= 0.05). No data were available from trials that enrolled participants
with atrial fibrillation. Significantly fewer deaths were recorded among participants who self-monitored
their therapy than among those who were routinely managed by their GP/physician (RR 0.52, 95% CI 0.30
to 0.90; p= 0.02) (Figure 14).
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Heterogeneity among trials
A significant statistical heterogeneity was observed for any bleeding outcomes (I2= 66%, p< 0.0001).
In contrast, there was no statistically significant heterogeneity across trials for thromboembolic outcomes
(I2= 36%, p= 0.08) or for mortality (I2= 11%, p= 0.34). The summary estimates of effect were influenced
considerably by five large trials: Eitz and colleagues,78 Körtke and colleagues,70 Fitzmaurice and colleagues64
and Menéndez-Jándula and colleagues61 for self-management, and Matchar and colleagues71 for
self-testing. The trial by Matchar and colleagues,71 which was the largest trial on self-testing, did not show
any significant difference between self-testing and standard care with regard to the incidence of major
events. Standard care was provided by means of high-quality clinic testing in this trial (a designated,
trained staff responsible for participants’ visits and follow-up; the use of a standard local procedure at each
site for anticoagulation management; and the performance of regular INR testing about once a month).
The estimated effect of self-testing versus standard care in the subgroup analysis was dominated by this
large trial, and, therefore, interpretation of this finding requires caution.
Adverse events
No other adverse events from INR testing, false test results, vitamin K antagonist therapy and sequelae
were reported in the included trials.
Intermediate results
Anticoagulation control: target range
Anticoagulation control can be measured as the time that INR is in the therapeutic range or as INR values
in therapeutic range. Data on INR TTR were available from 18 trials.55,56,58,60–69,71,73–75,77 However, there was
variation in the measures used for reporting TTR. Seven trials comparing self-monitoring with standard care
reported TTR as mean percentage;61,64,65,69,71,74,77 three as median percentage,58,62,75 five as overall
percentage63,66–68,73 and one as cumulative number of days.60 The two remaining trials, which compared
patient self-management with patient self-testing, reported the TTR as mean percentage time (one trial)55
and overall percentage time (the other trial).56 It proved impossible to convert median values into mean
values due to the lack of information on the maximum or minimum value required by the conversion
formula. Therefore, we were unable to pool the TTR results from the 18 trials which provided this
information. The results of these trials are shown in Table 7.
Time in therapeutic range ranged from 52%58 to 80%66,74 for self-monitoring and from 55%58 to 77%67
for standard care. In all but three trials,58,61,67 TTR was higher in self-monitoring participants than in
those receiving standard care and, in five of these trials, the difference between intervention groups was
statistically significant.62,66,71,73,77 Three of the UK-based trials reported no significant differences between
self-monitoring and standard care.64,67,69 Pooling of results was possible for 10 trials that provided suitable
data.61,64–69,71,74,77 No statistically significant differences were found between self-management and standard
care (RR 0.47, 95% CI –1.40 to 2.34; p= 0.62). A modest but significantly higher proportion of TTR was,
however, found for participants assigned to self-testing than for those in control care (WMD 4.44,
95% CI 1.71 to 7.18; p= 0.001) (Figure 15). It is worth noting that the overall estimate of effect was
dominated by the largest included trial on self-testing, THINRS.71 In two trials, one using CoaguChek XS66
and the other using ProTime,71 the WMD between self-testing and standard care for TTR was significantly
higher, indicating better anticoagulation control among self-testing participants.
The INR values in therapeutic range were reported in 12 trials.59–61,64,66–68,70,72,76,78,79 There was great variation
between trials in the measures used to assess INR values in therapeutic range and, therefore, the pooling
of data across trials proved unfeasible. In eight trials which reported the proportion of INR measurements
in the therapeutic range,59,60,66–68,70,76,78 the values ranged from 43.2%59 to 80.8%66 for self-monitoring and
from 22.3%59 to 72%67 for standard care. In four trials that reported the proportion of participants in the
therapeutic range instead,61,64,72,79 the values ranged from 53%72 to 72.9%79 for self-monitoring and from
43.2%79 to 72%64 for standard care. With the exception of two UK-based trials,64,67 all trials reported
higher proportion of INR measurements or larger proportions of participants in therapeutic range for
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self-monitoring than for standard care. Significant differences between interventions were detected in
six of these trials.60,61,66,70,78,79 The INR values in therapeutic range are summarised in Table 7.
Among participants with AHVs, self-monitoring resulted in a significantly higher INR TTR73,77 or INR values
in therapeutic range59,70,78,79 than standard care. In two trials that included participants with atrial
fibrillation,60,69 no TTR differences were found between self-monitoring and standard care.
Test failure rate
Only one trial45 reported one instrument defect and one test strip problem in the self-testing group.
No other failures were mentioned in the remaining included trials.
Time to receive test result
One trial74 reported the time for each INR monitoring (i.e. time from INR measurement to test results)
and the total time spent for anticoagulant management during the 4-month follow-up period. The time
spent for each INR monitoring by self-managed participants was significantly lower (mean 5.3 minutes,
SD 2.6 minutes) than the time spent by participants receiving standard care (mean 158 minutes,
SD 67.8 minutes; p< 0.001). During the 4-month follow-up, the total time spent for anticoagulation
monitoring by participants in standard care was significantly higher (mean 614.9 minutes, SD 308.8
minutes) than the total time spent by participants who self-managed their therapy (mean 99.6 minutes,
SD 46.1 minutes; p< 0.0001).
Patient compliance with testing
Gardiner and colleagues45 reported > 98% compliance with self-testing and stated that participants were
conscientious in performing and recording their weekly tests. Of those who did not comply with self-testing,
two had difficulties performing the test or experienced disruption due to hospitalisation and one lost the
CoaguChek meter. In the trial by Khan and colleagues,69 75% (30 out of 40) of participants did not
report any problems with the use of the device and expressed willingness to continue with self-monitoring.
On the other hand, participants who did not comply (25%) with the testing procedure reported difficulties
with the technique or problems placing the fingertip blood drop on the right position on the test strip.
This resulted in the need to use multiple strips to achieve a single reading.
Frequency of testing
Even though the frequency of self-testing was preplanned in 18 of the included trials,45,56,59,62–69,71–77 only
10 trials eventually reported it.59,62–68,71,76 The frequency of self-testing ranged on average (mean) from
every 4.6 days62 to every 12.4 days64 (Table 8).
Frequency of visits to primary or secondary care clinics
Frequency of visits to clinics was reported by 12 trials. Three trials reported three visits in approximately
6 months;62,69,72 five trials reported four visits per year;59,64,67,71,79 three trials reported two visits per
year;63,66,78 and the remaining trial73 reported that there were no routine clinic visits during the study
period (see Table 8).
Adherence to the self-monitoring
Generally, adherence to the self-monitoring was reported to be high in the included trials. In 13 trials,
> 90% of the participants completed self-monitoring,58,59,61–63,66,69,71,72,74–76,79 while in another nine trials the
dropout rates ranged from 12% to 25% (see Table 8).45,55–57,64,65,67,73,77 Few trials also provided information
on the number of people who were excluded during the recruitment phase because they were incapable
of performing self-monitoring.45,56,61,67,71,73,77,80 It is worth noting that up to 50% of the participants were
deemed unsuitable for inclusion. Main reasons for exclusion were old age, anxiety, lack of confidence,
inadequate cognitive abilities and poor dexterity.
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Patient-reported outcomes
People’s anxiety associated with waiting time for results and with not
knowing their current coagulation status and related risk
The trial by Bauman and colleagues,55 which compared self-management with self-testing in children,
reported that one parent (single parent of a 16-year-old male child) did not favour self-management
because of the increased anxiety related to INR measurements.
Preference and acceptability of the tests
Four trials45,55,57,62 conducted a questionnaire survey to assess acceptability to participants of self-testing and
self-management using point-of-care devices (Table 9). These trials reported high rates of acceptance for
both self-management and self-testing (77% to 98%).45,55,57,62 Two trials45,62 reported that 77% to 98% of
participants favoured self-testing with CoaguChek S over standard care.
Another crossover trial57 reported that 93% of participants rated their satisfaction with regard to
self-monitoring (using either INRatio or CoaguChek S) as high or good. When asked about the overall
relative satisfaction with the device, 43% of participants favoured INRatio, 36% favoured CoaguChek S,
and 21% liked both devices equally. The trial by Bauman and colleagues,55 which assessed self-management
over self-testing (usual care in this trial) in children, reported that the majority of participants (13 out of
14 participating families: 92%) opted for the use of CoaguChek XS device.
TABLE 9 Acceptability of the tests
Study ID Method Results
Gardiner
2005:45 PST
Participants in the self-testing group completed
a patient acceptability questionnaire after
3–4 months. The acceptability questionnaire
included patients’ views on ease of use of
CoaguChek S, frequency of repeated tests,
difficulty of getting an adequate sample, ease
of the use of QC materials, confidence in
the result and preference for home testing
vs. hospital testing
84% initially found it difficult to obtain an
adequate sample
55% subsequently found self-testing very easy
32% found self-testing easy
One patient found it difficult to use CoaguChek S
16% were still experienced difficulty in obtaining
sample
87% felt confidence in CoaguChek result they
obtained
77% preferred self-testing to attending the
anticoagulant clinic
Hemkens
2008:57 PSM
Participants completed a structured questionnaire
regarding the ease of use of the point-of-care
device
Satisfaction with point-of-care testing:
92% rated satisfaction with INRatio high or good;
86% rated satisfaction with CoaguChek S high or
good
Satisfaction with self-management:
93% rated satisfaction with self-management
high or good
Ease of use of point-of-care:
62% preferred INRatio and 23% CoaguChek S
Overall satisfaction with point-of-care:
43% preferred INRatio and 36% preferred
CoaguChek S; 21% reported no difference
between the two tests
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TABLE 9 Acceptability of the tests (continued )
Study ID Method Results
Ryan
2009:62 PST
One hundred and seventeen participants (88.63%)
completed the satisfaction survey
99.1% found the point-of-care monitor easy to
use
Most participants (figure not reported) felt
confident with the results they obtained
All participants (100%) agreed that the CoagCare®
questions and dosing instructions were clear and
easy to understand
87.6% felt that they were monitored more closely
by the pharmacist during the supervised PST arm of
the study
94.7% felt that their INR was better controlled
98.3% preferred supervised PST over attendance in
the AMS
Bauman
2010:55 PSM
Open-ended questionnaires (as a platform for
semistructured interviews) and semistructured
interviews were given. A conventional content
analysis approach was taken to interpret the
semistructured interviews
Except for one, all families preferred PSM.
Responses to PSM by participants were:
At first I didn’t think I would want to.
I thought I would want the protection of the
VPaT program but it worked out well
I like self-management better
Made us more aware of why we were
changing warfarin dosing and testing
more often
Inspires co-operation between
family members
Shared responsibility for managing health
More involved
Makes things simpler
Less stress
AMS, anticoagulation management service; PSM, patient self-management; PST, patient self-testing; QC, quality control;
VPaT, vascular patency and thrombosis.
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Health-related quality of life
Nine trials55,67–69,71,72,74,76,79 reported on health-related quality-of-life outcomes using one of the following measures:
1. Sawicki’s tool:68,72,74,76 a structured questionnaire containing 32 questions developed and validated by
Sawicki and colleagues.72 The questionnaire covered five treatment-related aspects: ‘general treatment
satisfaction’, ‘self-efficacy’, ‘daily hassles’, ‘distress’ and ‘strained social network’. The questions were
derived from the sentences formulated by the participants receiving anticoagulation describing their
feelings with regard to their treatment. Each item is graded on a scale ranging from a minimum of
1 (total disagreement) to a maximum of 6 (total agreement) as self-perceived by participants. Higher
scores for self-efficacy and general treatment satisfaction and lower scores for daily hassles,
psychological distress and strained social network are indicative of better quality of life.
2. Short Form questionnaire-36 items (SF-36) [UK Short Form Health Survey (UKSF-36),
SF-36v2]:69,79 SF-36 is a validated tool containing 36 items for the assessment of the health status
and quality of life. SF-36 covered physical functioning, physical role limitation, bodily pain, general
health perceptions, vitality, social functioning, emotional role limitation and mental health. UK SF-36
and the SF-36v2 questionnaire have been reported here.
3. Euroqol scores [European Quality of Life-5 Dimensions (EQ-5D)]:69 EQ-5D is a validated tool for
assessing health status and quality of life.
4. Lancaster’s instrument:67,69 Lancaster’s instrument is designed to measure health beliefs specific to the
use of warfarin in anticoagulant treatment.
5. Duke Anticoagulation Satisfaction Scale:71 Duke Anticoagulation Satisfaction Scale measures patient
satisfaction with anticoagulation. Scores on this scale range from 25 to 225, with lower scores
indicating higher satisfaction.
6. Health Utilities Index Mark 3 (HUI Mark 3):71 HUI Mark 3 is a tool to measure quality of life. Scores
for the HUI Mark 3 range from −0.36 to 1.00, with a negative score indicating a state worse than
being dead and a score of 1.00 indicating perfect health.
7. Schedule for Evaluation of Individual Quality of Life (SEIQoL) tool:67 SEIQoL is a semistructured
interview for the assessment of quality of life.
8. KIDCLOT-PAC-QL: KIDCLOT-PAC Parent-proxy QL© (parents’ quality of life and their assessment of the
child’s quality of life) and KIDCLOT-PAC Child-teen QL©.55
Four trials reported quality of life using Sawicki’s questionnaire (Table 10).68,72,74,76 Sawicki and colleagues72 and
Verret and colleagues74 reported improvements in treatment satisfaction and self-efficacy, and reduced level
of distress and daily hassles in both the self-management and the standard care groups, but the improvements
were significantly greater among participants self-managed. Similarly, Cromheecke and colleagues76 showed
significant improvements in treatment satisfaction and self-efficacy, and significant reductions in level of distress
and daily hassles for self-management participants, compared with those in standard care. Gadisseur and
colleagues68 showed increased treatment satisfaction and self-efficacy, and reduced level of distress and daily
hassles among self-monitoring participants (self-testing or self-management). On the other hand, they found
an increased level of distress among participants who received education but did not directly monitor their
anticoagulation therapy.
Two UK-based trials did not find significant differences in quality-of-life outcomes between self-management
and self-testing participants, compared with those receiving standard care (Table 11).67,69 Khan and colleagues69
reported quality-of-life data using the UK SF-36, the Euroqol scores and Lancaster’s instrument. No significant
differences were observed between self-testing participants and those who received education but did not
test themselves, for both the UK SF-36 parameters and the Euroqol scores. Emotional function was the only
parameter that showed a significant change at 24 weeks compared with baseline (p= 0.04). Fitzmaurice
and colleagues67 assessed participants’ attitude towards self-management and quality-of-life outcomes
through a semistructured interview given to a random sample of 16 participants (eight in self-management
and eight in standard care). Assessed themes were adapted from Lancaster’s instrument, the SEIQoL tool and
a series of focus groups. Five common themes emerged from the interviews conducted on participants in
self-management: knowledge and management of condition, and self-empowerment, increased anxiety and
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TABLE 11 Quality of life measured using SF-36
Study ID
Mean (SD) at 24 weeks
PST Control p-value
UK SF-36, Euroqol scores and Lancaster instrumenta
Khan 200469
Physical functioning 57 (29) 53 (29) NS
Physical role limitation 45 (44) 52 (42) NR
Bodily pain 65 (34) 65 (31) NS
General health perceptions 53 (23) 56 (21) NR
Vitality 53 (23) 52 (21) NR
Social functioning 71 (32) 72 (28) NS
Emotional role limitation 63 (42) 63 (46) NS
Mental health 78 (18) 76 (20) NS
EQ-5D score 0.75 (0.27) 0.7 (0.29) NR
Euroqol percentage 67 66 NR
Study ID
Mean % at 12 months’ follow-up
PSM Control p-value
SF-36v2 questionnaire
Soliman Hamad 200979
Physical functioning 13.2 15.8 NS
Role physical 27.4 28.3 NS
Bodily pain 7.3 –2.0 0.02
General health 13.4 9.9 NS
Vitality 25.9 17.6 0.01
Social functioning 13.3 10.8 NS
Role emotional 20 12.1 0.03
Mental health 14.2 9.2 NS
Physical component summary 20.9 9.8 0.03
Mental component summary 13.7 9.1 NS
NR, not reported; NS, not significant.
a Researchers interviewing were blinded.
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obsession with health, self-efficacy, relationship with health professionals, and societal and economic cost.
The trial investigators did not find any significant difference in quality of life between participants self-managed
and those in standard care. Soliman Hamad and colleagues79 measured quality of life in participants with
AHVs in the Netherlands by means of the SF-36v2. Significant improvements in quality-of-life scores were
observed in participants who self-managed their therapy, compared with those in standard care, with regard
to the physical component summary only (see Table 11).
Matchar and colleagues71 measured quality of life by means of the HUI Mark 3. They reported significant
gain in health utilities at the 2-year follow up among self-testing participants who used ProTime, compared
with those managed in high-quality anticoagulant clinics (p< 0.001). The same investigators71 also
measured anticoagulant satisfaction using the Duke Anticoagulation Satisfaction Scale. They found that
the degree of satisfaction was higher in self-testing participants than in those in standard care (p= 0.002).
Bauman and colleagues55 assessed self-management versus self-testing in children and provided
quality-of-life data using the KIDCLOT-PAC Parent-proxy QL© (parents’ quality of life and their assessment
of the child’s quality of life) and the KIDCLOT-PAC Child-teen QL©.
Both tools were completed pre and post intervention to assess potential changes in quality-of-life
outcomes related to warfarin use. The five common themes identified from the open-ended questionnaires
and the semistructured interviews were awareness, communication, relationship between parent and child,
flexibility and anxiety. No significant changes in ‘tasks’ related to warfarin use were found between
intervention groups.
Summary of the clinical effectiveness results
The evidence of the clinical effectiveness of self-monitoring (self-management and self-testing) of the
coagulation status in people receiving vitamin K antagonist therapy compared with standard care
was based on the findings of 26 RCTs. Four trials reported on CoaguChek XS (n= 414), 17 trials on
CoaguChek S/CoaguChek (n= 3910), one on CoaguChek Plus (n= 1155), two on CoaguChek and INRatio
(n= 222) and two on ProTime (n= 3062). No trials that exclusively assessed the clinical effectiveness of
INRatio were identified by this assessment. The main results are summarised below:
l Self-monitoring of anticoagulation therapy showed better control over thromboembolic events
than standard care. No significant reductions were found in the number of bleeding events and
all-cause mortality.
l In participants with AHVs, self-monitoring almost halved the risk of thromboembolic events and
all-cause mortality compared with standard care. No differences were observed between intervention
groups with regard to the number of bleeding events.
l Self-monitoring significantly reduced the risk of thromboembolic events, while self-testing did not.
l TTR varied from 52% to 80% among self-monitoring participants and from 55% to 77% in standard
care. Self-testing showed a modest but significantly higher percentage of TTR than in standard care.
No significant differences were observed between self-management and standard care. UK-based trials
did not find significant differences in the TTR between intervention groups.
l 77% to 93% of participants expressed a preference for self-monitoring (using CoaguChek or INRatio)
over standard care.
l Two UK-based trials did not find significant differences in quality-of-life outcomes between
intervention groups.
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Chapter 3 Assessment of cost-effectiveness
We assessed the cost-effectiveness of self-monitoring (self-testing and self-management) usingCoaguChek system and alternative point-of-care testing devices compared with standard monitoring
care in people receiving long-term vitamin K antagonist therapy.
Systematic review of existing cost-effectiveness evidence
Initial scoping searches revealed a number of previous systematic reviews of economic studies evaluating
point-of-care testing devices for people receiving long-term vitamin K antagonist therapy.21,32 Further systematic
searches of MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Science Citation Index,
Health Management Information Consortium, NHS Economic Evaluation Database and the HTA databases
were undertaken to identify any further relevant studies. The search strategies are detailed in Appendix 1.
The searches identified 12 economic evaluations of potential relevance to the scope of this assessment.
All of these evaluations comparing INR self-monitoring strategies with standard care were appraised
against the NICE reference case, and the methods and findings of each study are summarised briefly
below in a narrative fashion and tabulated for comparison in Table 12. The studies were assessed against
the NICE reference case and their relevance to the scope is shown in Table 13.
Critique of the included studies
Taborski 199982
This German study assessed the cost-effectiveness of patient self-management versus anticoagulation
clinic-based management by a family physician or specialist. The study included costs relevant to the
primary cost carrier: in this case, the government-controlled health insurance fund. Information regarding
the costs of self-management and clinic management, and the costs of acute treatment and rehabilitation
for complications were acquired from patients and published literature. Quality of life was not considered
in the analysis. When costs of complications were included in the analysis, self-management was
estimated to be less costly and more effective than clinic-managed care – owing to its estimated impact
on the incidence of both thromboembolic and bleeding events. However, the estimated effects of
self-management on these adverse events were selected from a small number of studies reporting high
baseline rates and large beneficial effects of self-management.
Lafata 200083
This study, carried out in the USA, constructed a Markov model with a 5-year time horizon to examine the
cost-effectiveness of three anticoagulation management strategies: usual care with a family physician
(without a point-of-care monitoring device), anticoagulation clinic testing with a point-of-care monitor,
and patient self-testing with a point-of-care monitor. The self-testing strategy required participants to
telephone their anticoagulation clinic for dosing instructions. For each strategy it was assumed that the
time within, above and below the therapeutic range differed and that time out of the target range
influenced the risk of complications. Time in range was modelled to be highest for self-testing, followed
by point-of-care anticoagulation clinic testing, followed by usual care. The actual estimates were based on
a number of cohort studies and clinical trials, but these did not appear to be systematically identified.
The Markov model parameter values were estimated from available literature, routine health service data,
and expert opinion where necessary. The analysis was conducted for a hypothetical cohort of participants,
aged 57 years, initiating long-term warfarin therapy. Both a health service provider (direct medical care
costs only) and a wider societal perspective (including costs incurred by participants and their caregivers)
were adopted. The patient self-testing strategy assumed the highest number of annual tests (n= 52),
compared with anticoagulation clinic testing (n= 23) and usual care (n= 14). The 5-year direct health
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service costs (per 100 participants) were higher for the self-testing strategy ($526,014) than for usual care
($419,514) or anticoagulation clinic testing ($405,560). However, when patient and caregiver costs were
included, self-testing accumulated lower 5-year costs than anticoagulation clinic testing ($622,727 vs.
$645,671). From the health service provider perspective, anticoagulation clinic testing with a point-of-care
monitor was considered the most favourable strategy. When patient and caregiver costs were included,
self-testing dominated point-of-care anticogulation clinic testing, but remained more costly and more
effective than usual care.
A number of one-way sensitivity analyses were conducted to test key parameter and structural
assumptions in the model. Model findings were found to be most sensitive to assumptions regarding the
frequency of yearly tests and time spent in the therapeutic range with the different strategies. Given that
the setting of this study was the USA, the results cannot be generalised to the UK.
Muller 200184
This economic analysis was conducted to assess the cost-effectiveness of patient self-management
compared with standard family physician-managed anticoagulation monitoring in people following a
mechanical heart valve replacement. The focus was on preventing coagulation-related complications.
The incidence of stroke was estimated for a hypothetical cohort of 10,000 patients from the German
Experience with Low Intensity Anticoagulation (GELIA) study.89 Data from the USA, adapted to German
standards, were used to inform lifetime costs of stroke. The study assumed that self-management would
reduce the incidence of severe complications by 30%, compared with family physician-managed care.
The incremental cost-effectiveness ratio (ICER) was estimated to be Deutsche Mark (DM) 105,000 per
life-year gained for self-management versus physician-managed care. The authors concluded that PSM may
reduce the incidence of fatal strokes at an acceptable ICER.
Sola-Morales 200385
This evaluation was published in Catalan by the Catalan Agency for HTA. It was assessed partially based
on a summary in a previous review21 and using a web-based translation interface to translate key passages.
The study compared several strategies including standard laboratory testing, patient self-management,
patient self-testing, point-of-care monitoring by a GP and point-of-care monitoring in a hospital setting.
A Markov model was constructed with a 5-year time horizon. Data to populate the model were acquired
from a systematic literature review. The study assumed a higher incidence of adverse clinical outcomes for
usual care than for those strategies utilising a point-of-care monitoring device. It was assumed that all
strategies involving the use of a point-of-care monitor had equivalent effects. Based on these assumptions,
the results indicated that, from a health insurer perspective, the use of point-of-care monitors in a hospital
setting was the preferred option on grounds of cost-effectiveness. However, it was not clear what the
relative cost-differences were between the monitoring strategies.
Jowett 200687
This cost–utility analysis was conducted alongside the largest UK-based RCT of patient self-management
versus standard primary or secondary care INR monitoring. The follow-up period was 12 months.
The analysis relied on individual patient-level cost and utility data (derived from responses to the EQ-5D),
collected alongside the RCT.
The cost-effectiveness of patient self-management (average 30 tests per year with CoaguChek S) versus usual
clinic management (average 10 tests per year at a combination of hospital and primary care clinics) was
estimated from the perspective of the NHS and also from a wider perspective incorporating patient costs.
The trial recruited 617 participants receiving long-term anticoagulation. Quality-adjusted life-years (QALYs)
were derived from participant responses to the EQ-5D at baseline, 6 weeks and 6 months. Multiple
imputations were used to replace missing EQ-5D data and a regression-based approach was used to estimate
incremental QALYs associated with self-management.
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Costs for patient self-management included training and assessment costs, device and testing
strip costs, costs of any telephone calls relating to INR or device queries, and costs associated with
any adverse events. Costs of standard care clinic monitoring visits were estimated for the various types
of standard care on offer (from a sample of participating centres) and applied on a per-visit basis.
Costs associated adverse events were taken from the NHS reference cost. Wider patient costs included
out-of pocket travel costs and the value of time lost from work to attend appointments.
Based on intention to treat, the results indicated that from both the health service and the wider
perspective, mean costs in the patient self-management arm were significantly higher than those in the
usual care arm (+£294 and +£282.93). There was a very small, non-significant increase in QALYs in
the self-management arm at 12 months (0.009, 95% CI –0.012 to 0.030).
From the health service provider perspective, the ICER for patient self-management was £32,716 per QALY
gained, and an ICER of £31,437 per QALY gained was reported from a wider societal perspective. At a
ceiling ratio of £20,000 per QALY gained, patient self-management had a 30% probability of being
cost-effective; this probability increased to 46% when the ceiling ratio rose to £30,000 per QALY gained.
The authors concluded that, based on the general decision rules for interpreting cost-effectiveness findings
in the UK, it was unlikely that self-management would be considered cost-effective compared with usual
care. However, it was noted that although patient self-management incurred a higher initial cost, it could
reduce the number of people attending outpatient clinics and, therefore, free up clinician time for other
patients. Furthermore, the results were based on only 12 months’ follow-up of a single trial that was not
powered to detect a difference in adverse events.
Regier 200686
This Canadian study assessed the cost-effectiveness of patient self-managed and family physician-managed
(with laboratory testing) long-term anticoagulation therapy. A Bayesian Markov model was constructed
from the perspective of a Canadian health-care payer, and analysed over a 5-year time horizon. The
adopted model structure accounted for the time spent by patients within, above or below the specified INR
therapeutic range, and determined patients’ risks of thromboembolic and haemorrhagic events based on this.
Model input parameter estimates were derived from a number of sources. TTR was obtained from a
Canadian trial of self-management versus physician-managed warfarin therapy. Event risks for time spent
in, above and below therapeutic range were derived from a prospective cohort of 2745 people with atrial
fibrillation, AHVs and venous thromboembolism. Cost and utility parameters were taken from a number
of different sources.
It was assumed that under the self-management strategy, people would perform 52 tests per year, while
under physician-managed care, only 14 tests would be performed each year, with dosing information from
the laboratory test being communicated to the patient by telephone.
The mean per-patient cost over the 5-year period was higher for the self-management strategy (C$6116) than
for the physician-managed strategy (C$5127). In terms of quality of life, self-management resulted in a QALY
gain at the 5 years of 0.07. This was due to a modelled reduction in both the number of thromboembolic
events and the number of haemorrhagic events. The reported ICER for self-management versus
physician-managed care was C$14,129 per QALY gained. The authors concluded that self-management
was cost-effective for people receiving long-term anticoagulation therapy.
The methods for calculating the costs and outcomes in this study were not transparent and the time spent
in the therapeutic range was derived from the results of a single clinical trial conducted in a Canadian
setting. Moreover, the perspective adopted was that of a Canadian health-care payer, which makes the
generalisability of these results to a UK setting difficult. In addition, the comparator in this study was
physician-managed care relying on laboratory testing, rather than anticoagulation clinic-managed care
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using point-of-care testing. As such, the result may be less generalisable to contexts where the latter
approach is used in standard practice.
Brown 200732
Another Canadian study conducted by Brown and colleagues32 adopted a decision-analytic modelling
approach to assess the cost–utility of patient self-testing (52 tests per year), compared with
physician-managed laboratory testing (20 tests per year) and physician-managed point-of-care testing
(23 tests per year). The 5-year model presented results from both the health-care provider (estimated
separately to include and exclude nursing home costs) and a wider societal perspective. The model was
similar in structure to other models reported in the literature, with thromboembolic and haemorrhagic
events modelled by time spent inside and outside the specified INR therapeutic range. The analysis was
conducted for a hypothetical cohort of people on long-term warfarin therapy, with input parameters
estimated from the published literature and a meta-analysis of studies assessing TTR. It was assumed
that self-testing and physician-managed point-of-care testing were equivalent in terms of clinical effects.
Cost parameters were identified from the published literature and were valued using Canadian sources.
Cumulative costs and QALYs were estimated over a 5-year period. From the health service provider
perspective, the results indicated that physician-managed point-of-care testing was cost saving compared
with usual care. Self-testing, on the other hand, was not found to be cost-effective in comparison with
usual care (ICER $57,595 per QALY gained) and was dominated by physician-managed point-of-care
testing. However, from a societal perspective self-testing was found to be cost saving over both usual
laboratory testing and physician-managed point-of-care testing. A probabilistic sensitivity analysis showed
that from the societal perspective, patient self-testing had a 52% probability of being cost saving
compared with usual care. An important limitation of this study was that it did not assess the impact of
extending the time horizon beyond 5 years, which presumably would have improved the cost-effectiveness
of self-testing versus usual care (physician-managed laboratory testing).
Connock 200721
The objective of this UK-based modelling study was to assess the cost-effectiveness of patient self-management
of anticoagulation therapy compared with usual care (a mixture of primary and secondary care testing).
A Markov model was constructed and analysed over a 10-year time horizon, adopting a NHS and personal
social services perspective. The base-case cohort was aged 65 years and was assumed to have an increased risk
of death, compared with the age-/sex-matched general population.
Model input parameters were derived from a number of sources. Estimates of time spent in therapeutic
range, warfarin monitoring costs and baseline health state utility (measured using the EQ-5D) were derived
from a previous RCT conducted in the UK with an accompanying economic evaluation.87 The cost of INR
devices (assumed to be paid for by the NHS) were annuitised over a 3-year period, and it was assumed
that where patients stopped using these for any reason within 3 years, 75% would be reused by another
patient. Risks of thromboembolic, major haemorrhagic and minor haemorrhagic events were estimated
from a variety of published sources by time spent in, above and below the specified INR therapeutic range.
Following major events, patients could either enter a state of permanent disability with associated costs
and utility decrements, or have no long-term consequences.
Following disabling events and minor haemorrhagic events, patients were modelled to be at an increased
risk of death from all causes. Within the model, it was assumed that there was a non-specific 2.5%
reduction in the risk of adverse events with patient self-management – mediated through patient
education and empowerment rather than improved INR control. This was based on the finding that
self-management was not found to have a significant impact on TTR in a pooled analysis of results from
eight trials where this outcome was available. This was despite it having a significant beneficial impact on
the risk of thromboembolic events and mortality (based on the pooled results from 15 trials).21
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The base-case results were presented for both a 5- and a 10-year time horizon. Over the 5-year time
frame, the incremental cost per QALY for self-management was estimated to be £122,365. The
cost-effectiveness of self-management improved over the longer time horizon, with the incremental cost
per QALY gained being £63,655 at 10 years. Cost-effectiveness acceptability curves were generated to
characterise the uncertainty surrounding the 10-year estimate. Applying a ceiling ratio of £30,000 per
QALY, patient self-management was found to have only a 44% chance of being cost-effective. However,
the authors also carried out a sensitivity analysis whereby the pooled estimate of effects (on major
complications) from all available trials were applied, and under this scenario found the incremental cost
per QALY gained to be £19,617 for self-management at 10 years. The authors concluded that patient
self-management of anticoagulation therapy was unlikely to be more cost-effective than usual care in
the UK, but that it might offer a cost-effective alternative for patients whose therapy could not be
satisfactorily controlled in usual care.
Gailly 200933
The objective of this study was to conduct a cost-effectiveness analysis of the use of point-of-care
devices for GP-managed care, anticoagulation clinic-managed care, patient self-testing and patient
self-management, compared with standard laboratory testing. The analysis focused on a cohort of
patients on long-term anticoagulation therapy. A decision-tree model, with a 10-year time horizon, was
constructed from the perspective of a Belgian health-care provider. The models input parameters were
estimated from a meta-analysis of published studies for clinical effects and Belgian health-care databases
for baseline risks and resource use.
As the meta-analysis of clinical effectiveness studies only identified evidence for a significant impact of
point-of-care testing on mortality for patient self-management, the cost-effectiveness analysis focused on
this modality of monitoring versus usual care (GP-managed testing with analysis of the blood sample in a
laboratory). Furthermore, the outcome measure was restricted to the number of life-years gained as it was
reported that no reliable quality-of-life data were identified. The annual number of point-of-care tests and
the number of GP consultations due to INR tests in usual care and patient self-management were varied in
a sensitivity analysis.
Applying the significant beneficial effects of self-management on mortality and thromboembolic events,
the results showed self-management to be the dominant strategy compared with usual care, except when
100% of the GP consultations observed in usual care were assumed to be maintained with patient
self-management and when the annual number of tests with self-management increased to 52 per year.
The probabilistic sensitivity analysis showed patient self-management to have a high chance of being a
dominant cost-saving strategy in comparison with usual care.
Medical Advisory Secretariat 200988
This Canadian study assessed the cost–utility of health service point-of-care testing, patient self-testing
and patient self-management versus standard care for patients on long-term anticoagulation therapy.
A Markov decision-analytic model was developed with a 5-year time horizon, and was analysed from
the perspective of the Ministry of Health and Long-Term Care. The model was analysed for a hypothetical
cohort of patients, and model inputs were derived from a systematic review of effectiveness, other
published literature and expert opinion. Time spent within and outside the therapeutic range was used to
estimate the likelihood of patients moving from one health state to another. The results indicated that all
of the evaluated point-of-care strategies were cost-effective compared with usual care, and that patient
self-management appeared to be the most cost-effective strategy.
Other studies
In addition to the above published evaluations, two abstracts were identified for potential relevance.
Visnansky and colleagues90 conducted a rapid HTA to explore the cost-effectiveness of patient self-testing
using CoaguChek compared with standard care (laboratory testing). A Markov model was constructed and
analysed for hypothetical cohorts (mean age 63 years) on long-term anticoagulation therapy for different
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indications, applying a lifetime horizon. The authors concluded that patient self-testing was a cost-effective
(dominant) strategy compared with usual care for all diagnosis subgroups.
Schmidt and colleagues91 conducted a cost–utility analysis of patient self-management compared with
standard monitoring among long-term OAT patients in an Austrian setting. A Markov model was
constructed adopting a lifetime horizon with an average baseline age of 67 years. This study found that
although self-management incurred higher costs initially, throughout follow-up these costs reduced
due to the lower number of health-care contacts over time. Adopting a lifetime perspective, it was
found that self-management was the dominant strategy based on both a cost-per-life-year and a
cost-per-QALY analysis.
Summary of findings from identified studies
The above overview of existing economic evaluations illustrates that the cost-effectiveness of patient
self-testing and self-management versus usual care is uncertain and largely dependent on a number of
key factors.
The adopted perspective appears to have a significant impact on estimated cost-effectiveness. Existing
studies have estimated costs from different perspectives, including those of health service providers, society
as a whole, health-care payers and health insurance funds. When a wider societal perspective has been
adopted, self-management and self-testing strategies have generally compared favourably with standard
clinic-based testing, as a result of lower time costs associated with fewer health service contacts. The initial
costs associated with patient self-management and self-testing also appear to be important determinants
of cost-effectiveness.
Variation between the studies in terms of the estimated or assumed effects of self-monitoring (on
thromboembolic and bleeding events) also helps to account for the variable findings and conclusions.
The two UK-based evaluations of greatest relevance to the scope of this diagnostic assessment report
(DAR)21,87 estimated or applied effect estimates consistent with small or negligible differences between
self-management and usual care with respect to TTR and adverse thromboembolic and haemorrhagic
events. They subsequently found there to be a low probability of patient self-management being
cost-effective. Contrary to this, several studies applied large effect estimates favouring self-monitoring in
terms of TTR, thromboembolic events and/or mortality, and, subsequently, found self-monitoring strategies
to be cost-saving or cost-effective.33,86,88
In relation to the scope of this assessment, the two most relevant studies are those reported by Jowett and
colleagues87 and Connock and colleagues.21 These economic evaluations were largely based on the same
trial conducted in the UK. Jowett and colleagues adopted a NHS and wider societal perspective and
Connock and colleagues21 adopted a health service and personal social services perspective, which was in
line with the NICE reference case. Key outcomes were measured directly within the trial-based evaluation,
including utility values and complications experienced. Self-testing and self-management strategies do
appear to increase the costs of INR monitoring in the short run, as demonstrated by these studies and
others. However, other studies have shown that these costs can be offset by future cost-saving and
quality-of-life gains, depending on the relative effectiveness of self-monitoring versus usual care in
reducing the incidence of mainly thromboembolic events.
The two UK-based economic evaluations suggest that for effect estimates consistent with those observed
in the largest UK-based trial of patient self-management, self-monitoring of INR is unlikely to be
cost-effective. However, no UK-based trials have been sufficiently powered to detect a significant difference
between standard INR monitoring and patient self-monitoring in terms of major thromboembolic or
haemorrhagic events. Meta-analysis of similar trials, given their rarity, provides a more powerful means of
estimating the true effect of self-monitoring on these clinical outcomes. An updated meta-analysis was
described and presented in Chapter 2, and included randomised evidence from a number of recent
European trials where standard care is similar to that provided in the UK in terms of approach, frequency
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and the level of INR control achieved. Therefore, the following section describes the construction and
analysis of a new economic model that builds on those described above, and which incorporates all of the
available evidence on the clinical effectiveness of self-testing and self-monitoring.
Independent economic assessment
A de novo economic model was developed in TreeAge Pro (TreeAge Software, Williamstown, MA, USA).
The model was designed to assess the cost-effectiveness of self-monitoring (self-testing and self-management)
using alternative point-of-care devices: CoaguChek XS system, INRatio2 PT/INR monitor and ProTime
Microcoagulation system. The model was structured based on the review of published models of INR
self-monitoring, and previous models evaluating the cost-effectiveness of new anticoagulant drugs compared
with warfarin therapy in people with atrial fibrillation.92,93 A further unpublished economic model of INR
self-monitoring was provided by Roche (the manufacturer of CoaguChek XS), and this model was also used
to inform the structure of the new economic model (J Craig, York Health Economics Consortium, 2013,
personal communication provided by Roche through NICE).
The model was populated using data derived from the systematic clinical effectiveness review, other
focused reviews to inform key parameters (e.g. baseline risks), routine sources of cost data,94,95 and, where
necessary, some study-specific cost estimates based on expert opinion. The model was built and analysed
in accordance with the NICE reference case for the evaluation of diagnostic tests and devices.29
Methods
Relevant patient population(s)
The model compared the alternative monitoring strategies for a hypothetical cohort of people with atrial
fibrillation or an AHV. These two groups represent the majority of people on long-term vitamin K
antagonist therapy. While self-monitoring of INR is relevant to other patient groups, including those with
venous thrombotic embolism, there were insufficient data to explicitly model cost-effectiveness for all
groups individually. Furthermore, the majority of studies informing the relative effects of alternative
monitoring strategies were derived from trials including predominantly people with atrial fibrillation and/or
an AHV. Therefore, the base-case modelling exercise was carried out for a mixed cohort consisting of
people with one or other of these two conditions. In the base-case analysis, 60% of the cohort was
modelled to have atrial fibrillation, with the remaining 40% having an AHV, in line with the observed
proportions of patients with these conditions in self-monitoring trials.
Monitoring strategies to be evaluated
The economic model incorporated the pathways of care that individuals currently follow under standard
practice in the NHS, as well as proposed new pathways for self-testing and self-management (informed by
a review of current guidelines and expert opinion). Current practice was dichotomised in the model as
standard monitoring in primary care and standard monitoring in secondary care. In the base-case analysis,
the proportional split between standard primary and secondary care INR monitoring was taken from the
manufacturer’s submission for technology appraisal 256 (TA256).96 Based on a survey of providers in
England and Wales carried out in 2011, it was estimated that 66.45% and 33.55% of warfarin monitoring
appointments were managed in a primary and secondary care setting, respectively. These figures were
accepted by the independent evidence review group (ERG) and appraisal committee for NICE TA256.97
In terms of self-monitoring, the model incorporated both self-testing and self-management strategies using
the alternative devices identified in the scope. However, the cost-effectiveness of self-monitoring was
assessed as a whole, and it was assumed in the base-case analysis that 50% of people would self-test while
50% would self-manage. Self-testing and self-management strategies were costed separately for each
device based on the assumption that self-testing people telephone in their results from all tests undertaken,
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while self-managing people manage their dosing independently. In reality, some self-monitoring people
are likely to fall somewhere in between these two strategies, and the potential impact of this was
addressed in sensitivity analysis by varying the proportional split between self-management and
self-monitoring.
Framework (method of synthesis)
The alternative monitoring pathways, informed by review of previous guidance and expert opinion,
were embedded in a Markov model simulating the occurrence of adverse events over time (Figure 16).
The adverse events that constituted the model were ischaemic stroke (minor, non-disabling, and major,
disabling or fatal), systemic embolism, minor haemorrhage and major haemorrhage [intracranial
haemorrhage (ICH), including haemorrhagic stroke, gastrointestinal bleed, and others]. Systemic embolism
was treated as a transient event within the model, such that people surviving this event returned to
baseline levels of quality of life and did not incur ongoing costs and morbidity. Minor haemorrhage was
handled in the same way. Ischaemic stroke and ICH were assigned post-event states associated with
additional costs and quality-of-life decrements.
The model simulated transitions between the discrete health states, and accumulated costs and QALYs on
a quarterly (3-month) cycle. Within each 3-month cycle, the simulated cohort was exposed to a risk of
the aforementioned events as well as death from other causes. A constraint was applied whereby
simulated people could experience only one event per cycle. A further simplifying structural assumption
was applied, such that, following a major ischaemic stroke or ICH, no further events were explicitly
modelled. However, all-cause mortality was inflated following these events to account for the increased
risk of death.
Baseline risks for the modelled events were derived from the observed event rates in cohorts of
people being managed under current standard models of care. RRs of these events resulting from
improved/reduced INR control, conferred by self-monitoring, were derived from the meta-analysis of RCTs
of self-monitoring versus standard practice. Appropriate costs and quality-of-life weights were attached
to modelled events and health states, allowing cumulative health and social care costs and QALYs to be
modelled over time. Further details of the event risks, transitions, costs and quality-of-life weights applied
in the model are provided in the following sections.
M
M
M
Self-monitoring
Cohort of
AF/AV
patients on
warfarin
Usual care Stable AF/AHV
Transient events
Systemic embolism/
minor bleed/non-fatal
major extracranial
bleed
Post major
stroke
(dependent)
Post minor
stroke
(independent)
Post ICH/HS
Death
FIGURE 16 Schematic of the model structure. AF, atrial fibrillation; HS, haemorrhagic stroke; M, Markov process.
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Modelled baseline risks for people with atrial fibrillation
Previous economic models relied on a variety of sources to inform the underlying baseline risks of adverse
events, ranging from single-centre trials to data pooled from a number of trials. The unpublished model
provided by Roche made use of event rates reported by TTR,98–100 based on data from the control arms of
large multinational trials comparing new anticoagulant drugs with standard treatment with warfarin for
people with atrial fibrillation.
The Randomised Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial of dabigatran etexilate
versus warfarin provides a detailed source of event-rate data by centre-level quartiles of mean TTR.99,101 The
advantage of these data is that they allow underlying risks to be modelled by the level of anticoagulation
control achieved, but there is a question surrounding their generalisability to the atrial fibrillation
population on warfarin therapy in the UK. However, a previous study assessed the representativeness of
the RE-LY clinical trial population to real-world atrial fibrillation patients in the UK,102 and found that the
majority of patients in the UK (65–74%) would have met the inclusion criteria. Furthermore, to assess the
generalisability of the annual risks of stroke derived from RE-LY data, these were compared with those
derived from a large cohort study of atrial fibrillation patients on warfarin in the UK. Gallagher and
colleagues103 analysed longitudinal data from the General Practice Research Database on 27,458 warfarin
users with atrial fibrillation, and provided a Kaplan–Meier plot of the probability of being stroke free
by different levels of TTR. Points on these plots were extracted using DigitizeIt software (DigitizeIt,
Braunschweig, Germany: www.digitizeit.de), and used to estimate the annual risks of stroke by
TTR groupings.
These stroke risks were found to be very similar to those for people in the corresponding TTR quartiles
of the RE-LY trial control arm. Therefore, the control arm of the RE-LY trial was considered to be an
appropriate source for estimating baseline risks by level of TTR in the economic model. The study by
Gallagher and colleagues103 also estimated a mean TTR (INR 2–3) of 63% for the UK cohort of people with
atrial fibrillation on warfarin, and so the baseline risks in the model were set to those observed in RE-LY
trial centres that achieved a mean TTR between 57.1% and 65.5%.
The analysis of RE-LY trial data by TTR quartiles99 provided estimated annual event rates for non-haemorrhagic
stroke and systemic embolism, major haemorrhage (including intracranial bleed, haemorrhagic stroke and
major gastrointestinal bleeds) and minor haemorrhage. These rates were entered in the model, where they
were converted into annual risks (Table 14). Following further adjustment, where appropriate, with RRs, the
annual risks were converted into quarterly risks using the following equation:
Quarterly risk=1−EXP½Ln(1− annual risk) 0:25 (1)
TABLE 14 Annual baseline event risks for people with atrial fibrillation by level of INR control (TTR)
Event
Annual risk by INR control (TTR)
< 57.1% 57.1–65.5% 65.6–72.6% > 72.6%
Non-haemorrhagic stroke and systemic embolism 0.0162 0.0162 0.0110 0.0097
Major bleeding 0.0353 0.0405 0.0334 0.0306
Minor bleeding (inferred) 0.1174 0.1323 0.1375 0.1387
The tabulated values were calculated within the model from the average event rates reported by Wallentin and
colleagues.99 The underlying rates were specified as gamma distributions in the model, with variance calculated from the
reported event numbers and person-years of follow-up.
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The events were modelled within each cycle of the model, and were further disaggregated based on the
observed numbers of different types of event observed within each composite outcome in the RE-LY
trial99,101 (Table 15).
Further adjustments were applied to the risk of stroke in atrial fibrillation patients, to reflect the
importance of age as a risk factor. For this purpose, the same approach as used in the model for NICE
TA256 (rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation)
was applied.96 RRs of stroke by age, compared with a 70- to 74-year-old cohort (the average age of
participants in RE-LY trial), were derived from a Framingham-based risk score calculator for patients with
atrial fibrillation,106 and applied to adjust the risk of stroke and systemic embolism by 5-year age bands.96
A similar approach was also used to inflate the risk of bleeding with increasing age, using data from
Hobbs and colleagues.107
Death following stroke was estimated by applying case fatality rates to these modelled events. Death
following stroke utilised the same approach as used in the model of dabigatran versus warfarin for NICE
TA249.105 Based on Hylek,104 the hospital case fatality rate was first applied, followed by the reported
30-day mortality by severity of stroke (Rankin score 0–2; 3–5) post discharge (see Table 15).
TABLE 15 Disaggregation of modelled composite outcomes
Composite event
Proportional
disaggregation Distributional form Source
Non-haemorrhagic stroke and
systemic embolism
Beta
Non-haemorrhagic stroke 0.909 (α= 14; β= 140) Connolly 2009101
SE 0.091 Connolly 2009101
Major bleeding Dirichlet
Intracranial bleed/haemorrhagic stroke 0.178 α= 89 Connolly 2009101
Other major bleed 0.426 α= 183 Connolly 2009101
Gastrointestinal bleed 0.396 α= 147 Connolly 2009101
Non-haemorrhagic stroke Beta
Non-disabling (Rankin score 0–2) 0.369 (α= 69; β= 118) Connolly 2009101
Disabling or fatal (Rankin score 3–6) 0.631 Connolly 2009101
Intracranial bleed/haemorrhagic stroke Beta
Fatal by 30 days 0.388 (α= 36.8; β= 58.1) NICE TA25696
Non-CNS major bleed Omitted from PSA
Proportion fatal 0.0155 NICE TA25696
Disabling or fatal stroke (Rankin score 3–6) Beta
Fatal in hospital 0.06 (α= 11; β= 177) Hylek 2003104
Fatal by 30 days post discharge 0.159 (α= 29; β= 151) Hylek 2003104
Non-disabling stroke Beta
Fatal by 30 days post discharge 0.01 (α= 2; β= 176) Hylek 2003104
Systemic embolism Omitted from PSA
Fatal 0.004 NICE TA249105
CNS, central nervous system; PSA, probabilistic sentitivity analysis; SE, systemic embolism.
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Modelled baseline risks for people with an artificial heart valve
Less extensive data were identified describing the baseline risk of adverse events for people with AHVs by
level of INR control. Previous economic models have tended to use overall event risks for mixed cohorts
rather than explicit event risks for individual patient groups included in the modelled cohort. However, the
model provided by Roche used a dichotomised cohort with event risks estimated separately for people
with atrial fibrillation and an AHV. This approach is useful for modelling subgroups and cohorts with
varying proportions of people with the two conditions. Therefore, the same general approach
was adopted.
As per the model provided by Roche (J Craig, York Health Economics Consortium, 2013, personal
communication provided by Roche through NICE), a recent meta-analysis of individual patient-level data
from 11 RCTs of self-monitoring versus standard care provided the source of event data.108 Heneghan and
colleagues108 presented a subgroup analysis where they presented the estimated pooled hazard ratio
and number needed to treat to prevent one major thromboembolic event (ischaemic stroke and systemic
embolism) and one major haemorrhagic event by year of follow-up (up to 5 years) based on 2243 people
with an AHV. The formula used by Heneghan and colleagues108 to estimate the number needed to
treat was:
NNT=1=½Sc(t)h−Sc(t) (2)
Sc(t) is the survival probability in the control group (standard monitoring) at time t, Sc(t)h is the
corresponding survival probability in the active treatment group (self-monitoring), and h is the hazard ratio.
The 5-year probability of experiencing a thromboembolic (0.089) and major haemorrhagic event (0.169)
in the control group were back calculated for people with an AHV, and converted into annual probabilities
(Table 16). These were incorporated in the model for subsequent adjustment and conversion into quarterly
probabilities for use as baseline risks.
A focused search was undertaken to identify alternative sources of data to inform the baseline risk of
thromboembolic events in people with an AHV. A previous meta-analysis estimated a pooled annual
linearised risk of 1.6% for people with a mechanical aortic valve. A further large Canadian series (including
1622 people with a mechanical heart valve) estimated linearised embolic stroke risks of 1.4% and 2.3%
per year for people with an artificial aortic and a mitral valve, respectively.109 These figures are generally
consistent with the baseline estimates used in the model. However, a smaller series from a single centre in
the south-west of England reported a lower rate of 1.15% per patient-year based on 2 years’ follow-up of
567 people with a Sorin Bileaflet third-generation prosthesis.110 The impact of applying this lower baseline
risk was assessed through sensitivity analysis.
In the absence of more detailed data for people with an AHV, the same proportional splits used to
disaggregate thromboembolic and major haemorrhagic events for people with atrial fibrillation were
applied (see Table 15). Furthermore, as data on minor bleeds were not available from Heneghan and
colleagues108 for people with an AHV, the same baseline risk applied for people with atrial fibrillation was
adopted. This was justified on the grounds of the two groups of people facing similar risks of a major
bleed (0.405 and 0.363).
TABLE 16 Annual baseline event risks for people with an AHV
Event Annual risk Distributional form
Non-haemorrhagic stroke and systemic embolism 0.0185 Beta (α= 19.2; β= 1020.8)
Major bleed 0.0363 Beta (α= 37.3; 977.7)
Minor bleed (assumed) 0.1323 See Table 14
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Further adjustments to baseline risks
Within the model, a number of simplifying structural assumptions were made. Following the occurrence
of a major disabling ischaemic stroke or an ICH/haemorrhagic stroke, no further events were modelled.
However, the risk of age-/sex-specific all-cause mortality was inflated following these events using RRs
estimated by Sundberg and colleagues.111 Deaths from other causes following minor stroke were also inflated
in the model to account for the observed increased risk of death from all causes following this event.111,112
The background risk of death from other causes also was increased for the atrial fibrillation and AHV cohorts
using standardised mortality ratios reported by Friberg and colleagues113 and Kvidal and colleagues114 (Table 17).
Baseline rates of death from all and other causes were modelled by age and sex based on interim life
tables. For other cause mortality, deaths due to stroke, systemic embolism and ICH were removed.116,117
Incorporation of relative treatment effects
Pooled estimates of RR derived from the meta-analysis of RCTs of self-monitoring versus standard practice
were used to adjust the baseline risks of events in the model (Table 18). Given the limitations of the
available data, it was not possible to accurately estimate the relative clinical effectiveness of using
TABLE 17 Parameters used in the model to adjust rates of death from all and other causes
Parameter Value SEM Distributional form Source
SMR: death from all causes for AF patients 1.30 0.082 Normal Friberg 2007113
RR: death post minor stroke 2.33a 0.276 Normal Sundberg 2003111
RR: death post disabling stroke 4.11 0.486 Normal Sundberg 2003111
SMR: death from all causes for AHV patients Kvidal 2000114
≤ 50 years 4.56 0.861 Normal
51–60 years 2.66 0.276 Normal
61–70 years 1.80 0.111 Normal
≥ 71 years 1.02 0.071 Normal
AF, atrial fibrillation; SEM, standard error of the mean; SMR, standardised mortality ratio.
a Figure adjusted to reflect the fact the death from stroke was modelled independently following a minor stroke, and to fit
observed survival probabilities following minor stroke.115
TABLE 18 Relative effects for self-monitoring applied in the model
Event/monitoring strategy RR 95% CI Distributional form
Any thromboembolic event
Self-management 0.51 0.37 to 0.69 Log-normal
Self-testing 0.99 0.75 to 1.31 Log-normal
Self-monitoring (overall) 0.58 0.40 to 0.84 Log-normal
Major bleed
Self-management 1.09 0.81 to 1.46 Log-normal
Self-testing 0.99 0.8 to 1.23 Log-normal
Self-monitoring (overall) 1.02 0.86 to 1.22 Log-normal
Minor bleed
Self-management 0.84 0.53 to 1.35 Log-normal
Self-testing 1.23 1.06 to 1.42 Log-normal
Self-monitoring (overall) 0.94 0.65 to 1.34 Log-normal
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the alternative self-monitoring devices. Therefore, in the first instance, equivalent effects were assumed
on the basis of several studies showing reasonable correlation between the instruments in terms of
precision and accuracy. However, it is worth noting that the majority of the clinical effectiveness evidence
relates to CoaguChek S, with only one trial included in the systematic review using the INRatio2 PT/INR
monitor (although not exclusively), and two trials using the ProTime Microcoagulation system (exclusively).
For the base-case analysis, relative effects were entered separately for the different types of event
(any thromboembolic event, major bleed and minor bleed) by type of self-monitoring strategy
(self-management and self-testing) (see Table 18). While not all effects were significant, the point
estimates were applied in the model with appropriate distributions assigned to reflect the uncertainty
surrounding them. These RRs, which represent pooled estimates obtained from trials with follow-up
periods varying between 3 and 24 months, were assumed to apply directly to the 12-month risk of an
event. Therefore, they were used to adjust the estimated annual baseline risk of events in the model, from
which constant 3-month transition probabilities were derived, assuming constant proportional hazards
over time. The RRs were applied only to people continuing on self-monitoring in the model.
Resource use estimation
Data on the resource use and costs associated with the alternative monitoring strategies were informed by
published literature, existing guidance, expert opinion, manufacturers’ and suppliers’ prices, and other
routine sources of unit cost data.94,95 As noted above, certain costs were informed by expert opinion where
suitable data from other sources were not available.
Costs of standard care
Resource use associated with standard monitoring was informed by a number of sources. The model
provided by Roche used estimates of monitoring costs (under standard primary and secondary care) based
on previous estimates calculated by the independent ERG for NICE technology appraisal TA249,
Dabigatran etixilate for the prevention of stroke and systemic embolism in atrial fibrillation.118 These
estimates of monitoring costs in standard care, which were later applied in the NICE costing template
for dabigatran,119 were derived by the ERG based on previous estimates used in the NICE costing report for
clinical guideline CG36 on atrial fibrillation.24 This report summarised the estimated annual resource use
required for monitoring people in primary care, assuming 20 monitoring visits per year. These measures of
resource use, per visit, are summarised in Table 19.
An alternative source of standard monitoring costs per visit was identified from the largest UK-based
RCT of self-monitoring.64 Jowett and colleagues carried out the economic analysis alongside the
Self-Management of Anticoagulation, a Randomised Trial (SMART), where people in the control arm
received a mix of standard primary and secondary care monitoring.87 A unit cost per visit (accounting for
staff time, equipment, consumables and overheads) was estimated for each care setting from a sample of
NHS providers. The resultant cost estimates (per visit) for different types of standard care are presented in
Table 20, inflated to 2011–12 prices.
Updated unit costs have been applied to provide a total cost per patient monitoring visit in 2011–12 GBP.
When calculating the variable cost per patient associated with monitoring in a secondary care setting, the ERG
in their report on dabigatran etexelate assumed that 33% of secondary care monitoring costs would be fixed
and not influenced by changes in the number of people being monitored. This assumption was based on the
observed proportional split between fixed and variable costs in the bottom-up calculation of the total cost of
INR monitoring in primary care.24 This same assumption was applied in our updated estimates.
When updating the unit costs for practice nurse time in primary care, we used an estimate per hour that
incorporates allocated overhead costs (including management and administration) and use of practice space.
Some of these allocated costs were not included in previous variable cost estimates for monitoring in primary
care. It was considered appropriate to include them here to capture the opportunity cost associated with use
of primary care facilities for INR monitoring.120 However, as the allocated costs account for administration,
additional administration time per patient visit was not costed separately as it was in previous estimates.24,93,118
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TABLE 19 Resource use and updated variable cost estimates per standard primary and secondary care INR
monitoring visit
Resource
Unit costs
(2011–12), £
Cost per patient
per visit (2011–12), £ Source/assumptions
Primary care
Reagents 2.80 2.80 Roche (assumes
point-of-care testing)
Lancet 0.04 0.04 Roche
Nursing time (15 minutes) 35.00 (per hour) 8.75 PSSRU, 201295
Administration time (15 minutes) Accounted for in
allocated costs for
nursing time
– PSSRU, 201295
Office consumables per clinic 2.52 0.21 CG36, costing report,
inflated to 2011–12
prices, assumes
12 patients per clinic24,119
Use of shared equipment
(equivalent annual cost)
171.65 0.29 Roche (CoaguChek XS
Plus, annuitised over
5 years, assuming 600
uses per year)
Total variable cost per patient monitoring visit 11.76
Total variable cost per year, assuming 20 visits 235.20
Total variable cost per year, assuming 12 visits 141.12
Cost per quartera 35.28
Secondary care
NHS anticoagulation services 23 (per visit) 23 NHS reference costs,
2012 (anticoagulation
services)94
Assumed variable cost component (0.6667) 15.33 (per visit) 5.33 TA249 ERG
report, 201193,118
Total variable cost per patient monitoring visit 15.33
Total variable cost per year, assuming 20 visits 306.94
Total variable cost per year, assuming 12 visitsa 184.16
Cost per quartera 46.04
a Standard-care monitoring costs were entered in the model as gamma distributions, with the mean based on
12 monitoring visits per year and the variance reflecting the uncertainty surrounding the annual number of visits.
TABLE 20 Alternative unit costs of standard care INR monitoring in different settings, reported by Jowett
and colleagues87
Care setting
Cost per visit
(2002–3), £
Inflation
factor
Cost per visit
(2011–12), £
Annual costs (assuming
20 visits per year), £
Hospital clinic 6.35 1.337 8.49 169.79
GP blood sample, hospital analysis and dosing 9.38 1.337 12.54 250.81
GP blood sample and dosing, hospital analysis 10.69 1.337 14.29 285.83
Practice based near patient testing clinic 14.16 1.337 18.93 378.62
Pharmacist-led practice clinic 17.66 1.337 23.61 472.20
MLSO-led practice clinic 11.62 1.337 15.54 310.70
MLSO, Medical Laboratory Scientific Officer.
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Given the slightly different approach to updating the unit costs for standard monitoring services, our cost
estimates based on 20 monitoring visits (£235.20 and £306.94 for primary and secondary care monitoring,
respectively) differ somewhat from those used in the NICE costing template for dabigatran (£220.90 and
£303.43, respectively, for monitoring in primary and secondary care in 2009–10 prices) and also from
those applied in the model provided by Roche (£231.33 and £317.90, respectively, for primary and
secondary care monitoring in 2012–13 prices).
For primary care monitoring, these unit costs are somewhat higher than those presented in Table 19.
However, the cost estimate for monitoring in a secondary care (hospital clinic) is substantially lower.
Furthermore, while the proportional mix of standard care service use was not reported in the study by
Jowett and colleagues,87 a total mean standard care monitoring cost of only £89.89 (£120.18 in 2011–12
prices) was reported at 12 months. The actual annual monitoring frequency observed in the control arm of
the SMART trial was 37.9 days.64
This suggests that an annual number of only ≈ 10 monitoring visits per year was required to achieve the
level of control reported for the standard-care arm of this pragmatic UK-based RCT.
The assumption of 20 visits being the average number of monitoring visits required for people on
long-term vitamin K antagonist therapy comes from the NICE costing report for the clinical guideline
on the management of atrial fibrillation.24,119 This was estimated based on the ratio of second to first
attendances at anticoagulation clinics (≈ 19 from reported activity in the 2004–5 NHS reference costs)
and a previous study by Jones and colleagues,121 which reported a median frequency of INR testing of
16 days for people receiving warfarin (equating to ≈ 22 tests per year). A repeat of the calculation based
on reference costs activity data for 2011–12 yielded a ratio of only 9.5. However, this lower value may
merely reflect a trend for more people to be followed up in primary care following initiation of therapy.
Given the uncertainty surrounding the average number of monitoring visits for people under standard
primary and secondary care, the DAR specialist committee members were consulted on this parameter.
Opinion on the frequency of monitoring suggested that 10–12 visits would be required on average in primary
and secondary care, but that the number of visits would be highly variable across participants. It was also
noted by one member that more monitoring visits may be required for people managed in secondary care,
as it tends to be the people with poorer control who are managed in this setting. A further question was
raised about the nursing time requirements for routine monitoring visits used in the previous cost estimates
informing TA249 (15 minutes of band 5 nurse time per patient visit). One source suggested that 10 minutes
would suffice for this.
Based on consideration of the all of the above evidence, it was assumed in the base-case analysis that, on
average, 12 monitoring visits would be required per year for people under standard primary and secondary
care monitoring. To retain consistency with previous analyses used to inform NICE guidance, we applied
the unit costs per visit based on the figures in Table 19.
The impact of altering the number of standard care monitoring visits per year was also assessed through
sensitivity analysis. We also conducted sensitivity analyses where the updated unit costs in Table 20 were
applied to cost monitoring visits, and where we assumed only 10 minutes of nurse time per standard care
monitoring visit.
Finally, given the reliance of some people on NHS transport for attending secondary care monitoring visits,
a cost of transport was applied for a percentage of people modelled to receive this form of monitoring.
The percentage of 8.55% was taken from a previous survey of patient pathways used to inform the
manufacturer’s model for NICE TA25696 and the return transport cost was taken from the NHS reference
costs (£30.96).94
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Costs of self-monitoring
An average testing frequency of 35 tests per year (every 10.42 days) was assumed for self-monitoring in the
base-case analysis. This number was chosen to be consistent with the trials from which the relative effect
estimates for self-monitoring were obtained. In a recent meta-analysis of patient-level data,108 11 of the
self-monitoring trials included in our review reported the mean increase in the number of tests performed
with self-monitoring versus control. There was an average of 24 additional tests by 12 months for people with
atrial fibrillation and 22 additional tests for people with an AHV. The average of these two values was added
to the estimated 12 tests per year for standard care, to give an estimate of 35 tests per year for self-monitoring.
The impact of altering the difference in testing frequency between standard care and self-monitoring,
through the 95% CIs reported by Heneghan and colleagues (13–30 per year), was assessed through sensitivity
analysis.108 Furthermore, we assessed scenarios where self-monitoring was not used to increase the frequency
of monitoring as a means to improve INR control, but simply used to replace primary and secondary care
testing. Under this scenario, we assumed no relative effects of self-monitoring on outcomes. The sections below
provide further details on the cost of self-monitoring, with a summary of cost elements provided in Table 21.
TABLE 21 Summary of self-monitoring device, training and testing costs
Self-monitoring unit cost
CoaguChek
XS (£)
ProTime
(£)
INRatio2
(£)
Device cost 299 884 275
Equivalent quarterly cost for use 16.56 48.95 15.23
Test strips (per unit) 2.81 4.96 2.75
Lancets (£ per unit) 0.04 0.10 0.05
Self-monitoring costs
Primary care (£) Secondary care (£)
CoaguChek XS ProTime INRatio2 CoaguChek XS ProTime INRatio2
Training
Self-testing 90 90 90 170 170 170
Self-management 180 180 180 340 340 340
Annual self-testing costs
Test strips and lancets (× 35) 99.62 177.24 98.00 99.62 177.24 98.00
External quality control twice a year
(two strips+ two lancets)
5.69 10.13 5.60 5.69 10.13 5.60
Routine clinic assessment twice per year 22.50 22.50 22.50 42.50 42.50 42.50
Telephone calls (5 minutes of nurse
time × 35 per year)
102.08 102.08 102.08 102.08 102.08 102.08
Cost per year based on 35 tests 229.90 311.95 228.18 249.90 331.95 248.18
Cost per quartera 57.47 77.99 57.05 62.47 82.99 62.05
Annual self-management costs
Test strips and lancets (× 35) 99.62 177.24 98.00 99.62 177.24 98.00
External quality control twice a year
(two strips+ two lancets)
5.69 10.13 5.60 5.69 10.13 5.60
Routine clinic assessment twice per year 22.50 22.50 22.50 42.50 42.50 42.50
Cost per year based on 35 tests 127.81 209.87 126.10 147.81 229.87 146.10
Cost per quartera 31.95 52.47 31.53 36.95 57.47 36.53
a Quarterly self-monitoring costs were entered in the model as gamma distributions, with the mean based on
35 monitoring visits per year and variance reflecting the uncertainty surrounding the increased number of tests over
standard monitoring (13–30).
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Equipment
Self-monitoring device costs were obtained from the manufacturers. However, no up-to-date cost could
be obtained for ProTime Microcoagulation System. The UK distributor of this device [International
Technidyne Corporation (ITC), NJ, USA] was contacted for information, but stated that the device was not
marketed for patient self-monitoring in the UK, and that the device was being superseded by the ProTime
InRhythm™ System, ELITech (Berkhamsled, Herts, UK), which is being marketed in the UK for professional
use only. For completeness, a self-monitoring strategy using the ProTime Microcoagulation System was
included in the economic model, by applying a NHS list price from 2008.122 Finally, a new promotional
price (of £195) was provided for INRatio2. The impact of using this price was assessed in a
sensitivity analysis.
Device costs were treated in the same way that capital investments are normally dealt with in economic
evaluation. It was assumed that the NHS would pay for these and loan them out to patients. As such, they
were annuitised over their expected use life to provide an equivalent annual/quarterly cost of use. While
these devices have a potentially long life span based on the advice of manufacturers, their costs were
annuitised over a 5-year period in the base-case analysis to account for the potential for loss and
accidental damage.
There was also a degree of uncertainty about the suitability of the devices for reuse following
discontinuation of self-monitoring by participants. In the base-case analysis, the same assumption that was
used in a previous UK-based economic modelling study21 was applied, i.e. three-quarters of devices are
reused by another patient in situations where a patient discontinues self-monitoring (see Training, for
details on assumptions about discontinuation).
Consumables
The cost of test strips were provided by the manufacturers, and it was assumed in the base-case analysis
that the annual cost of test strips would be equal to the number of tests performed annually multiplied by
the cost per strip (i.e. that there would be no wastage). It was further assumed that two more test strips
would be used annually to cross-check each device against a quality assured clinic-based machine. This
was modelled to take place during biannual assessments for self-monitoring participants (see Biannual
routine assessments).
NHS staff time
The staff time input required to oversee self-monitoring relied on expert opinion. People who are
self-monitoring can require varying degrees of input from clinical staff to check readings and respond
to queries. In the base case, it was assumed that all self-testing people would call in each and every test
result on a dedicated telephone line, and that a nurse would later check and enter each patient’s result,
and then telephone the patient back with instructions to either maintain or alter their warfarin dose.
This was assumed to incur 5 minutes of band 5 nurse time per patient (based on the opinion of the
specialist advisory committee), which was valued using nationally available unit costs.95 It was assumed
that self-managing people would not require any further support from nursing staff other than biannual
routine assessments (see next section).
Biannual routine assessments
It was assumed that quality control of self-monitoring devices would take place at biannual clinic
appointments, at the local anticoagulant clinic or practice from where self-monitoring was initiated. It was
assumed that this would involve checking the patient’s instrument against an externally validated one, and
that it would incur 15 minutes of direct face-to-face contact time with a practice nurse (£45 per hour) or
hospital clinic nurse (£85 per hour).95 In line with the base-case assumption that 34% of people are
monitored in secondary care under standard practice, it was assumed that 34% of self-monitoring people
would return to this setting for routine assessments, while the remainder would return to primary
care clinics.
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Training
Based on existing literature,123 as well as consultation with members of expert advisory committee, it was
assumed that self-testing people would require 2 hours of one-to-one training, while those progressing to
self-management would receive 4 hours of one-to-one training prior to initiation. These assumptions are
consistent with those applied in the model that was provided by Roche (J Craig, York Health Economics
Consortium, 2013, personal communication provided by Roche through NICE) and the literature on training
requirements from RCTs of self-monitoring. Training time was costed using hourly unit costs for direct
patient contact time (£45 per hour for practice nurse time and £85 per hour for hospital clinic nurse time).
The RCT literature64 and the expert advisory committee were also consulted with respect to training
success rates and ongoing adherence to self-monitoring. In light of this, we incorporated a training failure
rate of 15% – the mid-point between 5%, suggested by members of the expert advisory committee, and
24%, a pragmatic UK-trial-based estimate64 – and assumed that these people would incur the cost of
training but return to standard care without incurring the cost of a monitoring device.
In addition to including a training failure rate in the model, it was considered unrealistic to assume that 100%
of participants would continue to self-monitor after initiation. Therefore, we incorporated a discontinuation
rate of 10% by 12 months in the model, based on consideration of the views of the expert advisory committee
(≈ 5%) and a rate of 14% reported in the largest UK-based trial.64 Beyond 12 months, it was assumed that
self-monitoring people would continue to do so unless they experienced a fatal or disabling adverse event.
Warfarin costs
In line with previous evaluations, it was assumed that the quantity and cost of vitamin K antagonist drugs
would not vary significantly between self-monitoring and standard monitoring. Therefore, these costs were
excluded from the model.
Costs of adverse events
The cost of minor bleed was based on the NHS reference cost for VB07Z: Accident and emergency
services, category 2 with category 2 treatment (weighted average). A major non-intracranial bleed was
taken as the weighted average reference cost for the Healthcare Resource Group (HRG) codes related to
non-elective admissions for gastro-intestinal bleeds (Table 22).
For the cost of a systemic embolism, a weighted average of the reference costs for non-elective admissions
relating to the HRG for non-surgical peripheral vascular disease (QZ17A, QZ17B, QZ17C) was applied.
The initial cost of a minor stroke was taken as the weighted average of the 2011–12 non-elective
reference costs for the HRG codes AA22A and AA22B (non-transient stroke or cerebrovascular accident,
nervous system infections or encephalopathy, with and without complications and comorbidities).
This equates to a cost of £3082.
For major stroke, the cost used in the rivaroxaban submission was also updated, whereby the initial
treatment cost was taken as the weighted average of AA22A and AA22B (£3082), with the addition of
10.97 additional bed-days costed using the weighted average excess bed-day cost (£236.16 per day) for
AA22A and AA22B. The excess bed-days were estimated by subtracting the length of stay accounted
for in the reference costs for AA22A and AA22B – up to 24.43 days94 – from the average length of stay in
hospital for people suffering a major stroke (34.4 days based on Saka and colleagues124). In addition,
14 days’ rehabilitation was added at a cost per day of £313.41 – based on the HRG VC04Z (rehabilitation
for stroke) – to estimate the total cost of a major stroke to 3 months (£10,061). This estimate is lower than
that used in the model for NICE TA256 (updated cost of £13,547), as excess bed-day costs were applied
only to days above the costing trim-point for AA22A and AA22B, rather than days above the average
length of stay for these codes. This is conservative in favour of standard care.
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TABLE 22 Health and social care costs associated with adverse events
Health
states/events Cost element
Unit
costs, £ Cost source Assumptions/description
Total
cost, £
Transient events
Minor bleed Acute treatment 134 National schedule
of reference
costs 2011–1294
VB07Z: accident and emergency
services. Category 2 with
category 2 treatment
(weighted average)
134
Major bleed
(non-intracranial)
Acute treatment 975 Cost of a gastrointestinal
bleeding treatment episode.
Weighted average of codes:
FZ38D, FZ38E, FZ38F, FZ43A,
FZ43B, FZ43C
975
Systemic embolism Acute treatment 1639 Cost of non-surgical peripheral
vascular disease. Weighted
average of codes: QZ17A,
QZ17B, QZ17C
1639
Permanent events
Minor stroke Acute treatment 3082 National schedule
of reference
costs 2011–1294
AA22Z: non-transient stroke OR
cerebrovascular accident,
nervous system infections
or encephalopathy
3082
Post minor stroke
(Rankin score 0–2)
Follow-on care
costs per quarter
219 Wardlaw 2006,125
NICE clinical
guideline CG92126
Annual cost of stroke care per
year following an index event,
inflated to 2011–12 prices
and quartered
303
Major stroke Acute treatment 3082 National schedule
of reference costs
2011–12: non
elective inpatient94
AA22Z: non-transient stroke OR
cerebrovascular accident,
nervous system infections or
encephalopathy – with 10.97
excess bed-days
10,061
Acute treatment
cost per excess
bed-day
236
Rehabilitation
(cost per day) –
14 days
313 National schedule
of reference
costs 2011–1294
VC04Z: rehabilitation for stroke
(weighted average)
Post major stroke
(Rankin score 3–5)
Follow-on care
costs per quarter
2823 Wardlaw 2006,125
NICE clinical
guideline CG92126
Annual cost of stroke care per
year following an index event,
inflated to 2011–12 prices
and quartered
3906
Intracranial bleed Acute treatment 2250 National Schedule
of Reference
Costs 2011–1294
AA23Z: haemorrhagic
cerebrovascular disorders
(weighted average)
6638
Rehabilitation
(cost per day) –
14 days
313 VC04Z: rehabilitation for stroke
(weighted average)
Post intracranial
bleed/HS
Follow-on care
(costs per quarter)
2576 NICE clinical
guideline CG92126
Assumed weighted average of
quarterly costs following
ischaemic stroke (assumes 38%
of patients dependent, and
62% independent)
2576
HS, haemorrhagic stroke.
All costs associated with adverse events (except those occurring post stroke) were specified in the model as gamma
distributions, with variance reflecting the lower and upper quartiles reported in the NHS reference costs.
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The costs associated with adverse events were adapted from those used in the model informing NICE
TA256; rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation.96
These cost estimates were based largely on NHS reference costs, and were considered appropriate by the
independent ERG in their critique of the manufacturer’s submission.97 These costs were updated for the
current analysis using the National Schedules of NHS Reference Cost, 2011–12,94 where possible, or were
otherwise inflated from previously reported 2009–10 prices using the Hospital and Community Health
Services (HCHS) pay and prices index.95 These costs are presented in Table 22.
Further costs were applied on a quarterly basis in the years following ischaemic stroke. These costs were
adapted from those applied in NICE clinical guideline CG92, which were initially based on costs reported by
Wardlaw and colleagues125 of £11,292 per year for disabling stroke and £876 per year for non-disabling
stroke (2001–2) prices. These costs were inflated to 2011–12 values using the HCHS pay and prices index.95
For the acute treatment costs associated with an intracranial bleed, a weighted average of the non-elective
reference costs for HRG AA23Z (haemorrhagic cerebrovascular disorders) was applied. In addition, the
same rehabilitation costs as applied following major ischaemic stroke were applied following ICH, and the
following quarterly health and social care costs were taken as the weighted average of those following
minor (0.369) and major (0.631) ischaemic stroke. The cost of minor bleed was based on the NHS
reference cost for VB07Z: accident and emergency services, category 2 with category 2 treatment
(weighted average). A major non-intracranial bleed was taken as the weighted average reference cost for
the HRG codes related to non-elective admissions for gastrointestinal bleeds (see Table 22).
Health measurement and valuation
Time spent in different states of the model was adjusted using utility weights reflecting the desirability of
those states on a scale where 0 is equal to death and 1 is equal to full health. With the model structure
similar to that of the model used to inform NICE TA256 (rivaroxaban for the prevention of stroke and
systemic embolism in people with atrial fibrillation), a number of the utility values used in this previous
model were applied (acute major and minor stroke, acute major haemorrhage and ICH). These values
were considered appropriate by the independent ERG for NICE TA25697 and accepted by the appraisal
committee. However, the utility values applied to the states ‘post minor’ and ‘post major stroke’ in TA256,
were derived from a Norwegian study where values were elicited directly from participants and the general
population.127 Alternative values were identified for these states based on the EQ-5D responses of stroke
people in the UK. Dorman and colleagues128 used the EQ-5D to measure the health status of 867 people
enrolled in the International Stroke Trial.129 The reported values of 0.31 for dependent health states and
0.71 for independent health states were considered more consistent with the NICE reference case than the
directly elicited Norwegian values (0.482 and 0.719, respectively) used in TA256. Further, it was assumed
that for people experiencing an ICH or a haemorrhagic stroke, the proportion of people returning to
independent living would match that observed for ischaemic stroke, and that the same utilities for minor
and major ischaemic stroke would apply to dependent and independent states following ICH. This
approach was used as it was noted that the value used in the rivaroxaban submission92,96 was higher than
the age-specific UK EQ-5D population norm for people ≥ 75 years of age. Finally, the baseline utility value
for people with atrial fibrillation or mechanical heart valve who were stable was taken as the baseline
EQ-5D value of patients enrolled in the SMART trial (0.738).87
This value was applied to 65- to 70-year-old people. The difference between the UK EQ-5D population
norm for 65- to 70-year-olds and the utility estimate from the SMART trial (0.042) was used to
estimate age-specific baseline utilities in the model. The resultant utility values applied to events and
health states are provided in Table 23.
Utilities associated with acute events were applied for the 3-month period following the event. For
post-event states with associated ongoing morbidity, the appropriate health state utilities were applied
for all subsequent cycles spent in these states. Half-cycle corrections were applied, by assuming that people
experienced events on average at the mid-point of the cycle. Thus, a patient starting off in the well state
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and experiencing a major stroke in a given cycle of the model would accrue 6 weeks at the utility value for
well and 6 weeks at the utility value for major stroke.
Time horizon, and discounting of costs and benefits
Both costs and benefits (QALYs) were discounted at 3.5% per annum, in line with the NICE reference
case.29 The model was initially analysed over a 10-year period, but the impact of adopting longer time
horizons (including the patient’s lifetime) was explored in sensitivity analyses. It was anticipated that a
10-year time horizon would be sufficient to demonstrate the main health and cost impact of any identified
differences in adverse event rates between the alternative monitoring strategies, while avoiding the
uncertainty surrounding assumptions about event rates far into the future.
Analysis
The results of the model are presented in terms of a cost–utility analysis (i.e. costs for and number of
QALYs generated by each monitoring strategy). Each strategy was compared incrementally with its next
less costly, non-dominated comparator, to estimate its incremental cost per QALY gained. In addition,
given the uncertainty surrounding the relative effectiveness of the alternative self-monitoring devices,
self-monitoring using each device was also compared incrementally with the standard care monitoring
strategy (mixed primary and secondary care monitoring).
TABLE 23 Health state utility values applied to modelled events and states in the model
State/event
Utility value/
decrement Source Description
Stable AF/AHV
< 25 years 0.898 Kind 1999130 EQ-5D, UK population norm adjusted for AF/AHV
25–34 years 0.888 Kind 1999130 EQ-5D, UK population norm adjusted for AF/AHV
35–44 years 0.868 Kind 1999130 EQ-5D, UK population norm adjusted for AF/AHV
45–54 years 0.808 Kind 1999130 EQ-5D, UK population norm adjusted for AF/AHV
55–64 years 0.758 Kind 1999130 EQ-5D, UK population norm adjusted for AF/AHV
65–74 years 0.738 Jowett 200687 EQ-5D values for people with AF
≥ 75 years 0.688 Kind 1999130 EQ-5D, UK population norm adjusted for AF/AHV
Minor stroke 0.641 Robinson 2001131 Standard gamble, UK people
Post minor stroke 0.71 Dorman 2000128 EQ-5D, UK stroke people
Major stroke 0.189 Robinson 2001131 Standard gamble, UK people
Post major stroke 0.31 Dorman 2000128 EQ-5D, UK stroke people
Systemic embolism
(decrement)
–0.119 Sullivan 2006132 Based on EQ-5D scores from a US cohort
Minor bleed 0.7757 Sullivan 2006132 As above
> 75 years 0.7257 As above, adjusted for consistency with UK
population norms
Major bleed (decrement) –0.1814 Sullivan 2006132 As above
Post IC bleed 0.461 Assumption Weighted average of post minor and post major
stroke utilities
AF, atrial fibrillation; IC, intracranial.
All utility values and decrements were incorporated in the model as beta distributions with variance derived from the
reported source, except for baseline values based on population norms.
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Further analyses were undertaken to assess cost-effectiveness by age, indication for anticoagulation
therapy (atrial fibrillation, AHV), the standard care comparator (primary care monitoring, secondary care
monitoring), and the active intervention (self-monitoring, self-management). The impact of altering key
parameter values and assumptions was also assessed through extensive sensitivity analysis.
Given the computational burden of running the model probabilistically for each scenario assessed, results of
main analyses and sensitivity analyses are presented based on deterministic runs of the model using the
point estimates for input parameters. To characterise the joint uncertainty surrounding point estimates of
incremental costs and effects, probabilistic sensitivity analysis was also undertaken.133 Each parameter was
assigned an appropriate distribution as indicated in the preceding parameter tables. The model was then run
iteratively 1000 times, with a value drawn randomly for each input parameter from its assigned distribution
for each run. The estimated mean cost and effects for each strategy, based on these 1000 iterations,
are presented for comparison with the deterministic results. The results of the probabilistic analysis are
also presented in the form of incremental cost-effectiveness scatterplots and cost-effectiveness acceptability
curves – for self-monitoring using each device compared with standard practice. As no direct evidence for
the relative clinical effectiveness of the alternative monitoring devices could be identified, the strategies have
not been compared simultaneously in the probabilistic analysis. Parameters excluded from the probabilistic
analysis were self-monitoring training costs; in-hospital fatal stroke costs; post-stroke costs; the proportion of
the cohort with atrial fibrillation; the proportion male; the proportional split between primary and secondary
standard care monitoring; discontinuation rates; and unit costs of devices, consumables and staff time.
Results
Base-case analysis
This section presents the results of the base-case analysis. The following assumptions were applied:
l 66.45% of standard care monitoring occurs in primary care with practice nurses.96
l 60% of the cohort have atrial fibrillation, 40% have an AHV.108
l Average age of the cohort is 65 years, and 55% are male.108
l 50% of self-monitoring people self-test, 50% self-manage (assumption).
l The increase in the number of tests performed per year with self-monitoring is 23.108
l Relative treatment effects are estimated and applied separately for self-testing and self-management
(see Table 10).
l 15% of participants do not commence self-monitoring following training (see Training).
l 10% of participants discontinue self-monitoring within a year of commencing (see Training).
l Self-monitoring device costs are annuitised over 5 years (see Equipment).
l 75% of devices are reused by another patient when a patient discontinues self-monitoring
(see Equipment).
Figure 17 indicates the modelled proportion of the cohort (under standard monitoring care) experiencing a
stroke, thromboembolic event, major bleeding event, and death by time in years. Figure 18 presents the
same outcomes under the self-monitoring strategy. Applying the base-case assumptions, the results
indicate that over a 10-year period, the introduction of self-monitoring would reduce the proportion of
people suffering a thromboembolic event by 2.5%, while slightly increasing the proportion suffering a
major haemorrhagic event by 1.4% (Table 24).
While the predicted monitoring costs are higher with self-monitoring (see Table 24), the total health and
social care costs are similar and in some cases lower, and the QALY gains are greater. Thus, under the
base-case scenario, the self-monitoring strategies compare favourably with standard care, except for with
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FIGURE 17 Modelled cumulative probability of a first thromboembolic and major haemorrhagic event, and death
from all causes (standard-care cohort).
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FIGURE 18 Modelled cumulative probability of a first thromboembolic and major haemorrhagic event, and death
from all causes (self-monitoring cohort).
TABLE 24 Mean costs and outcomes over a 10-year time horizon
Strategy Mean costs, £
Cumulative monitoring/
device costs, £
First
thromboembolic
event, %
First major
bleed, %
Mean
QALYs
Standard monitoring 7324 1269 14.2 30.2 5.479
Self-monitoring: INRatio2 7295 1908 11.7 31.6 5.507
Self-monitoring:
CoaguChek XS
7333 1944 11.7 31.6 5.507
Self-monitoring: ProTime 8609 3192 11.7 31.6 5.507
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
ProTime, where the incremental cost per QALY gained is £47,640 (Table 25, Figure 19). Furthermore, due
to the lower cost of the INRatio2 device and testing strips, coupled with the assumption of equivalent
clinical effectiveness of the alternative self-monitoring devices, INRatio2 dominates CoaguChek XS.
However, it should be noted that no direct evidence of clinical effectiveness was identified exclusively for
INRatio2 from the systematic review.
Incremental analysis of alternative scenarios
Table 26 shows the results of further scenario analyses. For exclusive self-testing and self-management
versus mixed primary/secondary care standard monitoring, and for mixed self-monitoring versus exclusive
primary and secondary care clinic testing. Exclusive self-management with INRatio2 and CoaguChek XS was
cost saving under the base-case assumptions, whereas self-testing was not cost-effective. The results also
showed the mixed self-monitoring strategy (50% self-testing, 50% self-management) to be cost saving
with CoaguChek XS and INRatio2 in comparison with exclusive secondary care testing. When applying the
pooled RR for adverse events (derived from all self-monitoring studies) to both self-testing and self-managing
participants, the cost savings and QALY gains associated with self-monitoring increased (see Table 26,
scenario 5). This is because under this scenario self-testing becomes independently more effective. The
same pattern of results was identified when self-monitoring was compared with exclusive secondary care
anticoagulation clinic testing (see Table 26, scenario 6) using the point estimates of RRs derived only from
trials making this comparison (see Figures 6 and 14). Finally, scenario 7 (see Table 26) shows the results when
restricting the comparison to CoaguChek XS versus standard monitoring, using the pooled point estimates
of RR derived only from trials of CoaguChek versus standard practice.
TABLE 25 Mean and incremental costs and effects over a 10-year time horizon
Strategy
Mean
costs
Incremental
costs
Mean
QALYs
Incremental
QALYs ICERa ICER vs. SC
Self-monitoring: INRatio2 £7295 £0 5.507 0 – Dominant
Standard monitoring £7324 £29 5.479 –0.027 Dominated –
Self-monitoring: CoaguChek XS £7333 £37 5.507 0 Dominated £319
Self-monitoring: ProTime £8609 £1314 5.507 0 Dominated £47,604
SC, standard care.
a ICER expressed relative to the next less costly, non-dominated alternative, assuming equivalent effects for the alternative
self-monitoring devices.
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FIGURE 19 Cost-effectiveness frontier (base case).
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TABLE 26 Cost-effectiveness by type of self-monitoring and standard-care comparator (primary/secondary care)
Strategy
Mean
costs
Incremental
costs
Mean
QALYs
Incremental
QALYs ICERa ICER vs. SC
Base case (100% self-management vs. standard care)
Self-monitoring: INRatio2 £6370 – 5.534 – – Dominant
Self-monitoring: CoaguChek XS £6407 £37 5.534 0 Dominated Dominant
Standard monitoring £7324 £954 5.479 –0.054 Dominated –
Self-monitoring: ProTime £7691 £1321 5.534 0 Dominated £6797
Base case (100% self-testing vs. standard care)
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £8221 £897 5.479 0 £2,699,665 £2,699,665
Self-monitoring: CoaguChek XS £8258 £37 5.479 0 Dominated £2,811,298
Self-monitoring: ProTime £9528 £1306 5.479 0 Dominated £6,631,414
Base case (100% primary care)
Standard monitoring £7132 – 5.479 – – –
Self-monitoring: INRatio2 £7208 £75 5.507 0.027 £2749 £2749
Self-monitoring: CoaguChek XS £7245 £37 5.507 0 Dominated £4108
Self-monitoring: ProTime £8522 £1314 5.507 0 Dominated £50,689
Base case (100% secondary care)
Self-monitoring: INRatio2 £7469 – 5.507 – – Dominant
Self-monitoring: CoaguChek XS £7506 £37 5.507 0 Dominated Dominant
Standard monitoring £7704 £235 5.479 –0.027 Dominated –
Self-monitoring: ProTime £8783 £1314 5.507 0 Dominated £39,963
Self-monitoring (50–50 split between self-testing and self-management) vs. standard care, but applying pooled RR
estimates for all self-monitoring as a whole
Self-monitoring: INRatio2 £6753 – 5.530 – – Dominant
Self-monitoring: CoaguChek XS £6790 £37 5.530 0 Dominated Dominant
Standard monitoring £7324 £571 5.479 –0.051 Dominated –
Self-monitoring: ProTime £8073 £1321 5.530 0 Dominated £14,690
Self-monitoring (50–50 split between self-testing and self-management) vs. secondary care anticoagulation clinic testing,
applying pooled RR estimates from RCTs where this represented the comparator (see Chapter 2, Figures 6 and 11)
Self-monitoring: INRatio2 £7064 – 5.532 – – Dominant
Self-monitoring: CoaguChek XS £7102 £37 5.532 0 Dominated Dominant
Standard monitoring £7704 £639 5.479 –0.053 Dominated –
Self-monitoring: ProTime £8386 £1321 5.532 0 Dominated £12,872
Self-monitoring with CoaguChek (50–50 split between self-testing and self-management) vs. standard care, applying
pooled RR estimates trials including only CoaguChek (see Chapter 2, Table 6)
Self-monitoring: CoaguChek XS £7019 – 5.531 – – –
Standard monitoring £7324 £305 5.479 –0.052 Dominated Dominated
SC, standard care.
a ICERs expressed relative to the next less costly non-dominated alternative, assuming equivalent effects for the alternative
self-monitoring devices.
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Table 27 presents the results of alternative non-base-case scenarios, assessing the impact of using
self-monitoring not to increase the number of tests performed annually, but to replace standard
monitoring tests (average 12 per year). For these analyses it was assumed that no difference in clinical
effectiveness exists between self-management, self-testing and standard care. Under most of these
scenarios, standard monitoring was found to be less costly than self-monitoring. However, self-testing and
self-management with INRatio2 and CoaguChek XS remained cost saving in comparison with exclusive
secondary care anticoagulation clinic monitoring.
TABLE 27 Cost-minimisation scenarios assuming of no difference in the number of monitoring tests or clinical
effectiveness between patient self-monitoring and standard monitoring
Strategy
Mean
costs
Incremental
costs
Mean
QALYs
Incremental
QALYs ICERa ICER vs. SC
Self-monitoring (50% self-test, 50% self-manage) with no increase in number of tests performed, compared with standard
care (66% primary care, 34% secondary care)
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7423 £99 5.479 0 Dominated Dominated
Self-monitoring: CoaguChek XS £7457 £34 5.479 0 Dominated Dominated
Self-monitoring: ProTime £8435 £978 5.479 0 Dominated Dominated
100% self-test with no increase in the number of tests performed, compared with standard care (66% primary care,
34% secondary care)
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7463 £139 5.479 0 Dominated Dominated
Self-monitoring: CoaguChek XS £7498 £34 5.479 0 Dominated Dominated
Self-monitoring: ProTime £8475 £978 5.479 0 Dominated Dominated
100% self-manage with no increase in number of tests performed, compared with standard care (66% primary care,
34% secondary care)
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7383 £59 5.479 0 Dominated Dominated
Self-monitoring: CoaguChek XS £7417 £34 5.479 0 Dominated Dominated
Self-monitoring: ProTime £8395 £978 5.479 0 Dominated Dominated
100% self-test with no increase in number of tests performed, compared with standard care (compared with standard
monitoring in secondary care)
Self-monitoring: INRatio2 £7638 – 5.479 – – Dominant
Self-monitoring: CoaguChek XS £7672 £34 5.479 0 Dominated Dominant
Standard monitoring £7704 £66 5.479 0 Dominated –
Self-monitoring: ProTime £8650 £1012 5.479 0 Dominated Dominated
100% self-manage with no increase in number of tests performed, compared with standard care (compared with standard
monitoring in secondary care)
Self-monitoring: INRatio2 £7557 – 5.489 – – Dominant
Self-monitoring: CoaguChek XS £7592 £34 5.489 0 Dominated Dominant
Standard monitoring £7704 £146 5.489 0 Dominated –
Self-monitoring: ProTime £8570 £1012 5.489 0 Dominated Dominated
SC, standard care.
a ICERs expressed relative to the next less costly, non-dominated alternative, assuming equivalent effects for the alternative
self-monitoring devices.
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Differential results for subgroups
Table 28 presents the results for self-monitoring versus standard care by indication (atrial fibrillation and
AHVs) and cohort age. Compared with standard monitoring, self-monitoring in a 65-year-old cohort with
atrial fibrillation was estimated to cost £2574 and £4160 per QALY gained with INRatio2 and CoaguChek
XS, respectively. Self-monitoring with ProTime was estimated to cost £58,584 per QALY gained. For a
65-year-old AHV cohort, self-monitoring with INRatio2 and CoaguChek XS was found to be more effective
and less costly (dominant) than standard monitoring.
A further analysis was carried out for the atrial fibrillation cohort using the baseline risks observed for
participants with better INR control in standard care, assuming a constant RR reduction for thromboembolic
events associated with self-monitoring. As the INR TTR increased in the control group, and the baseline risk
of thromboembolic events consequently dropped, the cost-effectiveness of self-monitoring also decreased.
However, the ICERs for CoaguChek XS and INRatio2 rose above £20,000 per QALY only when the baseline
TTR was set at > 72.6%.
While cost-effectiveness was found to decrease slightly in a younger mixed cohort (due to the lower
baseline risk of thromboembolic events), the ICERs for CoaguChek XS and INRatio2 remained below
£20,000 per QALY gained. Self-monitoring was found to be most cost-effective in a 75-year-old cohort.
Further analysis of uncertainty (sensitivity analysis)
Deterministic sensitivity analysis was undertaken to test the robustness of the model, based findings to
various parameter and structural assumptions (Table 29). The findings were found to be most sensitive
to the baseline risk of thromboembolic events and the effectiveness of self-monitoring for preventing
these events (see Table 29, scenarios 14–16). Applying a baseline risk of 1.15% coupled with the
upper 95% confidence limit of the RR estimate for self-management (0.69), the ICERs for the mixed
self-monitoring strategies rose above £30,000 per QALY gained (see Table 29, scenario 17). The same was
found when the lower baseline risk (1.15%) was coupled with the upper confidence limit for the RR
(for thromboembolic events) associated with self-monitoring as a whole (0.84 applied for self-testing and
self-management). One hundred per cent self-management remained cost saving under the former
combined scenario but not the latter.
The cost-effectiveness of self-monitoring improved further when the modelled time horizon was extended
to 20 and 30 years, with both CoaguChek XS and INRatio2 dominating standard primary/secondary
care-based monitoring. The incremental cost per QALY gained for self-monitoring with CoaguChek XS
and INRatio2 also remained below £20,000 when higher training failure and discontinuation rates were
applied, and when higher self-monitoring testing frequencies were applied (with no change in effects).
The cost-effectiveness findings were also robust to the number of tests performed annually in standard
primary/secondary care-based clinic monitoring.
A final sensitivity analysis was conducted to approximate the cost-effectiveness of self-monitoring for a
cohort of children with an AHV on long-term vitamin K antagonist therapy. For this analysis, the cohort
age was set to 10 years, the baseline risk of thromboembolic events was reduced to 1.4%, and the
annual risk of all-cause mortality following a stroke was set at 14.5.134 Under this scenario, the ICERs for
self-monitoring with CoaguChek XS and INRatio2 remained favourable. However, it should be noted that
no good data were identified to appropriately adjust the risk of death from all causes in children with an
AHV, and therefore the standardised mortality ratio estimated for an 18- to 55-year-old cohort of AHV
participants was applied.
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TABLE 28 Cost-effectiveness results by patient subgroups
Strategy
Mean
costs
Incremental
costs
Mean
QALYs
Incremental
QALYs ICERa ICER vs. SC
Atrial fibrillation cohort (aged 65 years)
Standard monitoring £6951 – 5.533 – – –
Self-monitoring: INRatio2 £7012 £61 5.557 0.024 £2574 £2574
Self-monitoring: CoaguChek XS £7049 £37 5.557 0 Dominated £4160
Self-monitoring: ProTime £8335 £1323 5.557 0 Dominated £58,584
Mechanical heart valve cohort (aged 65 years)
Self-monitoring: INRatio2 £7721 – 5.431 – – Dominant
Self-monitoring: CoaguChek XS £7758 £37 5.431 0 Dominated Dominant
Standard monitoring £7884 £163 5.398 –0.033 Dominated –
Self-monitoring: ProTime £9020 £1300 5.431 0 Dominated £34,449
Atrial fibrillation cohort with TTR 65.6–72.6% (aged 65 years)
Standard monitoring £5522 – 5.608 – – –
Self-monitoring: INRatio2 £5780 £257 5.623 0.016 £16,409 £16,409
Self-monitoring: CoaguChek XS £5817 £38 5.623 0 Dominated £18,817
Self-monitoring: ProTime £7117 £1337 5.623 0 Dominated £101,677
Atrial fibrillation cohort with TTR > 72.6% (aged 65 years)
Standard monitoring £5090 – 5.631 – – –
Self-monitoring: INRatio2 £5401 £310 5.645 0.014 £22,768 £22,768
Self-monitoring: CoaguChek XS £5438 £38 5.645 0 Dominated £25,548
Self-monitoring: ProTime £6743 £1342 5.645 0 Dominated £121,280
Mixed cohort (aged 55 years)
Standard monitoring £6956 – 5.945 – – –
Self-monitoring: INRatio2 £7050 £94 5.965 0.02 £4592 £4592
Self-monitoring: CoaguChek XS £7088 £38 5.965 0 Dominated £6465
Self-monitoring: ProTime £8411 £1361 5.965 0 Dominated £71,262
Mixed cohort (aged 75 years)
Standard monitoring £6560 – 4.452 – – –
Self-monitoring: INRatio2 £6563 £4 4.484 0.032 £116 £116
Self-monitoring: CoaguChek XS £6598 £35 4.484 0 Dominated £1209
Self-monitoring: ProTime £7771 £1208 4.484 0 Dominated £37,776
Mixed cohort (aged 85 years)
Standard monitoring £3705 – 3.008 – – –
Self-monitoring: INRatio2 £3922 £218 3.037 0.029 £7485 £7485
Self-monitoring: CoaguChek XS £3952 £29 3.037 0 £0 £8491
Self-monitoring: ProTime £4874 £951 3.037 0 £0 £40,169
SC, standard care.
a ICERs expressed relative to the next less costly non-dominated alternative, assuming equivalent effects for the alternative
self-monitoring devices.
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TABLE 29 Sensitivity analysis scenarios
Strategy
Mean
costs
Incremental
costs
Mean
QALYs
Incremental
QALYs ICERa ICER vs. SC
Assume 10 minutes of nurse time per standard primary care monitoring visit, rather than 15 minutes
Standard monitoring £7146 – 5.479 – – –
Self-monitoring: INRatio2 £7249 £103 5.507 0.027 £3,760 £3760
Self-monitoring: CoaguChek XS £7287 £37 5.507 0 Dominated £5119
Self-monitoring: ProTime £8563 £1314 5.507 0 Dominated £51,699
Unit costs of standard care as per Jowett and colleagues87
Self-monitoring: INRatio2 £7333 – 5.507 – – Dominant
Self-monitoring: CoaguChek XS £7370 £37 5.507 0 Dominated Dominant
Standard monitoring £7468 £136 5.479 –0.027 Dominated –
Self-monitoring: ProTime £8647 £1314 5.507 0 Dominated £43,640
10 standard care visits per year (with no change in the baseline risk of adverse events)
Standard monitoring £7112 – 5.479 – – –
Self-monitoring: INRatio2 £7241 £128 5.507 0.027 £4676 £4676
Self-monitoring: CoaguChek XS £7278 £37 5.507 0 Dominated £6035
Self-monitoring: ProTime £8555 £1314 5.507 0 Dominated £52,616
20 standard care visits per year (with no increase in baseline risk adverse events)
Self-monitoring: INRatio2 £7514 – 5.507 – – Dominant
Self-monitoring: CoaguChek XS £7551 £37 5.507 0 Dominated Dominant
Standard monitoring £8170 £656 5.479 –0.027 Dominated –
Self-monitoring: ProTime £8828 £1314 5.507 0 Dominated £24,365
Self-monitoring training failure rate 24% and subsequent discontinuation rate 14%
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7328 £4 5.503 0.023 £190 £190
Self-monitoring: CoaguChek XS £7361 £32 5.503 0 Dominated £1563
Self-monitoring: ProTime £8459 £1131 5.503 0 Dominated £48,488
26 self-monitoring tests per year with the same relative effects
Self-monitoring: INRatio2 £7079 – 5.507 – – Dominant
Self-monitoring: CoaguChek XS £7115 £36 5.507 0 Dominated Dominant
Standard monitoring £7324 £245 5.479 –0.027 Dominated –
Self-monitoring: ProTime £8277 £1198 5.507 0 Dominated £35,287
52 self-monitoring tests per year with the same relative effects
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7704 £380 5.507 0.027 £13,879 £13,879
Self-monitoring: CoaguChek XS £7744 £39 5.507 0 Dominated £15,309
Self-monitoring: ProTime £9237 £1533 5.507 0 Dominated £69,814
Reduce the increased number of tests with self-monitoring by 50% (+12) and halve the relative effect sizes
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7353 £29 5.494 0.015 £1,990 £1990
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TABLE 29 Sensitivity analysis scenarios (continued )
Strategy
Mean
costs
Incremental
costs
Mean
QALYs
Incremental
QALYs ICERa ICER vs. SC
Self-monitoring: CoaguChek XS £7389 £36 5.494 0 Dominated £4440
Self-monitoring: ProTime £8522 £1169 5.494 0 Dominated £81,724
Higher acute costs for major stroke, based on the application of excess bed-day costs for each day over the mean HRG
length of stay
Self-monitoring: INRatio2 £7478 – 5.507 – – Dominant
Self-monitoring: CoaguChek XS £7515 £37 5.507 0 Dominated Dominant
Standard monitoring £7547 £69 5.479 –0.027 Dominated –
Self-monitoring: ProTime £8792 £1314 5.507 0 Dominated £46,101
Cost-effectiveness over a 20-year time horizon
Self-monitoring: INRatio2 £13,002 – 7.711 – – Dominant
Self-monitoring: CoaguChek XS £13,055 £53 7.711 0 Dominated Dominant
Standard monitoring £13,417 £415 7.635 –0.076 Dominated –
Self-monitoring: ProTime £14,892 £1890 7.711 0 Dominated £19,407
Cost-effectiveness over a 30-year time horizon
Self-monitoring: INRatio2 £13,877 – 8.156 – – Dominant
Self-monitoring: CoaguChek XS £13,934 £57 8.156 0 Dominated Dominant
Standard monitoring £14,300 £424 8.054 –0.102 Dominated –
Self-monitoring: ProTime £15,910 £2034 8.156 0 Dominated £15,784
60% of self-monitoring patients self-test, 40% self-manage
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7480 £157 5.501 0.022 £7166 £7116
Self-monitoring: CoaguChek XS £7518 £37 5.501 0 Dominated £8808
Self-monitoring: ProTime £8793 £1312 5.501 0 Dominated £66,792
40% of self-monitoring patients self-test, 60% self-manage
Self-monitoring: INRatio2 £7110 – 5.512 – – Dominant
Self-monitoring: CoaguChek XS £7147 £37 5.512 0 Dominated Dominant
Standard monitoring £7324 £214 5.479 –0.033 Dominated –
Self-monitoring: ProTime £8426 £1315 5.512 0 Dominated £33,383
Baseline risk of thromboembolic events set at 1.15%
Standard monitoring £5999 – 5.537 – – –
Self-monitoring: INRatio2 £6214 £215 5.554 0.017 £12,729 £12,729
Self-monitoring: CoaguChek XS £6252 £37 5.554 0 Dominated £14,944
Self-monitoring: ProTime £7538 £1323 5.554 0 Dominated £91,005
RR for thromboembolic events associated with self-management= 0.69 (self-testing 0.99 as per base case)
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7564 £240 5.495 0.016 £15,318 £15,318
Self-monitoring: CoaguChek XS £7601 £37 5.495 0 Dominated £17,688
Self-monitoring: ProTime £8875 £1311 5.495 0 Dominated £98,856
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TABLE 29 Sensitivity analysis scenarios (continued )
Strategy
Mean
costs
Incremental
costs
Mean
QALYs
Incremental
QALYs ICERa ICER vs. SC
RR for thromboembolic events associated with self-monitoring= 0.84 for self-testing and self-management
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7552 £228 5.495 0.016 £13,964 £13,964
Self-monitoring: CoaguChek XS £7589 £37 5.495 0 Dominated £16,241
Self-monitoring: ProTime £8863 £1311 5.495 0 Dominated £94,228
Baseline risk of thromboembolic events 1.15%, RR associated with self-management 0.69
Standard monitoring £5999 – 5.537 – – –
Self-monitoring: INRatio2 £6397 £398 5.546 0.009 £44,308 £44,308
Self-monitoring: CoaguChek XS £6434 £37 5.546 0 Dominated £48,478
Self-monitoring: ProTime £7718 £1321 5.546 0 Dominated £191,567
Baseline risk of thromboembolic events 1.15%, RR associated with self-management and self-testing 0.84
Standard monitoring £5999 – 5.537 – – –
Self-monitoring: INRatio2 £6388 £389 5.546 0.009 £41,225 £41,225
Self-monitoring: CoaguChek XS £6425 £37 5.546 0 Dominated £45,193
Self-monitoring: ProTime £7709 £1321 5.546 0 Dominated £181,371
Mechanical heart valve cohort (approximation for children aged 10 years)
Self-monitoring: INRatio2 £7897 – 7.324 – – Dominant
Self-monitoring: CoaguChek XS £7936 £39 7.324 0 Dominated Dominant
Standard monitoring £7946 £49 7.291 –0.033 Dominated –
Self-monitoring: ProTime £9296 £1399 7.324 0 Dominated £40,906
Self-monitoring device costs annuitised over 3 years
Standard monitoring £7324 – 5.479 – – –
Self-monitoring: INRatio2 £7526 £202 5.507 0.027 £7387 £7387
Self-monitoring: CoaguChek XS £7584 £57 5.507 0 Dominated £9480
Self-monitoring: ProTime £9352 £1826 5.507 0 Dominated £74,001
50% of devices are reused following patients discontinuing self-monitoring
Self-monitoring: INRatio2 £7301 – 5.507 – – Dominant
Standard monitoring £7324 £23 5.479 –0.027 Dominated –
Self-monitoring: CoaguChek XS £7338 £38 5.507 0 Dominated £533
Self-monitoring: ProTime £8626 £1326 5.507 0 Dominated £48,234
Lower cost of £195 applied for the INRatio2 PT/INR monitor
Self-monitoring: INRatio2 £7185 – 5.507 – – Dominant
Standard monitoring £7324 £139 5.479 –0.027 Dominated –
Self-monitoring: CoaguChek XS £7333 £147 5.507 0 Dominated £319
Self-monitoring: ProTime £8609 £1424 5.507 0 Dominated £47,604
SC, standard care.
a ICERs expressed relative to the next less costly, non-dominated alternative, assuming equivalent effects for the alternative
self-monitoring devices.
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Probabilistic sensitivity analysis of the base case
Table 30 presents the mean costs and effects, and mean incremental cost-effectiveness results, for the four
strategies based on 1000 probabilistic simulations. Compared with the deterministic analysis presented in
Table 25, the results are very similar.
Figure 20 shows the scatterplot of the estimated mean incremental costs and effects of self-monitoring
with CoaguChek XS compared with standard monitoring, derived from 1000 probabilistic iterations of the
model. Approximately 50% of the points lie below zero on the cost axis and above zero on the effect axis,
indicating a 50% chance of the self-monitoring strategy (50% self-testing, 50% self-managing)
dominating standard care monitoring. The acceptability curve (Figure 21) indicates an 80% chance of
self-monitoring with CoaguChek XS being cost-effective compared with standard monitoring at a
willingness-to-pay threshold of £20,000 per QALY gained.
Figures 22 and 23 show the corresponding incremental cost and effect scatterplot, and acceptability curve
for self-monitoring with INRatio2 versus standard care. This analysis assumes equivalent effects for INRatio2
compared with CoaguChek XS. Self-monitoring with INRatio2 was estimated to have an 81% chance of
being cost-effective at a threshold of £20,000 per QALY gained under these assumptions. However, it
should be noted that no direct RCT evidence was identified for the effect of INRatio2 on long-term adverse
outcomes, with the majority of RCT evidence relating to versions of CoaguChek.
TABLE 30 Mean and incremental costs and effects over a 10-year time horizon
Strategy
Mean
costs
Incremental
costs
Mean
QALYs
Incremental
QALYs ICERa ICER vs. SC
Self-monitoring: INRatio2 £7290 – 5.507 – – Dominant
Standard monitoring £7312 £22 5.479 –0.028 Dominated –
Self-monitoring: CoaguChek XS £7327 £37 5.507 0 Dominated £533
Self-monitoring: ProTime £8603 £1313 5.507 0 Dominated £46,632
SC, standard care.
a ICER expressed relative to the next less costly, non-dominated alternative, assuming equivalent effects for the alternative
self-monitoring devices.
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FIGURE 20 Incremental cost-effectiveness scatterplot: self-monitoring with CoaguChek XS vs. standard monitoring.
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FIGURE 22 Incremental cost-effectiveness scatterplot: self-monitoring with INRatio2 vs. standard monitoring.
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FIGURE 23 Cost-effectiveness acceptability curves: self-monitoring with INRatio2 vs. standard care.
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FIGURE 21 Cost-effectiveness acceptability curves: self-monitoring with CoaguChek XS vs. standard care.
WTP, wllingness to pay.
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Figures 24 and 25 summarise the results of the probabilistic analysis for self-monitoring with ProTime
versus standard monitoring. Owing to the higher cost of the device, this strategy was found to have a
lower chance of being cost-effective in than standard practice.
Finally, Figures 26 and 27 summarise the uncertainty surrounding the cost-effectiveness of self-monitoring
with CoaguChek XS versus secondary care anticoagulation clinic testing (applying RR distributions based
on the pooled estimates from trials making this comparison) and mixed (primary/secondary care) standard
monitoring (using RRs derived from trials using only CoaguChek).
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FIGURE 24 Incremental cost-effectiveness scatterplot: self-monitoring with ProTime vs. standard monitoring.
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FIGURE 25 Cost-effectiveness acceptability curves: self-monitoring with ProTime vs. standard care.
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Summary
Self-monitoring, and in particular self-management, of anticoagulation status appears cost-effective
when pooled estimates of clinical effectiveness are applied. However, if self-monitoring does not result
in significant reductions in thromboembolic events, it is unlikely to be cost-effective from the NHS and
personal social services perspective at the frequency of testing observed in RCTs.
We are most confident in the applicability of the base-case cost-effectiveness findings to self-monitoring
strategies using CoaguChek XS. The majority of clinical effectiveness evidence relates to a previous version
of CoaguChek (CoaguChek S), to which the current version (CoaguChek XS) has been shown to have very
similar or slightly superior performance in terms of accuracy and precision (see Independent economic
assessment). While INRatio and ProTime have been shown to have acceptable performance in relation to
laboratory testing, very few studies have directly compared CoaguChek XS with the INRatio2 PT/INR
monitor and/or ProTime Microcoagulation system. Further studies are needed to assess relative diagnostic
and clinical performance.
The main findings and uncertainties are discussed further in Chapter 4.
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FIGURE 27 Cost-effectiveness acceptability curves: self-monitoring with CoaguChek XS vs. secondary care
anticoagulation clinic monitoring (applying RRs for self-monitoring vs. specialised anticoagulation clinic testing).
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FIGURE 26 Cost-effectiveness acceptability curves: self-monitoring with CoaguChek XS vs. standard monitoring
(based on pooled RR estimates from CoaguChek studies only).
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Chapter 4 Discussion
Statement of principal findings
Clinical effectiveness
This assessment is based on 26 RCTs evaluating the use of point-of-care devices for the self-monitoring
(self-testing and self-management) of people receiving AOT. The results of this assessment indicate that:
l Self-monitoring (self-testing or self-management) of anticoagulation therapy leads to significantly fewer
thromboembolic events than standard primary care or anticoagulation control in specialised clinics
(RR 0.58, 95% CI 0.40 to 0.84; p= 0.004).
l There is no evidence of a difference in bleeding events (RR 0.95, 95% CI 0.74 to 1.21; p= 0.66).
l Self-monitoring almost halved the risk of thromboembolic events in people with AHVs.
l A statistically significantly greater reduction in thromboembolic events was observed among
self-managed people than among those in self-testing.
l Among people who self-monitored their therapy, there was a trend towards fewer thromboembolic
events when compared with those who were managed by their GPs or physicians than those managed
in specialised anticoagulation clinic. The subgroup analysis was not, however, statistically significant.
l Self-monitoring significantly reduced the risk of mortality among people with AHVs but not among
those with mixed clinical indication. There was lower all-cause mortality through self-management but
not through self-testing. In particular, significantly fewer deaths were observed among people who
self-managed their AOT than those who received primary standard care (control care by a GP or
a physician).
l Compared with standard care, self-monitoring (self-testing and self-management) did not demonstrate
a significant reduction in the number of major and minor bleeding events.
l In the majority of included trials (23 out of 26), the INR TTR was higher in self-monitoring people than
in people receiving standard anticoagulation control, and in five of these trials there was a statistically
significant difference between intervention groups.
l The overall percentage of participants who completed self-monitoring was fairly high (at least 80%),
and in the few trials that collected participant views, participants expressed high satisfaction and
willingness to continue with the intervention at home.
l Six of the trials were conducted in the UK and there was no evidence that the UK trial populations
were importantly different from the rest of the included studies.
l The majority of the trials (22 out of 26) investigated the use of the CoaguChek system, the results are,
therefore, more robust for CoaguChek than for ProTime and INRatio.
l Four of the 22 trials investigating the CoaguChek system used the CoaguChek XS system. There was
insufficient evidence to determine whether or not the CoaguChek XS outcomes differed from those for
previous versions of CoaguChek systems.
l A brief overview of diagnostic performance of the various CoaguChek systems demonstrated that
across several studies INR results were more accurate in adults and children when comparing
CoaguChek XS with other CoaguChek models. We are of the opinion that this provides evidence that
the clinical outcomes can be compared across different versions of the CoaguChek system.
Comparison with other studies
Our findings are in line with those of previously published systematic reviews on self-monitoring using
point-of-care devices for the management of anticoagulation therapy, which found that self-monitoring
was associated with a significantly lower incidence of thromboembolic events21,31,33,88,108,135–137
and deaths.21,31,33,135–138
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The results of the subgroup analyses according to the type of control care (for thromboembolic events and
mortality) may be considered broadly in line with the current published evidence, which suggests that
people managed by their GPs or physicians in primary care settings have poorer anticoagulation control
than those managed in specialised anticoagulation clinics.65,139
Cost-effectiveness
The base-case model assessed the impact on costs and outcomes of using self-monitoring to increase the
number of INR tests performed annually (by 23), so as to improve INR control and prevent adverse
outcomes. The primary findings are detailed below.
l While self-monitoring (50% self-testing, 50% self-management) is likely to increase the INR monitoring
cost compared with mixed primary/secondary care standard monitoring, it is likely to be cost-effective
as a result of its impact on the incidence of thromboembolic events. This finding assumes that the
pooled relative effects of self-testing and self-management, obtained from the meta-analysis of all
RCTs, are applicable to the UK setting.
l Underlying this general observation is the finding that the pooled effect estimate for self-testing
on thromboembolic events is small and non-significant (RR 0.99), while the effect estimate
for self-management is large (RR 0.51) and significant. Thus, within the base-case model,
self-management alone is highly cost-effective (or dominant), while self-testing is not cost-effective.
l In an alternative specification, the overall pooled effect estimates obtained from all self-testing and
self-management trials were applied to both the self-testing and self-management strategies in the
model. Under this scenario, both self-testing and self-management, with CoaguChek XS or INRatio2,
were found to be dominant or highly cost-effective compared with standard monitoring.
l Two key parameters underpinning the above findings are the baseline risk of thromboembolic events,
and the relative effect of self-monitoring on these events. The model findings were robust to individual
changes in these parameters through feasible ranges. However, when the lower baseline risk of
thromboembolic events was combined with the upper confidence limit for the RR for associated
self-management (RR 0.69), the ICERs for self-monitoring as a whole rose above £30,000 per QALY.
The same was found when the lower baseline risk of thromboembolic events was coupled with the
upper confidence limit of the pooled RR for self-monitoring as whole (RR 0.89). It should be noted,
however, that self-management on its own remained cost saving under the former combined scenario.
l Further uncertainty relates to the applicability of the pooled effect estimates to the UK setting. The few
identified UK-based trials of self-monitoring versus standard practice did not demonstrate significant
effects on thromboembolic or bleeding events. Applying these effect estimates, self-monitoring would
not be cost-effective at the self-monitoring testing frequency observed in RCTs.
l Alternative scenarios assessed the potential for self-monitoring to be cost-effective if used to replace
clinic-based testing without increasing the frequency of testing. Under these scenarios, it was
assumed that there would be no effect on the number of thromboembolic or bleeding events and
a cost-minimisation approach was adopted. This showed that when holding all other base-case
parameters constant, self-monitoring (50% self-testing, 50% self-managing) was more costly than
standard primary care monitoring, but less costly than standard secondary care monitoring. These
findings were, however, sensitive to the unit costs applied to standard care monitoring visits. Applying
the alternative standard monitoring unit costs estimated by Jowett and colleagues,87 the opposite was
observed, with self-monitoring dominating secondary care monitoring but being dominated by primary
care monitoring.
Comparison with other economic evaluations
The findings of the model are generally consistent with those of previous evaluations, depending on
the assumptions and input values applied. In line with previous models that have assumed or applied
significant reductions in thromoembolic events with self-management,33,82,84,86,88 our model suggests
that self-monitoring is likely to be cost-effective under this scenario.
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Our model also produces findings that are generally consistent with the previous UK-based economic
evaluations, in that self-monitoring (under base assumptions) will increase the monitoring costs to the
NHS. However, our base case differs from previous UK evaluations in that the pooled relative effects for
self-management and self-testing, compared with standard care, were applied. This results in significant
future cost savings and quality-of-life gains from a significant reduction in the number of thromboembolic
events. This in turn translates into more favourable estimates of cost-effectiveness. Further differences
between the current analysis and the previous UK-based model include the application of higher standard
secondary care monitoring costs, lower self-monitoring device costs (in line with current prices), and
higher acute treatment costs for stroke and major bleeding events. Our analyses suggest that the
cost-effectiveness of self-monitoring is robust to variations in these parameters when pooled clinical effect
estimates are applied.
Uncertainties from the assessment
Clinical effectiveness
Although our assessment has been conducted according to current standards and recommendations,
and is the most up-to-date review undertaken, we need to acknowledge some potential limitations and
uncertainties. The areas of uncertainty were:
l The included trials varied considerably in terms of clinical indications for anticoagulation therapy, type
of control care, reporting structure for the time and/or values in therapeutic range, type and structure
of the pre-intervention training and education programme, length of follow-up and methodological
study quality. While the meta-analysis results demonstrated low statistical heterogeneity (which makes
it statistically reasonable to combine the studies), there remains uncertainty around the fact that clinical
heterogeneity could have over- or underestimated the effects.
l Quantifying the impact of the potential risk of bias in the estimates was not possible. Only four
trials55,61–63 were judged at low risk of bias. In some trials, outcomes were not assessed blinded,
allocation of participants to intervention groups was not concealed, statistical analyses were not
conducted according to an intention-to-treat principle, or many methodological details were lacking.
l All included trials enrolled highly selected samples of people requiring anticoagulation therapy, and so
it was uncertain whether or not there was strong external validity (i.e. applicability of the study results
to the entire population of eligible participants). To be enrolled in the trials, participants needed to
demonstrate adequate cognitive and physical abilities, as well as dexterity and confidence in using the
point-of-care device. In some of the included trials,61,64,67,68 a considerable proportion of eligible
participants (up to 50%) ultimately were not considered suitable for inclusion.
l The frequency of testing was not consistently reported in the included studies. This hampered the
possibility to conduct further analyses with regard to different monitoring strategies. The frequency of
INR testing in the trials was generally weekly for self-monitoring participants and monthly in standard
care. It was unclear what the optimal frequency might be, especially at long-term follow up where
there was little evidence.
l There remains some uncertainty on the applicability of the pooled results to the UK population. In our
view, the greatest uncertainty relates to the applicability of the standard-care comparators in the trials
and not to the participants in the trial.
l The majority of the trials included participants with mixed clinical indications for anticoagulation
therapy, which made it challenging to extrapolate the results to specific clinical populations. In
particular, only limited data were available for people with atrial fibrillation and, consequently, no
reliable conclusions could be drawn in relation to this patient population.
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l The majority of trials investigated the use of the CoaguChek system (22 out of 26) for the self-monitoring
of anticoagulation therapy and it proved unfeasible to conduct reliable comparisons according to the
type of point-of-care device. While the CoaguChek device has the most robust evidence, ProTime and,
particularly, INRatio do not. Given the broadly similar performance of all the devices compared with the
gold-standard laboratory test, we are of the opinion that it is not unreasonable to consider pooled
estimates of effect across all studies and devices. However, this is an assumption that currently has no
direct comparative evidence available and so a degree of caution is necessary.
l The subgroup analysis according to the type of anticoagulation therapy management (self-management
vs. self-testing) was limited due to the results being dominated by the largest trial published so far,
THINRS,71 which enrolled 2922 people and assessed patient self-testing using the ProTime device versus
routine clinical care. The trial results showed similar rates of main clinical outcomes between intervention
groups with the exception of a small but significant improvement in the percentage of time in target
range for self-testing people. It is worth pointing out that this trial had a highly specialised routine care
and the longest follow-up period (mean 3 years). It is probable that the quality of the standard care
in this trial exceeds current routine care for anticoagulation monitoring and the lack of significant
differences between self-testing and routine monitoring could be explained by the rigorous criteria used
to ensure high-standard care.
Cost-effectiveness
The model developed for this assessment has built upon previous models developed to assess the
cost-effectiveness of INR self-monitoring strategies and new pharmaceuticals compared with warfarin
therapy under standard INR monitoring arrangements. Where possible, the input parameter values used
have previously been reviewed for NICE submissions by independent ERGs and accepted by appraisal
committees. A further strength of the model comes through the dichotomisation of indication for warfarin
use (atrial fibrillation/AHVs), mode of standard-care monitoring (primary/secondary care) and mode of
self-monitoring (self-testing/self-management). This allowed assessment of cost-effectiveness by subgroups
based on these indicators. Nevertheless, the main uncertainties are given below:
l A weakness of the modelling relates to the uncertainty surrounding the pooled clinical effectiveness
estimates (for self-testing and self-management) and, in particular, their applicability to the NHS setting.
l A further weakness relates to the structural assumptions required to estimate cost-effectiveness in
younger cohorts, i.e. those below the average age of cohorts used to inform the baseline risks of
events and standardised mortality ratios associated with the clinical indications and adverse events.
To reflect the importance of age as a risk factor for thromboembolic events, RRs by 5-year age bands
were taken from a previous atrial fibrillation model92,96,97 and applied. Given a lack of similar evidence
relating to people with a mechanical heart valve, the same RRs were also applied to this subgroup
in the model. While this is not ideal, the model results were found to be robust to a range of
alternative baseline risks when applied in isolation.
l Owing to data limitations, very young cohorts were not formally included in subgroup analyses for the
economic modelling. A sensitivity analysis was conducted to approximate the results for a cohort of
children, but the estimates of baseline risk and self-monitoring effects were not well informed.
l It should finally be noted that the perspective of the cost-effectiveness analysis was that of the NHS and
personal social services. Therefore, our modelling does not capture any wider benefits or cost savings
to patients and their families, such as a reduction in time spent travelling to and waiting in clinics.
Implications for research
Trials investigating the longer-term outcomes of self-management versus usual care are needed, and direct
comparisons of the various point-of-care coagulometers ought to be incorporated into any future evaluation.
The technology related to point-of-care testing devices is constantly changing and future research needs to
target larger cohorts of people with different clinical indications requiring long-term anticoagulation therapy
who may benefit from the use of these new generations of devices.
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Appendix 1 Search strategies
Point-of-care tests for coagulation self-monitoring:
clinical effectiveness
EMBASE
Searched: 1980 to week 22 2013.
Ovid MEDLINE(R)
Searched: 1946 to week 5 May 2013.
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
Searched: 5 June 2013.
OVID Multifile searched
Searched: 5 June 2013.
URL: https://shibboleth.ovid.com/
Search strategy
1. exp 4-Hydroxycoumarins/ use mesz
2. exp coumarin anticoagulant/ use emez
3. antivitamin k/ use emez
4. warfarin.tw
5. vitamin k antagonist$.tw.
6. *anticoagulants/ad use mesz
7. *anticoagulant agent/ad use emez
8. Prothrombin Time/
9. prothrombin time.tw.
10. or/1-9
11. Self Administration/ use mesz
12. Self Care/
13. Self-monitoring/ use emez or Home Monitoring/ use emez
14. point-of-care systems/
15. poc.tw
16. point-of-care.tw.
17. (((patient$ or self) adj1 (monitor$ or manag$ or measur$)) or (self adj1 test$)).tw.
18. or/11-17
19. 10 and 18
20. coaguche?k$.tw,dv
21. INRatio$.tw,dv
22. (ProTime$ or pro time$).tw,dv
23. coagulometer$.tw.
24. or/19-23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. exp clinical trial/ use emez
28. randomization/ use emez
29. randomi?ed.ab.
30. drug therapy.fs.
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31. randomly.ab.
32. trial.ab.
33. groups.ab.
34. or/25-33
35. exp animals/ not humans/
36. 34 not 35
37. 19 and 36
38. limit 37 to yr="2007 -Current"
39. (coaguche?k$ or INRatio$ or ProTime$ or pro time$).tw,dv.
40. 38 or 39
41. limit 40 to english language
42. 41 not conference abstract.pt
43. 41 and conference abstract.pt. and ("2012" or "2013").yr.
44. 42 or 43
45. remove duplicates from 44
Science Citation Index
Searched: 1970 to 5 June 2013.
BIOSIS
Searched: 1956 to 5 June 2013.
Conference Proceedings Citation Index – Science
Searched: 2012 to 5 June 2013.
ISI Web of Knowledge
Searched: 5 June 2013.
URL: http://wok.mimas.ac.uk/
Search strategy
# 1 TS=anticoagulant*
# 2 TS=vitamin k antagonist*
# 3 TS=warfarin
# 4 TS=prothrombin time
# 5 #1 or #2 or #3 or #4
# 6 TS= ((patient* or self) N1 (monitor* or manag* or measur*))
# 7 TS=(self N1 test*)
# 8 TS=poc
# 9 TS=point-of-care
# 10 #9 or #8 OR #7 OR #6
# 11 #10 AND #5
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# 12 TS=(CoaguChek* OR CoaguChek*)
# 13 TS=(INRatio* OR ProTime*)
# 14 #13 OR #12 OR #11
# 15 (#14) AND Language=(English) AND Document Types=(Article) Timespan=2007-2013
# 16 (#14) AND Language=(English) AND Document Types=(Meeting Abstract) Timespan=2012-201
# 17 #16 OR #15 Timespan=2007-2013
The Cochrane Library, Issue 4, 2013 (Cochrane Central Register of Controlled
Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of
Review of Effects, HTA database)
Searched: May 2013.
URL: www3.interscience.wiley.com/
Search strategy
#1 MeSH descriptor: [4-Hydroxycoumarins] explode all trees
#2 warfarin or vitamin k antagonist*:ti,ab,kw
#3 MeSH descriptor: [Anticoagulants] this term only and with qualifiers: [Administration & dosage - AD]
#4 international normali?ed ratio?:ti,ab,kw
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Self Administration] explode all trees
#7 MeSH descriptor: [Self Care] explode all trees
#8 MeSH descriptor: [Point-of-Care Systems] this term only
#9 poc:ti,ab,kw
#10 (patient near/3 (monitor or manage or measure)):ti,ab,kw
#11 (self near/3 (manage or monitor or measure)):ti,ab,kw
#12 #6 or #7 or #8 or #9 or #10 or #11
#13 #5 and #12
#14 CoaguChek or INRatio or ProTime or coagulometer
#15 #13 or #14
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HTA/Database of Abstracts Reviews of Effects, Centre for Reviews
and Dissemination
Searched: May 2013.
URL: http://nhscrd.york.ac.uk/welcome.htm
Search strategy
1. MeSH DESCRIPTOR 4-Hydroxycoumarins EXPLODE ALL TREES
2. (warfarin) OR (vitamin k antagonist*)
3. MeSH DESCRIPTOR anticoagulants EXPLODE ALL TREES WITH QUALIFIER AD
4. #1 OR #2 OR #3
5. MeSH DESCRIPTOR self administration
6. MeSH DESCRIPTOR self care
7. MeSH DESCRIPTOR Point-of-Care Systems
8. (poc) OR (self NEAR3 (monitor* or manag* or measur*)) OR (patient* NEAR3 (monitor* or manag*
or measur*))
9. #5 OR #6 OR #7 OR #8
10. #4 AND #9
Additional conference proceedings
ASH 2012, 54th ASH Annual Meeting and Exposition, Atlanta, GA, 8–11 December 2012.
EHA 2012, 17th Congress, Amsterdam, 14–17 June 2012.
ISTH 2011, XXIII Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC
Meeting, ICC Kyoto, Kyoto, Japan, 23–28 July 2011.
Proceedings of the 12th National Conference on Anticoagulant Therapy, Phoenix, Arizona, 9–11 May 2013.
Clinical Trials
Searched: June 2013.
URL: http://clinicaltrials.gov/ct/gui/c/r
Search strategy
CoaguChek OR INRatio OR ProTime OR ((“point-of-care” or self) AND anticoagulant OR warfarin))
Searched: International Clinical Trials Registry Platform (ICTRP)
Date of search: June 2013.
World Health Organization
Searched: 5 June 2013.
URL: www.who.int/ictrp/en/
Search strategy
CoaguChek OR INRatio OR ProTime OR ((“point-of-care” or self) AND
anticoagulant OR warfarin))
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Point-of-care tests for coagulation self-monitoring: acceptability
EMBASE
Searched: 1980 to week 23 2013.
Ovid MEDLINE(R)
Searched: 1946 to week 5 May 2013.
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
Searched: 7 June 2013.
OVID Multifile
Searched: 5 June 2013.
URL: https://shibboleth.ovid.com/
Search strategy
1. exp 4-Hydroxycoumarins/ use mesz
2. exp coumarin anticoagulant/ use emez
3. antivitamin k/ use emez
4. warfarin.tw
5. vitamin k antagonist$.tw.
6. *anticoagulants/ad use mesz
7. *anticoagulant agent/ad use emez
8. Prothrombin Time/
9. prothrombin time.tw.
10. or/1-9
11. Self Administration/ use mesz
12. Self Care/
13. Self-monitoring/ use emez or Home Monitoring/ use emez
14. point-of-care systems/
15. poc.tw.
16. point-of-care.tw.
17. (((patient$ or self) adj1 (monitor$ or manag$ or measur$)) or (self adj1 test$)).tw.
18. or/11-17 (197928)
19. 10 and 18 (2639)
20. exp patient acceptance of health care/ use mesz
21. exp patient attitude/ use emez
22. consumer satisfaction/ use mesz
23. (patient? adj3 (compliance or participat$ or accept$ or refus$)).tw.
24. (patient? adj2 (attitude? or prefer$ or perception? or satisfaction)).tw.
25. qualitative research/
26. questionnaires/
27. (qualitative or interview$ or focus group? or questionnaire$ or survey$).tw.
28. (ethno$ or grounded or thematic or interpretive or narrative).tw.
29. or/20-28
30. 19 and 29
31. remove duplicates from 30
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Point-of-care tests for coagulation self-monitoring:
cost-effectiveness
EMBASE
Searched: 1980 to week 22 2013.
Ovid MEDLINE(R)
Searched: 1946 to week 5 May 2013.
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
Searched: 5 June 2013.
OVID Multifile
URL: https://shibboleth.ovid.com/
Search strategy
1. exp 4-Hydroxycoumarins/ use mesz
2. exp coumarin anticoagulant/ use emez
3. antivitamin k/ use emez
4. warfarin.tw.
5. vitamin k antagonist$.tw.
6. *anticoagulants/ad use mesz
7. *anticoagulant agent/ad use emez
8. Prothrombin Time/
9. prothrombin time.tw.
10. or/1-9
11. Self Administration/ use mesz
12. Self Care/
13. Self-monitoring/ use emez or Home Monitoring/ use emez
14. point-of-care systems/
15. poc.tw.
16. point-of-care.tw.
17. (((patient$ or self) adj1 (monitor$ or manag$ or measur$)) or (self adj1 test$)).tw
18. or/11-17
19. 10 and 18
20. coaguche?k.tw.
21. INRatio.tw.
22. ProTime.tw.
23. coagulometer$.tw
24. or/19-23
25. exp “costs and cost analysis”/ use mesz
26. exp economic evaluation/ use emez
27. economics/
28. health economics/ use emez
29. exp economics,hospital/ use mesz
30. exp economics,medical/ use mesz
31. economics,pharmaceutical/ use mesz
32. exp budgets/
33. exp models, economic/ use mesz
34. exp decision theory/
35. monte carlo method/
36. markov chains/
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37. exp technology assessment, biomedical/
38. cost$.ti.
39. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
40. economics model$.tw.
41. (economic$ or pharmacoeconomic$).tw.
42. (price or prices or pricing).tw.
43. (value adj1 money).tw
44. markov$.tw.
45. monte carlo.tw.
46. (decision$ adj2 (tree? or analy$ or model$)).tw.
47. or/25-46
48. 24 and 47
49. remove duplicates from 48
Health Management Information Consortium
Searched: 1979 to March 2013.
URL: https://auth.athensams.net/
Search strategy
1. anticoagulant agent/
2. warfarin.tw.
3. vitamin k antagonist$.tw.
4. prothrombin time.tw.
5. or/1-4
6. Self Care/
7. self management/
8. (((patient$ or self) adj1 (monitor$ or manag$ or measur$)) or (self adj1 test$)).tw.
9. point-of-care.tw.)
10. poc.tw.
11. or/6-10
12. 5 and 11
13. (coaguche?k$ or INRatio$ or ProTime$ or pro time$).tw.
14. 12 or 13
NHS Economic Evaluation Database
Searched: May 2013.
Centre for Reviews and Dissemination
Searched: May 2013.
URL: http://nhscrd.york.ac.uk/welcome.htm
Search strategy
1. MeSH DESCRIPTOR 4-Hydroxycoumarins EXPLODE ALL TREES
2. (warfarin) OR (vitamin k antagonist*)
3. MeSH DESCRIPTOR anticoagulants EXPLODE ALL TREES WITH QUALIFIER AD
4. #1 OR #2 OR #3
5. MeSH DESCRIPTOR self administration
6. MeSH DESCRIPTOR self care
7. MeSH DESCRIPTOR Point-of-Care Systems
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8. (poc) OR (self NEAR3 (monitor* or manag* or measur*)) OR (patient* NEAR3 (monitor* or manag*
or measur*))
9. #5 OR #6 OR #7 OR #8
10. #4 AND #9
RePEc (Research Papers in Economics)
Searched: June 2013.
URL: http://repec.org/
anticoagulation | anticoagulants | warfarin | “vitamin k antagonist”|prothrombin
self management | self-monitoring | self-testing|prothrombin
Point-of-care tests for coagulation self-monitoring:
quality of life
EMBASE
Searched: 1980 to week 22 2013.
Ovid MEDLINE(R)
Searched: 1946 to week 5 May 2013.
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
Searched: 5 June 2013.
Ovid Multifile
URL: https://shibboleth.ovid.com/
Search strategy
1. exp 4-Hydroxycoumarins/ use mesz
2. exp coumarin anticoagulant/ use emez
3. antivitamin k/ use emez
4. warfarin.tw.
5. vitamin k antagonist$.tw.
6. *anticoagulants/ad use mesz
7. *anticoagulant agent/ad use emez
8. Prothrombin Time/
9. prothrombin time.tw.
10. or/1-9
11. Self Administration/ use mesz
12. Self Care/
13. Self-monitoring/ use emez or Home Monitoring/ use emez
14. point-of-care systems/
15. poc.tw.
16. point-of-care.tw.
17. (((patient$ or self) adj1 (monitor$ or manag$ or measur$)) or (self adj1 test$)).tw.
18. or/11-17
19. 10 and 18
20. coaguche?k.tw.
21. INRatio.tw.
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22. ProTime.tw
23. coagulometer$.tw.
24. or/19-23
25. quality of life/
26. quality adjusted life year/
27. “Value of Life”/ use mesz
28. health status indicators/ use mesz
29. health status/ use emez
30. sickness impact profile/ use mesz
31. disability evaluation/ use mesz
32. disability/ use emez
33. activities of daily living/ use mesz
34. exp daily life activity/ use emez
35. cost utility analysis/ use emez
36. rating scale/
37. questionnaires/
38. (quality adj1 life).tw.
39. quality adjusted life.tw.
40. disability adjusted life.tw.
41. (qaly? or qald? or qale? or qtime? or daly?).tw.
42. (euroqol or euro qol or eq5d or eq 5d).tw.
43. (hql or hqol or h qol or hrqol or hr qol).tw.
44. (hye or hyes).tw
45. health$ year$ equivalent$.tw.
46. (hui or hui1 or hui2 or hui3).tw.
47. (health adj3 (utilit$ or disutili$)).tw.
48. (health adj3 (state or status)).tw.
49. (sf36 or sf 36 or short form 36 or shortform 36).tw.
50. (sf6 or sf 6 or short form 6 or shortform 6).tw.
51. (sf12 or sf 12 or short form 12 or shortform 12).tw.
52. (sf16 or sf 16 or short form 16 or shortform 16).tw.
53. (sf20 or sf 20 or short form 20 or shortform 20).tw.
54. willingness to pay.tw
55. standard gamble.tw.
56. trade off.tw.
57. conjoint analys?s.tw.
58. discrete choice.tw.
59. or/25-58
60. (case report or editorial or letter).pt.
61. case report/
62. (24 and 59) not (60 or 61)
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CEA Registry June 2013
URL: https://research.tufts-nemc.org/cear4/default.asp
Search strategy
Oral anticoagulation
Websites consulted
Agency for Healthcare Research and Quality: www.ahrq.gov/
American Heart Association: www.americanheart.org/
Alere: www.alereINRatio.com/
Belgian Health Care Knowledge Centre: https://kce.fgov.be/
Canadian Agency for Drugs and Technologies in Health: www.cadth.ca/
CoaguChek System: www.CoaguChek.com/uk/
European Society of Cardiology: www.escardio.org/
French National Authority for Health: www.has-sante.fr/
Health Information & Quality Authority: www.hiqa.ie/
Institute for Clinical and Economic Review: www.icer-review.org/
Institute for Quality and Efficiency in Health Care: www.iqwig.de/
International Society of Thrombosis and Haemostasis: www.med.unc.edu/welcome.htm
International Technidyne Corporation: www.itcmed.com/
Medicines and Healthcare Products Regulatory Agency: www.mhra.gov.uk/
Medical Services Advisory Committee, Australia: www.msac.gov.au/
National Institute for Health and Care Excellence: www.nice.org.uk/
NHS Quality Improvement Scotland: www.healthcareimprovementscotland.org/
US Food and Drug Administration: www.fda.gov/default.htm
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Appendix 2 Data extraction form
CoaguChek, INRatio and ProTime microcoagulation system for
self-monitoring in people taking long-term vitamin K antagonists:
data extraction form
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Reviewer ID
Date 
ADMINISTRATION DETAILS
Study ID
Publication status
Papers this study may link with 
AIM OF THE STUDY
STUDY DETAILS
Study design 
Country
Number of centres
Sample identification 
Method of recruitment
Allocation method
Study dates
Duration of the study
Length of follow up
Eligibility criteria for the study
Inclusion criteria
Exclusion criteria
Interventions and comparators
Comparisons (Intervention 
versus comparator)
1. 
2.
Settings 
Details of the intervention
Details of the comparator
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Details of education and 
training provided
Details of person involved in 
the study
Details of point-of-care tests 
used for INR monitoring 
Details of laboratory analysers 
used for INR monitoring 
Type of vitamin K anatagonists 
used by participants
Time on anticoagulant therapy
Primary outcomes reported 
Secondary outcomes reported 
Adverse events reported 
Study power and statististical 
analysis 
Additional information 
Source of funding
PARTICIPANTS CHARACTERISTICS
Number of 
participants, n (%) Total Intervention Comparator
Screened 
Excluded
Enrolled
DOI: 10.3310/hta19480 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 48
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
Excluded
Randomised
Excluded
Analysed
Excluded
Discontinued study
Primary analysis data 
cut-off date
Patient baseline 
characteristics
Total Intervention Comparator Difference between 
the groups
Total participants, n
Adult, n
Children, n
Age (years) 
(mean/median, 
SD/range)
Gender (M/F), n ( %)
Reason for 
anticoagulation
Atrial fibrillation, n 
(%)
Artificial heart valves, 
n (%)
Venous 
thromboembolism, 
n(%)
Other indication, n(%)
INR target range,n(%) 
2 to 3
2.5 to 3.5
3
Time on anticoagulant 
therapy, n(%)
3 months
6 months
12 months
Receiving treatment 
with any other blood 
thinning drugs e,g., 
clopidogrel, aspirin), 
n(%)
Additional information (e.g., comorbidity present, coronary risk factors etc.)
Feasibility of testing, n (%)
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Total Intervention Comparator Additional 
information
Total invited
Response rate
Willing to participate
Provided consent
Attended training
Completed training
Completed intervention
Reason for the drop-outs, 
pre randomisation
Reason for the drop-outs, 
after randomisation
OUTCOMES
Clinical 
Outcomes/ 
Adverse events
Intervention Control Difference 
between 
groups
p
value
Additional 
information
Events 
(n)
Total 
(N)
Events 
(n)
Total 
(N)
Number of bleeds 
or blood clots
Major 
haemorrhage
Minor 
haemorrhage
Thromboembolic 
events
Cerebrovascular 
events
Number of deaths
Number of deaths 
from INR testing
Number of deaths 
from VKA 
therapy
Adverse events
Adverse events 
from INR testing
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Adverse events 
from false test 
results
Adverse events 
from VKA 
therapy and 
sequelae
Intermediate 
Outcomes
specify 
measures 
eg mean 
(SD)
Intervention
n=
Control
n= Difference 
between 
groups
p
value
Additional 
information
value
SD, 
range 
etc.
value
SD, 
range, 
etc.
Time in 
therapeutic 
range for 
INR (ITT 
analysis)
INR values 
(mean, 
median/SD, 
range)
Test failure 
rate
Time to test 
results
Patient 
compliance 
with testing 
Patient 
compliance 
with 
treatment
Frequency of 
testing
Frequency of 
visits to 
primary care 
clinics
Frequency of 
visits to 
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secondary 
care clinics
Patient 
reported 
outcomes
specify 
measures 
eg, mean 
(SD)
Intervention
(n=)
Control
(n=)
Difference 
between 
groups
values 
(variance)
p
value
Additional 
information
values SD, 
range 
etc
values SD, 
range 
etc
People 
anxiety 
associated 
with waiting 
time for 
results and 
not knowing 
their current 
coagulation 
status
Health-
related 
quality of 
life
Acceptability 
of the tests 
Give details of any other outcomes 
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Appendix 3 Quality assessment
The Cochrane Collaboration’s tool for assessing risk of bias
Domain Support for judgement Review authors’ judgement
Selection bias
Random sequence generation Describe the method used to generate
the allocation sequence in sufficient
detail to allow an assessment of whether
or not it should produce comparable
groups
Selection bias (biased allocation to
interventions) due to inadequate
generation of a randomised
sequence
Allocation concealment Describe the method used to conceal
the allocation sequence in sufficient
detail to determine whether or not
intervention allocations could have
been foreseen in advance of, or during,
enrolment
Selection bias (biased allocation to
interventions) due to inadequate
concealment of allocations prior
to assignment
Performance bias
Blinding of participants and
personnel Assessments should be
made for each main outcome (or class
of outcomes)
Describe all measures used, if any,
to blind study participants and personnel
from knowledge of which intervention
a participant received. Provide any
information relating to whether or not
the intended blinding was effective
Performance bias due to knowledge
of the allocated interventions by
participants and personnel during
the study
Detection bias
Blinding of outcome assessment
Assessments should be made for each
main outcome (or class of outcomes)
Describe all measures used, if any,
to blind outcome assessors from
knowledge of which intervention a
participant received. Provide any
information relating to whether or not
the intended blinding was effective
Detection bias due to knowledge
of the allocated interventions by
outcome assessors
Attrition bias
Incomplete outcome data
Assessments should be made for each
main outcome (or class of outcomes)
Describe the completeness of outcome
data for each main outcome, including
attrition and exclusions from the analysis.
State whether or not attrition and
exclusions were reported, the numbers in
each intervention group (compared with
total randomised participants), reasons
for attrition/exclusions where reported,
and any reinclusions in analyses
performed by the review authors
Attrition bias due to amount, nature
or handling of incomplete
outcome data
Reporting bias
Selective reporting State how the possibility of selective
outcome reporting was examined by the
review authors, and what was found
Reporting bias due to selective
outcome reporting
Other bias
Other sources of bias State any important concerns about bias
not addressed in the other domains in
the toolIf particular questions/entries
were pre-specified in the review’s
protocol, responses should be provided
for each question/entry
Bias due to problems not covered
elsewhere in the table
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Appendix 4 List of included randomised
controlled trials and linked reports
Azarnoush 2011
Primary study
Azarnoush K, Camilleri L, Aublet-Cuvelier B, Geoffroy E, Dauphin C, Dubray C, et al. Results of the first
randomized French study evaluating self-testing of the International Normalized Ratio. J Heart Valve
Dis 2011;20:518–20.
Secondary study
Dauphin C, Legault B, Jaffeux P, Motreff P, Azarnoush K, Joly H, et al. Comparison of INR stability between
self-monitoring and standard laboratory method: preliminary results of a prospective study in 67 mechanical
heart valve patients. Arch Cardiovasc Dis 2008;101:753–61.
Bauman 2010
Primary study
Bauman ME, Black K, Bauman ML, Bruce AA, Kuhle S, Bajzar L, et al. EMPoWarMENT: Edmonton pediatric
warfarin self-management pilot study in children with primarily cardiac disease. Thromb Res
2010;126:e110–15.
Secondary study
Bauman ME, Conroy S, Massicotte MP. Point-of-care INR measurement in children requiring warfarin: what
has been evaluated and future directions. Pediat Health 2008;2:651–9.
Christensen 2011
Christensen H, Lauterlein JJ, Sorensen PD, Petersen ER, Madsen JS, Brandslund I. Home management of
oral anticoagulation via telemedicine versus conventional hospital-based treatment. Telemedicine J
E-Health 2011;17:169–76.
Christensen 2006
Primary study
Christensen TD, Maegaard M, Sorensen HT, Hjortdal VE, Hasenkam JM. Self-management versus
conventional management of oral anticoagulant therapy: a randomized, controlled trial. Eur J Intern Med
2006;17:260–6.
Secondary study
Christensen TD, Maegaard M, Sorensen HT, Hjortdal VE, Hasenkam JM. Self-versus conventional
management of oral anticoagulant therapy: effects on INR variability and coumarin dose in a randomized
controlled trial. Am J Cardiovasc Drugs 2007;7:191–7.
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Cromheecke 2000
Cromheecke ME, Levi M, Colly LP, Mol BJ, Prins MH, Hutten BA, et al. Oral anticoagulation self-management
and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet
2000;356:97–102.
Eitz 2008
Primary study
Eitz T, Schenk S, Fritzsche D, Bairaktaris A, Wagner O, Koertke H, et al. International normalized ratio
self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement.
Ann Thorac Surg 2008;85:949–54.
Secondary study
Koertke H, Zittermann A, Mommertz S, El AM, Litmathe J, Koerfer R. The Bad Oeynhausen concept of INR
self-management. J Thromb Thrombolysis 2005;19:25–31.
Fitzmaurice 2002
Primary study
Fitzmaurice DA, Murray ET, Gee KM, Allan TF, Hobbs FD. A randomised controlled trial of patient self
management of oral anticoagulation treatment compared with primary care management. J Clin Pathol
2002;55:845–9.
Secondary study
Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE. Oral anticoagulation management in
primary care with the use of computerized decision support and near-patient testing: a randomized,
controlled trial. Arch Intern Med 2000;160:2343–8.
Fitzmaurice 2005
Primary study
Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S, et al. Self management of oral
anticoagulation: randomised trial. BMJ 2005;331:1057.
Secondary studies
Murray E, Fitzmaurice D, McCahon D, Fuller C, Sandhur H. Training for patients in a randomised controlled
trial of self management of warfarin treatment. BMJ 2004;328:437–8.
McCahon D, Fitzmaurice DA, Murray ET, Fuller CJ, Hobbs RF, Allan TF, et al. SMART: self-management of
anticoagulation, a randomised trial. BMC Fam Pract 2003;4:11.
Gadisseur 2003
Primary study
Gadisseur AP, Breukink-Engbers WG, Meer FJ, Besselaar AM, Sturk A, Rosendaal FR. Comparison of the
quality of oral anticoagulant therapy through patient self-management and management by specialized
anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med 2003;163:2639–46.
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Secondary study
Gadisseur AP, Kaptein AA, Breukink-Engbers WG, Meer FJ, Rosendaal FR. Patient self-management of oral
anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life.
J Thromb Haemost 2004;2:584–91.
Gardiner 2006
Gardiner C, Williams K, Longair I, Mackie IJ, Machin SJ, Cohen H. A randomised control trial of patient
self-management of oral anticoagulation compared with patient self-testing. Br J Haematol
2006;132:598–603.
Gardiner 2005
Gardiner C, Williams K, Mackie IJ, Machin SJ, Cohen H. Patient self-testing is a reliable and acceptable
alternative to laboratory INR monitoring. Br J Haematol 2005;128:242–7.
Hemkens 2008
Hemkens LG, Hilden KM, Hartschen S, Kaiser T, Didjurgeit U, Hansen R, et al. A randomized trial
comparing INR monitoring devices in patients with anticoagulation self-management: evaluation of a novel
error-grid approach. J Thromb Thrombolysis 2008;26:22–30.
Horstkotte 1996
Primary study
Horstkotte D, Piper C, Wiemer M, Schulte H.D. Improvement of prognosis by home prothrombin
estimation In patients with life-long anticoagulant therapy. Euro Heart J 1996;17:230.
Secondary study
Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral
anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5:19–24.
Khan 2004
Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the
management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol
2004;126:557–64.
Koertke 2001
Primary study
Körtke H, Minami k, Breymann T, Seifert D, Baraktaris A, Wagner O, et al. INR self-management after
mechanical heart valve replacement. Z Kardiol 2001;9(Suppl. 6):VI/118–24.
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Secondary studies
Koertke H, Minami K, Bairaktaris A, Wagner O, Koerfer R. INR self-management following mechanical
heart valve replacement. J Thromb Thrombolysis 2000;9(Suppl. 1):S41–5.
Körtke H, Körfer R. International normalized ratio self-management after mechanical heart valve
replacement: is an early start advantageous? Ann Thorac Surg 2001;72:44–8.
Koertke H, Zittermann A, Wagner O, Koerfer R. Self-management of oral anticoagulatin therapy improves
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Appendix 6 Quality assessment results for the
individual included studies
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TABLE 32 Risk factors, comorbidity or history of previous complications reported in the included studies
Study ID
Risk factors/comorbidity History of previous complications
SM RC p-value SM RC p-value
Azarnoush
201177
Systemic HT, % 40 38 NS
Diabetes, % 9 14 NS
CABG, % 15 20 NS
EuroSCORE,
mean (SD)
4.2 (2.1) 4.7 (2.0) NS
LVEF at 3 months,
mean (SD)
60 (8.3) 58 (9.5) NS
LVEF at 6 months,
mean (SD)
61 (6.9) 61 (7.9) NS
Christensen
200675
Major
thromboembolic
events
2 8 NR
Major bleeding 10 8 NR
Fitzmaurice
200564
HT, % 42.43 48.57 NS
Hyperlipidaemia, % 24.92 21.78 NS
Matchar
201071
DM, % 32.22 33.97 0.31
HT, % 71.06 69.32 0.31
Previous stroke, % 9.28 9.61 0.76
CHADS2 score for AF without AHV, % 0.42
0 11.5 9.79
1 29 29
2 29.38 31.79
3 17.88 18.52
4 8.62 7.3
5 3.05 3.2
6 < 1 < 1
Mean CHADS2 score 1.94 1.95
Menendez-
Jandula
200561
Arterial HT, % 48.6 42.80 NS Severe bleeding, % 11.10 9.8 NS
DM, % 15.40 13.60 NS Thromboembolic
events, %
13.50 7.90 NS
Gastric ulcer, % 17.80 15.70 NS
Cancer, % 9.20 8.70 NS
Liver disease, % 9.70 8.40 NS
Sawicki
199972
Minor bleeding, % 11.11 11.23 NR
Major bleeding, % 1.11 1.12 NR
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TABLE 32 Risk factors, comorbidity or history of previous complications reported in the
included studies (continued )
Study ID
Risk factors/comorbidity History of previous complications
SM RC p-value SM RC p-value
Siebenhofer
200863
Cardiovascular
disease other than
AF or AHV, %
78 84 0.24 Thromboembolic
events, %
45 49 0.624
HT, % 43 49 0.439 Severe bleeding, % 4 6 0.484
DM, % 23 25 0.773
Pulmonary
disease, %
13 12 0.895
GI tract disease, % 12 11 0.886
Cancer, % 7 8 0.741
AF, atrial fibrillation; CABG, concomitant coronary artery bypass graft; CHADS2, Congestive heart failure, Hypertension,
Age, Diabetes, prior Stroke (stroke risk prediction); DM, diabetes mellitus; GI, gastrointestinal; HT, hypertension; LVEF, left
ventricular ejection fraction; NR, not reported; NS, not significant.
TABLE 33 Description of training and education reported in the included studies
Study ID Country
Type of OAT
management Care provider
Training
Training provider Time spent
Training
description
Azarnoush
201177,140
France PST Cardiologist and
or GP
NR NR Group session;
3–6 additional
practical sessions
Bauman
201055,141
Canada PSM vs. PST Nurse practitioner
or physician
within VPat
NR 1 hour Group session
Christensen
200675,142
Denmark PSM Physician NR Daily for
3 weeks
NR
Christensen
201166
Denmark PST Attending AC
clinic doctor
Training on
point-of-care test
by biomedical
laboratory
scientists
2 hours NR
Cromheecke
200076
Netherlands PSM NR NR 2 hours
per session
Two group
sessions;
4–6 per group
Eitz
200878,143
Germany PSM GP (SC); staff at
outpatient
clinic (SM)
NR NR NR
Fitzmaurice
200267,144
UK PSM Nurse led, GP Research staff,
practice staff
1–2 hours
per session
Two sessions
Fitzmaurice
200564,123,145
UK PSM Anticoagulant
nurse at
practice-based
clinics
Trained AC nurse Two sessions
Gadisseur
200368,80
Netherlands PSM Physician, nurse Specialised teams
including physician
and paramedical
personnel
90 to 120
minutes
per session
Three group
sessions:
4–5 per group
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TABLE 33 Description of training and education reported in the included studies (continued )
Study ID Country
Type of OAT
management Care provider
Training
Training provider Time spent
Training
description
Gardiner
200545
UK PST Nurse practitioner
(SC); clinic
staffs (SM)
Trained nurse
practitioner
Two sessions
Gardiner
200656
UK PST vs. PSM Clinic staffs (SM) Trained and
experienced nurse
Two sessions
Hemkens
200857
Germany PSM Nurse Skilled teaching
nurse
NR Four weekly
sessions
Khan 200469 UK PST Study researchers
(SM); clinic
staffs (SC)
Clinic doctor 2 hours Group session;
2–3 per group
Körtke
200170,147–149
Germany PSM Family
practitioner
NR NR NR
Horstkotte
199659,146
Germany PSM Private physician NR NR NR
Matchar
201071,150,151
USA PST Trained clinic
staff
NR NR NR
Menéndez-
Jándula
200561
Spain PSM Haematologists,
trained nurse,
physician
Trained nurse 2 hours
per session
Two
group sessions
Rasmussen
201258
Denmark PSM Physician NR NR NR
Ryan
200962,152
Ireland PST Clinic pharmacist
or doctor
Research
pharmacists
and haematologist
90 minutes 1–3 per group
Sawicki
199972,153
Germany PSM Family
practitioner or
clinic staff at
outpatient clinic
Trained nurse
and physician
(2 days’ training)
60 to 90
minutes
per group
Three group
sessions;
3–6 per group
Sidhu 200173 UK PSM Family physician
or AC clinic staff
NR 3 hours
per session
Two group
sessions;
2–5 per group
Siebenhofer
200863,81
Austria PSM GP or specialised
AC clinic staff
Trained nurse
and physician
(2 days’ training)
90 to 120
minutes
per group
Four group
sessions;
3–6 per group
Soliman
Hamad
200979
Netherlands PSM Physician NR At least 1 week NR
Sunderji
200465,154
Canada PSM Physician (SC);
clinical
pharmacist (SM)
Probably study
pharmacist
First session
2–3 hours;
second session
1–2 hours
Two sessions
Verret
201274
Canada PSM Pharmacist (SM) Pharmacist First session
3 hours; second
session 2 hours
23 sessions held;
1–9 per group
Völler
200560,155
Germany PSM Family physician
or specialist
physician
NR NR NR
AC, anticoagulant clinic; NR, not reported; POC, point-of-care; PSM, patient self-management; PST, patient self-testing;
SC, standard care; SM, self-monitoring; VPaT, vascular patency and thrombosis.
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Appendix 8 Sensitivity analysis results
(Table 34, Figures 28–47)
TABLE 34 Sensitivity analysis results restricted to non-UK trials, UK trials and trials at low risk of bias
Outcomes
All included studies,
RR (95% CI)
Non-UK trials, RR
(95% CI)
UK trials, RR
(95% CI)
Trials at low risk of
bias, RR (95% CI)
Any bleeding 0.95 (0.74 to 1.21);
p= 0.66
0.91 (0.70 to 1.20);
p= 0.51
1.40 (0.61 to 3.23);
p= 0.43
0.72 (0.41 to 1.26);
p= 0.25
PSM 0.94 (0.68 to 1.30);
p= 0.69
0.90 (0.63 to 1.28);
p= 0.56
1.38 (0.53 to 3.59);
p= 0.50
0.74 (0.42 to 1.32);
p= 0.31
PST 1.15 (1.03 to 1.28);
p= 0.02
1.14 (1.02 to 1.28);
p= 0.02
1.46 (0.26 to 8.28);
p= 0.67
0.28 (0.01 to 6.71);
p= 0.43
Thromboembolic
events
0.58 (0.40 to 0.84);
p= 0.004
0.50 (0.32 to 0.76);
p= 0.001
1.16 (0.58 to 2.29);
p= 0.68
0.42 (0.22 to 0.77);
p= 0.006
PSM 0.51 (0.37 to 0.69);
p< 0.00001
0.40 (0.28 to 0.58);
p< 0.00001
1.16 (0.58 to 2.29);
p= 0.68
0.38 (0.20 to 0.69);
p= 0.002
PST 0.99 (0.75 to 1.31);
p= 0.95
0.99 (0.75 to 1.31);
p= 0.95
Not estimable 1.67 (0.15 to 17.93);
p= 0.67
Mortality 0.83 (0.63 to 1.10);
p= 0.20
0.83 (0.60 to 1.15);
p= 0.26
0.52 (0.11 to 2.58);
p= 0.43
0.85 (0.40 to 1.81);
p= 0.68
PSM 0.68 (0.46 to 1.01);
p= 0.06
0.71 (0.43 to 1.16);
p= 0.17
0.52 (0.11 to 2.58);
p= 0.43
0.85 (0.40 to 1.81);
p= 0.68
PST 0.97 (0.78 to 1.19);
p= 0.74
0.97 (0.78 to 1.19);
p= 0.74
Not estimable Not estimable
PSM, patient self-management; PST, patient self-testing.
Four of the trials included in meta-analysis were UK based (Fitzmaurice 2002,67 Fitzmaurice 2005,64 Khan 200469 and
Sidhu 2001).73
Three of the trials were judged to be at low risk of bias (Menéndez-Jándula 2005,61 Ryan 200962 and Siebenhofer 200863).
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